Effect of glycated opticin on angiogenesis: mechanism & relevance to

proliferative diabetic retinopathy by Benjama, Ahmeda Ibrahim
Benjama, Ahmeda Ibrahim (2014)Effect of glycated opticin on angiogenesis:
mechanism & relevance toproliferative diabetic retinopathy. Doctoral thesis
(PhD), Manchester Metropolitan University.
Downloaded from: http://e-space.mmu.ac.uk/623733/
Usage rights: Creative Commons: Attribution-Noncommercial-No Deriva-
tive Works 4.0
Please cite the published version
https://e-space.mmu.ac.uk
Effect of glycated opticin on angiogenesis: 
mechanism & relevance to 
Proliferative Diabetic Retinopathy 
 
 
 
 
 
 
 
 
Ahmeda Ibrahim Benjama 
 
 
 
A Thesis submitted in partial fulfilment of the 
requirements of the Manchester Metropolitan 
University for the degree of 
Doctor of Philosophy 
 
 
 
 
 
School of Healthcare Sciences 
Manchester Metropolitan University 
July 2014 
 
Table of Contents 
Table of Contents .......................................................................................................... I 
List of figures .............................................................................................................. IX 
List of tables ............................................................................................................... XII 
Abstract ........................................................................................................................... XIII 
Declaration ....................................................................................................................... XV 
Dedication ...................................................................................................................... XVI 
Acknowledgment .......................................................................................................... XVII 
Abbreviations ............................................................................................................... XVIII 
Chapter 1: Introduction .............................................................................................. XXI 
1. Introduction..................................................................................................................... 1 
1.1 Ocular angiogenesis ............................................................................................ 1 
1.2 Angiogenesis ............................................................................................................ 2 
1.3 Vasculogenesis ....................................................................................................... 4 
1.3.1 Vascular development and growth ............................................................. 4 
1.3.2 Structure of the blood vessels ..................................................................... 5 
1.3.3 Function and structure of the lymphatic vasculature ..................................... 8 
1.3.4 Types of Angiogenesis ................................................................................... 9 
1.3.4.1 Sprouting angiogenesis..................................................................….10 
1.3.4.2 Splitting angiogenesis…………………………………………..…..10 
1.4 Mechanisms of blood vessel growth: .................................................................. 12 
1.5 Formation of blood vessels .............................................................................. 15 
1.6 Stabilisation of general networks. ..................................................................... 17 
1.7 Remodelling of general networks by angiogenesis ......................................... 17 
1.8 Angiogenic stimuli ............................................................................................ 20 
1.9 The key process of angiogenesis ..................................................................... 20 
1.10 Notch signaling .............................................................................................. 23 
I 
1.11 Angiogenesis in Disease and treatment ......................................................... 23 
1.12 Blood vessels cells ......................................................................................... 25 
1.12.1 Endothelial cells ........................................................................................ 25 
1.12.2 Endothelial cell differentiation ................................................................... 26 
1.12.3 Mural cells (MCs) .................................................................................. 27 
1.12.4 Pericytes ...................................................................................................... 28 
1.12.5 Smooth muscle cells ................................................................................... 29 
1.13 Extracellular matrix.......................................................................................... 29 
1.14 Basement membrane layers ........................................................................... 31 
1.15 Degradation of cellar membrane layers .......................................................... 33 
1.16 Integrins and cell-matrix communications ....................................................... 35 
1.17 Cytoskeletal proteins ........................................................................................ 41 
1.17.1 Vinculin ........................................................................................................... 41 
1.17.2 Paxillin ........................................................................................................ 41 
1.17.3 Talin ............................................................................................................ 41 
1.18 Collagen receptor integrins ............................................................................. 42 
1.18.1 Modulation of integrin mission by conformational modification .............. 42 
1.18.2 Crosstalk in between integrin and growth factor receptors ........................ 43 
1.19 Growth Factors ................................................................................................ 44 
1.19.1 Vascular endothelial growth factor ......................................................... 44 
1.19.2 Fibroblast growth factor ............................................................................. 45 
1.19.3 Other growth factors .............................................................................. 46 
1.20 Endothelial cell migration ............................................................................... 47 
1.21 Endothelial cell filopodia ................................................................................ 48 
1.22 Endothelial cell proliferation ......................................................................... 49 
1.23 Protein phosphorylation in cell signalling ..................................................... 49 
1.23.1 Phosphorylation by tyrosine kinases .......................................................... 49 
1.23.2 FGF-2 signalling pathways ..................................................................... 51 
1.24 The optical system ......................................................................................... 52 
1.24.1 The eye ................................................................................................... 52 
1.24.2 Vitreous balance ......................................................................................... 53 
1.24.3 Vitreous supramolecular organisation ........................................................ 55 
1.24.4 Inhibition of general cell development by the vitreous humor .................. 56 
1.25 Ocular conditions ............................................................................................ 57 
1.26 Glycation General Introduction ..................................................................... 57 
1.27 Diabetes mellitus .............................................................................................. 58 
1.28 Diabetes mellitus types: .................................................................................. 59 
1.28.1 Type 1 diabetes mellitus:........................................................................ 59 
1.28.2 Type 2 diabetes mellitus:........................................................................ 59 
1.29 Diabetic complications ..................................................................................... 59 
1.29.1 Short term complications ........................................................................ 60 
1.29.2 Long Term Complications ...................................................................... 60 
1.29.3 Diabetic cataract ......................................................................................... 60 
1.29.4 Diabetic nephropathy ............................................................................. 60 
1.30 Advanced glycation endproducts and macrovascular complications ............... 61 
1.31 Diabetes and atherosclerosis ........................................................................... 61 
1.32 Obesity metabolic syndrome and insulin resistance ..........................................61 
1.33 Introduction of Diabetic retinopathy ............................................................... 62 
1.34 Epidemiology....................................................................................................... 65 
1.35 Epidemiology of Diabetes in UK. ................................................................... 66 
1.35.1 Background Diabetic Retinopathy (BDR) .............................................. 66 
1.35.2 Proliferative diabetic retinopathy (PDR) ................................................ 66 
1.36 Differences between the PDR and BDR ........................................................... 67 
1.37 Pathophysiology of Diabetic Retinopathy ..................................................... 69 
1.37.1 Accumulation of Sorbitol ........................................................................... 69 
1.37.2 Formation of protein kinase C (PKC) ....................................................... 70 
1.37.3 Formation of Advanced Glycation End Products (AGE) .......................... 70 
1.37.4 Formation of Reactive Oxygen Species ..................................................... 71 
1.38 AGE-driven angiogenesis in vitro ................................................................. 71 
1.39 Pharmacologic Management of DR .............................................................. 73 
A. Corticosteroids: .................................................................................................... 72 
B. VEGF Inhibitors ........................................................................................ 72 
C. Renin-Angiotensin System (RAS) ............................................................ 72 
D. Antiplatelet Drugs ..................................................................................... 72 
E. Protein Kinase C (PKC) Inhibitors: .......................................................... 72 
F. Advance Glycation End-Product (AGE) Inhibitors .................................. 72 
1.40 Diabetic retinopathy treatment .................................................................. 74 
1.40.1 Laser surgery ................................................................................ 74 
1.40.2 Medication injection ....................................................................... 74 
1.40.3 Vitrectomy surgery ........................................................................ 74 
1.41 Small leucine-rich proteoglycans (SLRP) .............................................. 75 
1.42 Opticin ........................................................................................................ 77 
1.43 Methylglyoxal .............................................................................................. 80 
1.43.1 Functionality involving methyalglyoxal ............................................... 80 
1.43.2 MG and AGEs .......................................................................................80 
1.44 Protein glycation........................................................................................... 81 
1.44.1 Chemistry of protein glycation .............................................................. 81 
1.44.2 Advanced Glycation end products ......................................................... 82 
1.44.3 AGEs groups: ........................................................................................ 82 
1.44.4 RAGE (receptor for advanced glycation end products) ......................... 83 
1.44.5 Sources of AGEs .................................................................................... 85 
1.45.1 Exogenous sources of AGEs ............................................................ 85 
1.45.2 AGEs inhibitors ................................................................................. 86 
1.45.3 RAGE blockers ................................................................................. 86 
1.45.4 Measurement of glycation reaction products ..................................... 87 
 
1.45.4.1 Measurement of early glycation products……………………..87 
 
1.45.4.2 Measurement of intermediate glycation products…………….88 
 
1.45.4.3 Measurement of advanced glycation products………………..88 
1.45.5 Methylglyoxal reacts with proteins to form AGEs ............................ 88 
1.45.6 Reactive carbonyl species ................................................................. 88 
1.46 Carbonyls in pathological conditions ....................................................... 89 
Aim ...............................................................................................................................90 
Chapter 2:Material and Methods ............................................................................. 89 
2 Material and Methods........................................................................................ 93 
2.1 Material ........................................................................................................ 93 
2.2 Solutions ....................................................................................................... 95 
2.3 Equipments ................................................................................................... 97 
2.4 Methods ........................................................................................................ 98 
2.4.1 Dialysis procedure .......................................................................... 98 
2.4.1.1 Coomassie brilliant blue……………..………………………………99 
2.4.2 MALDI TOF Mass Spectrometry .................................................. 99 
2.4.3 Sliver staining of polyacrylamide gels ............................................ 99 
2.4.4 Silver Stain Protocol ....................................................................... 100 
2.4.5 Image analysis of SDS-PAGE gels ................................................ 100 
2.5 Preparations of samples ........................................................................... 100 
2.5.1 Preparation of MG-treated opticin ................................................... 100 
2.5.2 Detection of AGE using MALDI/TOF ............................................ 101 
2.5.3 Cell culture ...................................................................................... 101 
6 
 
  
2.5.3.1 Routine culture of bovine aortic endothelial cells…………………….101 
2.5.3.2 Sub-culturing of endothelial cells……………………………………...102 
2.5.3.3 Trypsinization……………………………………………………..…...102 
2.6 Storage of cells in liquid nitrogen ............................................................. 102 
2.7 Thawing Frozen Cells ................................................................................103 
2.8 Cell counting .............................................................................................. 103 
2.9 Preparations of medium ............................................................................ 103 
2.9.1 Preparation of complete medium (15% FBS); ................................. 103 
2.9.2 Preparation of 2.5 % FBS and 0.1% FBS........................................ 104 
2.10 Proliferation assay ..................................................................................... 104 
2.11 Wound healing assay ................................................................................ 105 
2.12 Boyden chamber ....................................................................................... 106 
2.12. A. Expression and purification of recombinant bovine Opticin....……107 
2.13 Formation of tube-like structures in MatrigelTM ......................................... 107 
2.14 Formation of tube-like structures in type-I Collagen.................................. 108 
2.15 SDS-PAGE ..................................................................................................... 108 
2.16 Protein extraction for total proteins ............................................................ 109 
2.17 Protein estimation for Western blotting ..................................................... 110 
2.17.1 Western blotting .............................................................................. 110 
2.17.2 Blotting ................................................................................................ 112 
2.17.3 Blocking ............................................................................................... 112 
2.17.4 Developing ........................................................................................... 112 
2.18 Binding assay Opticin (native and glycated) binding to collagen type-I...113 
2.19 Binding assay with opticin and FGF-2/FGFR complex ............................. 113 
2.20 The frozen section ...................................................................................... 114 
2.21 Immunocytochemistry .................................................................................... 114 
III 7 
 
  
2.22 Immunohistochemistry ........................................................................... 115 
2.23 Statistical analysis ............................................................................. 115 
Chapter 3: Results ................................................................................................. 117 
Section 1: Opticin glycation .................................................................................. 118 
3 Results ..................................................................................................................... 119 
3.1 Glycation ..................................................................................................... 119 
3.1.1 Quantification and localisation of opticin glycation ..................... 119 
3.1.2 Opticin detection by SDS-PAGE ................................................. 119 
3.1.3 Elecreophoretic analysis of Glycated opticin ............................... 120 
3.1.3.1 Glycation of opticin in vitro using SDS-PAGE analysis…… ....... 120 
3.1.3.2 Glycation of opticin for up to 24 hours with MG………………..121 
3.1.3.3 Glycated of opticin with MG in vitro using SDS-PAGE analysis.122 
3.1.3.4 Glycation of opticin for up to 72 hours with MG………………...123 
 
3.1.4 Glycation of opticin in vitro by glucose, fructose, and ribose ....... 124 
 
3.1.4.1 Glycation of opticin by glucose………………………………...125 
3.1.4.2 Glycation of opticin by fructose……………………………….126 
 
3.1.4.3 Glycation of opticin by ribose…………………………...…….127 
 
3.1.5 Detection of AGE using MALDI/TOF Spectra .............................. 128 
Section 2: in vitro and in vivo angiogenesis assays ................................................ 130 
 
3.2 In vitro angiogenesis assays ..................................................................... 131 
 
3.2.1 Cell Proliferation assay .................................................................. 131 
3.2.2 Cell Migration assay a (Wound healing) ........................................ 134 
 
3.2.2.1 Cell migration using the chemotaxis assay (Boyden chamber)…...137 
3.2.3 EC formation of tube-like structures in different matrices .................... 139 
 
3.2.3.1 EC tube formation in a type-I collagen gel-‘sandwich’ method….139 
 
3.2.3.2 EC tube formation of BAECs in a MatrigelTM matrix…………….141 
 
3.2.3.3 EC tube formation of HRECs in a MatrigelTM matrix…………….145 
VIII  
3.2.3.4 EC tube formation of HRECs in collagen type-I……...…………. ... 147 
3.2.4 Anti-anti-angiogenic effects of Opticin (native and glycated) and EGF 
on BAEC tube formation in collagen type-I ...................................................... 150 
Section 3: Opticin modulated signalling pathways identified ..................................... 153 
3.2.5 Protein phosphorylation of ERK in BAEC treated with GOPT ………154 
3.2.6 Protein phosphorylation of MEK/2 in BAEC treated with GOP……...156 
3.2.7 Protein phosphorylation of AKT in BAEC treated with GOPT ............ 158 
3.2.8 Protein phosphorylation of p38 in BAEC treated with GOPT............... 160 
3.2.9 Protein phosphorylation of JNK2 in BAEC treated with GOPT……...162 
3.2.10 Measurement of CML in diabetic mice ................................................. 163 
3.2.11. Glycated opticin reduce binding to collagen type-I…………………..164 
3.2.12 Glycated opticin binding to FGFR............................................……. ... 165 
Section 4: Immunochemistry .................................................................................... 166 
3.2.13 Immunofluorescence Analysis ............................................................ 167 
3.2.14 Immunolocalization of opticin and AGEs in same section ..................171 
3.2.15 Immunolocalization of opticin and AGEs separated in different 
sections………………………………………………………………………..174 
Chapter 4: Discussion............................................................................................... 175 
4. Discussion ............................................................................................................ 177 
Conclusion. .................................................................................................................... 188 
Future work .............................................................................................................. 189 
Chapter 5: References............................................................................................... 191 
5. Refrences .................................................................................................................. 193 
IX  
 
Table of figures: 
 
Figure 1.1 Schematic overview of the vascular system ................................................. 5 
 
Figure 1.2 Blood vessel morphology ............................................................................. 8 
 
Figure 1.3 Schematic drawing of a lymphatic vessel ..................................................... 9 
 
Figure 1.4 Schematic outline of angiogenesis by two different mechanisms ................. 11 
 
Figure 1 .5 Mechanisms of blood vessel growth. .......................................................... 13 
 
Figure 1 .6 Outline of the vasculogenic process. ........................................................... 16 
 
Figure 1 .7 Schematic layouts standing for the progress of the angiogenic response.  . 
18 
Figure 1 .8 Vacuoles compartments and lumen. .......................................................... 19 
 
Figure 1 .9 The angiogenic balance between angiogenic activators and angiogenic 
inhibitors regulate vascular homeostasis ..................................................................... 21 
 
Figure 1.10 Key steps in angiogenesis ........................................................................ 22 
 
Figure 1.11 Schematic cross section of a capillary ...................................................... 25 
 
Figure 1.12 The members of the collagen family of proteins and their molecular 
assemblies. ........................................................................................................................ 31 
 
Figure 1.13 Integrin signalling .................................................................................... 37 
Figure 1.14 The integrin receptor family ..................................................................... 40 
 
Figure 1.15 The human eye ............................................................................................. 52 
 
Figure 1.16 The structure of the vitreous. .................................................................... 55 
 
Figure 1.17 Schematic diagram of the pathogenesis of diabetic retinopathy…. ........... 64 
 
Figure 1 .18 Diabetic retinopathy ................................................................................. 68 
 
Figure  1.19  shows  the  probable  mechanism  of  the  development  of  diabetic 
microangiopathy ................................................................................................................ 72 
 
Figure  1.20  Dendrogram  representing  the  evolutionary  relationship  between  the 
members  of  the  SLRP  family .................................................................................. 76 
Figure 1.21 The amino acid sequence of opticin chain .................................................. 78 
 
Figure 1.22 Formation of advanced glycation products ................................................ 82 
10  
Figure 1.23 Schematic representation of RAGE ............................................................ 84 
Figure 1.24 The cycle of endogenous and exogenous AGEs. ……. ............................. 85 
Figure 2.1 The dialysis process by using the dialysis cassette. ..................................... 98 
Figure 2.2 BAEC migration after 24 hours incubation. ............................................... 106 
Figure 3.1 Opticin detection by SDS-PAGE. ............................................................. 119 
Figure 3.2 The image is demonstrated glycation of opticin with MG (0.1M)……...120 
Figure 3.3 AGE formation in the opticin-MG system for 24 hours…........................121 
Figure 3.4 Glycation of opticin (1 mg/ml) with MG (0.1M) up to 72 hours .............. 122 
Figure 3.5 Incubation of opticin for up to 72 hours with MG…. ................................. 123 
Figure 3.6 Glycation of opticin with glucose, fructose, and ribose for 72 hours……..124 
Figure 3.7 AGE formation in the opticin-glucose system. ......................................... 125 
Figure 3.8 AGE formation in the opticin-fructose system. ........................................ 126 
Figure 3.9 AGE formation in the opticin- ribose system. ............................................ 127 
Figure 3.10 MALDI-TOF analysis of opticin incubated in MG. ............................... 129 
Figure 3.11Time course study of average number of moles of MG attached to each 
mole of opticin. ......................................................................................................... 125 
Figure 3.12 Anti-anti-angiogenic effects of GOPT combined with FGF-2 on BAEC 
proliferation. .................................................................................................................... 133 
Figure 3.13 Effect of opticin1mg/ml (native and Glycated), on cell migration induced 
by FGF-2 on BAEC using a wound healing assay ....................................................... 135 
Figure 3.14 The effect of GOPT on FGF-2-induced BAEC migration. ....................... 136 
Figure 3.15 Effect of GOPT, FGF-2 and their combination on BAEC 
migration.          ... 138 
Figure 3.16 Anti-anti-angiogenic effects of GOPT and FGF-2 on BAEC tube 
formation. ........................................................................................................................ 140 
Figure 3.17 Photomicrograph showing the anti-anti-angiogenic effects of 
GOPT on FGF-2 on BAEC tube formation in collagen type I ................................... 137 
Figure 3.18 Anti-anti-angiogenic effects of GOPT and FGF-2 on BAEC tube 
formation. ........................................................................................................................ 143 
Figure 3.19 Photomicrograph showing the pro-angiogenic effects of Opticin on 
XI  
FGF-2 on BAEC tube formation (in Matrigel). ........................................................... 144 
Figure 3.20 Anti-anti-angiogenic effects of GOPT and FGF-2 on HRECs tube 
formation. ........................................................................................................................ 145 
Figure 3.21 Photomicrograph showing the inhibition of anti-angiogenic effects of 
Opticin on FGF-2 on HREC tube formation (in Matrigel). ......................................... 146 
Figure 3.22 EC tube formation of HRECs in collagen type-I ..................................... 148 
Figure 3.23 Photomicrograph showing the anti-anti-angiogenic effects of 
Opticin on FGF-2 on HREC tube formation in collagen type-I ................................... 149 
Figure 3.24 Anti-angiogenic effects of GOPT and EGF on BAECs tube         
formation. ........................................................................................................................ 151 
Figure 3.25 Photomicrograph showing the anti-anti-angiogenic effects of Opticin with 
EGF on BAEC tube formation (in collagen type I). ...................................................... 152 
Figure 3.26 Protein phosphorylation of ERK-1 and ERK-2 in BAEC…… ................. 155 
Figure  3.27  Protein  phosphorylation  of  MEK/2  in  BAEC  treated  with  GOPT 
....................................................................................................................................157 
Figure 3.28 Protein phosphorylation of AKT in BAEC treated with GOPT……...….159 
Figure 3.29 Protein phosphorylation of p38 in BAEC treated with GOPT. ................. 161 
Figure 3.30 Protein phosphorylation of JNK2 in BAEC GOPT. ................................. 162 
Figure 3.31 Western blots showing the expression of CML ........................................ 163 
Figure 3.32 Opticin (native and glycated) binding to collagen type-I ......................... 164 
Figure 3.33 Glycated opticin binding to FGFR ........................................................... 165 
Figure 3.34 Immunofluorescence detection /Anti vinculin.......................................... 168 
Figure 3.35 Immunofluorescence detection /Anti paxillin. ......................................... 169 
Figure 3.36 Immunofluorescence detection / α2β1. .................................................... 170 
Figure 3.37 The localization of AGEs in diabetic mouse eye ...................................... 171 
Figure 3.38 The co- localization of opticin and AGEs in diabetic mouse eye…...…..172 
Figure 3.39 The co-localization of opticin and AGEs in diabetic mouse eyes……. ..... 173 
Figure 3.40 The localization of AGEs in diabetic mouse eyes. ................................... 174 
Figure 3.41 The localization of opticin in nondiabetic mouse eyes. ............................ 174 
12  
Figure 3.42 Diabetic mouse eye .................................................................................. 174 
Figure 4.1 Signal pathways ........................................................................................ 187 
 
List of tables 
 
Table 1.1 Summary of the molecular basis underlying new blood vessel growth ........... 13 
 
Table 1.2 Members of the MMP family ........................................................................ 35 
Table 1.3 Leading causes of visual impairment and ocular discomfort ......................... 57 
Table 2.1 Preparation of 15% FBS culture medium. ................................................... 103 
Table 2.2 Preparation of 2.5% and 0.1% FBS culture medium .................................... 104 
Table 2.3 BSA dilution to establish the standard curve ............................................... 110 
Table 2.4 Preparation of stacking and separating gels for Western blotting ................ 111 
XIII  
Abstract 
Diabetic retinopathy is one of the major microvascular complications of diabetes and 
considered as the common cause of blindness worldwide. Various studies have 
indicated that increased AGE formation during diabetes might play an essential role in 
the development and progression of retinopathy. Preretinal neovascularisation is 
responsible for the onset of diabetic retinopathy and ultimately blindness. CollagenIV 
of the vitreous humour provides an essential substrate for this process. 
The blindness is normally associated with pathologies including non proliferative 
diabetic retinopathy (NPDR), retinopathy of prematurity (ROP), and retinal vein 
occlusion. It is characterised by the angiogenic growth of neovessels from the 
preexisting inner retinal vasculature into the vitreous humour. Visual loss is caused by 
vitreous haemorrhage and/or tractional retinal detachment induced by the contraction 
of fibrous tissue associated with these new blood vessels which are immature, with a 
low pericyte and smooth muscle cell covering, and often abnormally shaped. 
Opticin is an extracellular matrix glycoprotein and a member of the small leucine– rich 
repeat protein/proteoglycan family. It is highly expressed in the eye throughout life and 
localises to the vitreous humour. It has been previously shown to be a potent 
endogenous inhibitor of angiogenesis, although the signalling mechanisms responsible 
for its action have not been determined. Here, it is demonstrated that opticin 
significantly inhibited migration and tube-like structure formation of bovine aortic 
endothelial cells (BAEC) and human retinal microvessel endothelial cells (HREC) in 
matrigel, induced by FGF-2. Regarding cellular signalling, opticin also inhibited FGF- 
2-induced phosphorylation of MEK1/2, p38 and JNK2, confirmed by Western blotting, 
which could explain its anti-angiogenic properties. We also observed increasing in Akt 
expression. Protein glycation is also a feature of chronic diabetes and can result in 
modified cellular function. Here we show that exposure of opticin to high 
methyalglyoxal produces glycation that inhibited its ability to reduce endothelial cell 
migration and tube-formation, and reduced its ability to inhibit cell signalling through 
ERK/MEK and JNK. This may be one mechanism through which the angiogenic switch 
is altered in pro-angiogenic proliferative retinopathy. 
14  
Here it was observed that when opticin became glycated, it was less able to bind to 
collagen, the collagen, thereby inhibiting α2β1 integrin binding to collagen affecting 
the angiogenesis inhibiting properties of opticin. 
AGEs are localized in retinal vessels and neuroglia of diabetic patients where they exert 
a range of deleterious effects on cell function. In vivo and in vitro studies suggest that 
elevated AGE level occurring in diabetes may be an important factor in retinopathy 
initiation and progression. Our result shows the distributions of the opticin mostly in 
front of the eye with a small amount in retina and vitreous. Furthermore, the diabetic 
mouse has more AGEs than the non-diabetic mouse, and the increased co-localization 
of AGEs with opticin was very clear in diabetic mouse compared with non-diabetic 
mouse. 
We can conclude the opticin become glycated if exposed to high sugar level and this 
reduces its ability to bind to collagen and impair angiogenic signalling. The 
accumulation of AGEs in retina may play a causative role in the development of corneal 
epithelial disorders of diabetic patients. Glycation of opticin could one of mechanisms 
allowing venel growth into the vitreous during PDR. 
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1 Introduction 
 
 
1.1 Ocular angiogenesis 
Ocular angiogenesis is one of the most common complications in many 
pathological conditions affecting different structures in the eye, for instance, the 
cornea, retina and choroid. Corneal angiogenesis, ‘corneal neovascularization’ 
(Faraj et al., 2011) is related to the second most common cause of blindness 
worldwide, trachoma, (Whitcher et al., 2001) and to the most common cause of 
corneal blindness in the industrialized countries, herpetic keratitis (Liesegang et 
al., 1989). The corneal neovascularization rate in USA is 4%, affecting 1.4 
million people (Lee et al., 1998; Chang et al., 2001) inducing visual damage 
through edema, lipid deposition and scarring. Furthermore, corneal vascularity 
introduces circulating immune cells, decreasing the immune privilege and 
subsequently grafts survival probability after transplantation (Niederkorn, 2003; 
Cursiefenet et al., 2004; Chongand Dana, 2008; Hos et al., 2008). Diabetic 
retinopathy (DR) effects the posterior part of the eye. It is the leading cause of 
blindness in Americans of working age and the third leading cause of blindness 
in the US (Morrello, 2007). In DR, retinal hypoxia, caused by a subsequent 
breakdown of capillaries, induces the release of a number of vasoactive factors 
such as VEGF and IGF, which promote angiogenesis, tissue remodelling and 
consequently visual impairment. Age related macular degeneration (AMD) is a 
major cause of blindness and visual impairment in older adults (>50 years).There 
are two types of AMD - "wet" or neovascular and "dry" or atrophic. There is no 
cure for AMD, but new treatments are available for the wet form of the disease 
is a multi-factorial disease that progresses from damage of the retinal pigment 
epithelium. In the exudative form (10-15 % of cases), abnormal angiogenesis 
causes choroidal neovascularization under or above the pigment epithelium, 
inducing severe visual impairment in untreated cases (Qazi et al., 2009). 
Retinopathy of prematurity (ROP) or Terry syndrome, previously known as 
retrolental fibroplasias (RLF) is a blinding eye disease of premature infants 
(Terry, 1942), The causes of ROP are not completely understood , 55% of babies 
who are premature develop ROP. The retinal blood vessels in ROP are not 
completely developed, with peripheral retinal avascularity. It results in 
disorganized growth of retinal blood vessels, which may lead to scarring and 
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retinal detachment. When such infants are brought out of the hyperoxic incubator 
into normoxia, relative retinal hypoxia will occur and consequently widespread 
hypoxia-induced retinal angiogenesis. (Jager et al., 2008) 
 
 
1.2 Angiogenesis 
Judah Folkman first used term of angiogenesis to describe new blood vessel 
growth. In 1787, John Hunter discovered that interrupting the blood flow in stag 
antlers resulted in newly formed blood vessels to carry the existent blood flow, 
and that gunshot wounds only healed if there was an adequate blood supply 
(Greenberg and Jin, 2004). Angiogenesis is a multi-step process that is crucial in 
developmental, physiological and pathological processes and involves the 
formation of new blood vessels from pre-existing vasculature. This is distinct 
from vasculogenesis, which refers to the differentiation of angioblasts 
(precursors of endothelial cells) into blood islands that fuse to form a primitive 
cardiovascular system or vascularise endodermal organs (Biancone et al., 1997). 
Angiogenesis is two types sporting and intrsussotion. 
The blood vessel wall surface is made up of endothelial cells, found in a 
monolayer lining the lumen and covered by mural cells; smooth muscular tissue 
cells for macro-vessels (vein and artery) and pericytes for micro-vessels 
(capillary). In pathological conditions, the dysregulation of pro- and 
antiangiogenic factors can increase vascularisation and may lead to conditions 
such as tumour development and arthritis, or inadequate vascularisation in the 
context of ischemia and myocardial infarction (Hall and Ran, 2010). Promoted 
by inflammatory mediators or hypoxia-inducible factors, the procedure of 
angiogenesis takes place in numerous steps, with the key players being 
endothelial and mural cells and the destruction of the micro-environment 
extracellular matrix (e.g. cellar membrane layer, bordering cells) (Hickey and 
Simon, 2006; Presta et al., 2009). This results in cell membrane destruction 
causing the migration and sprouting of Epithelium cell (EC) in to the 
extracellular space towards angiogenic stimulations by VEGF. In the sprouting, 
ECs elongate and align to develop a lumen, and ultimately develop in to tubular 
structures that anatomise with neighbouring vessels enabling blood circulation 
(Folkman,  1995;  Risau,  1995;  Risau,  1997).  Vascular  remodelling  and 
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regeneration takes place through paracrine signals. The endothelial cells 
proliferate and migrate, to increase the length of the neo-vessel, and then 
differentiate into a sprout, which undertakes stabilisation with the recruitment of 
mural cells permitting vessels growth with the deposition of extracellular matrix 
proteins. In adults, ECs are quiescent unless activated during tissue repair, 
endometrial modifications throughout menstruation and body regeneration 
(Stephen et al., 1996; Feldman et al., 2002). Angiogenic disease is caused by 
either the extreme development of blood vessels (e.g. cancers cells, diabetic 
retinopathy and skin psoriasis) or insufficient capillary formation (e.g. chronic 
wounding and ischaemic heart disease) (Carmeliet, 2005; Tai et al., 2006). 
Angiogenesis may be divided into four stages (Chuan-Yuan et al., 2000): (I) 
activation of the endothelial cells leading to the localized degradation of the basal 
membrane of the parent vessel and of the extra-cellular surrounding matrix; (II) 
oriented migration of endothelial cells in the extracellular matrix; (III) 
proliferation of endothelial cells; (IV) differentiation of these cells with 
organization into tubular structures with a new basal lamina. Through these 
stages, the new capillaries form a new vascular network. It is well established 
that angiogenesis plays a crucial function in atherosclerotic plaque development 
and in tumour growth, with a boost in the build-up of immature capillary that are 
badly spent by mural cells (Slevin et al., 2009). The weakness of these vascular 
structures facilitates the infiltration of red blood cells and inflammatory cells, 
which lead to plaque build-up weakness with hemorrhagic danger of stroke 
and/or tumour spread (Slevin et al., 2009; Izquierdo et al., 2009). Tumor 
vascularization occurs via a number of potential mechanisms. Endothelial 
progenitor cells (EPCs), which can reside in the vascular wall or migrate from 
bone marrow in response to chemoattractants from the tumor cell, can 
differentiate into ECs and contribute to vessel formation. Vascular mimicry can 
also occur, whereby tumor cells can act as replacement cells for ECs. Another 
possibility is that chromosomal abnormalities in putative cancer stems cells allow 
tumor cells to differentiate into ECs. Other mechanisms by which tumor cells can 
obtain a blood flow include vessel cooption, whereby the tumor cell arises near 
to (or migrates toward) a preexisting blood vessel, or the process of 
intussusception, whereby a preformed vessel splits into two daughter vessels by 
the insertion of a tissue pillar.( Jonathan et al., 2013). 
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1.3 Vasculogenesis: 
 
1.3.1 Vascular development and growth 
The cardiovascular system consists of the heart and blood, and blood vessels, that 
is the very first body organ to develop during embryogenesis. The vascular 
system appears in the human embryo during the thirth week of development and 
the heart begins to beat after roughly 23 embryonic days (Van Leeuwen et al., 
1999). The vascular system is made up of a network of blood vessels composed 
of the endothelium; a monolayer of EC lining the lumen of the vessel, vascular 
smooth muscle cells that surround the EC and a basement membrane covering 
the vascular tube (Gerhardt and Betsholtz, 2003). Larger arteries and veins have 
a thick layer of vascular smooth muscle cells to stabilize the vessels and to enable 
vessel contraction. In contrast, the smallest vessels (capillaries) are partially 
covered by solitary smooth muscle cells (SMCs), called pericytes that promote 
vessel stabilization (Casley-Smith, 1987; Gerhardt and Betsholtz, 2003) 
(Figure1.1). 
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Figure 1 .1 Schematic overview of the vascular system 
The arteries carry oxygenated blood to the organs of the body. Oxygen and 
nutrient   exchange   takes   place   in   the   smallest   vessels,   the   capillaries. 
Deoxygenated blood is carried back to the heart via the veins to be re-circulated 
to the lungs where it becomes oxygenated. (Take from; 
http://www.infibeam.com/Books/info/Randall-Phillis/Biology- 
ofCancer/0805348670.html). 
 
1.3.2 Structure of the blood vessels 
Blood flow proceeds from the upstream arteries to the downstream veins through 
the capillaries. However, its spatial organisation is more complicated, since it is 
a three-dimensional ramified structure covering a wide range of diameter scales 
from centimetres (cm) at heart level to tens of micrometers (µm) at the capillary 
compartment (microcirculation). A single, continuous monolayer of ECs lined of 
the vessels arranged in a mosaic pattern around a central lumen in which the 
blood can flow. In some tissues, such as the liver, spleen and basement membrane 
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(BM), the ECs are discontinuous, whereas in the kidneys, joints and intestines, 
the ECs are fenestrated (Risau and Flamme, 1995). The EC layer controls the 
passage of nutrients and other materials between the blood stream and around the 
tissue and is attached to the luminal side of a basement membrane. The ECs are 
separated from the surrounding connective tissue by the basement membrane that 
is composed of laminins, collagen IV, perlecan and other matrix components 
(Plank and Sleeman, 2003). The basement membrane separates ECs and SMCs 
in smaller vessels, but in larger vessels, basement membrane is separated with a 
layer of mesenchymal cells and  extracellular matrix (ECM) (Gerhardt and 
Betsholtz, 2003; Armulik et al., 2005). Although ECs share common 
characteristics, they also display considerable heterogeneity. Differences have 
been observed in their morphology, function and gene expression profile. 
Morphological diversity includes changes in size, shape and thickness. For 
instance, ECs on micro-vessels are flattened and elongated while the ECs of large 
vessels are thicker and polygonal (Thorin and Shreeve, 1998). 
ECs can be characterised by specific cell surface marker proteins. Hematopoietic 
precursor cells or mature blood cells (Garlanda and Dejana, 1997) also express 
many of these proteins. For example, platelet/EC adhesion molecule-1 
(PECAM1), also referred to as CD31, a glycoprotein of the Ig super-family, is 
expressed on the surface of some hematopoietic precursor cells, circulating 
platelets, subsets of leukocytes and in the intercellular junctions of ECs 
(Baumann et al., 2004). Vascular endothelial cadherin (VE-Cadherin) is an EC 
specific adhesion molecule expressed by most EC populations in large and small 
vessels, arteries and veins. It is localised at cell-cell junctions of EC. VE- 
Cadherin differs from other EC markers in that it is not expressed on blood cells 
or HSCs (Breier et al., 1996). 
Specialised cells, the pericytes (PCs), are located at the abluminal side of the 
basement membrane. PCs distributed tightly on capillaries and small vessel, 
while large vessels coated by smooth muscle cells (SMCs) (Risau and Flamme, 
1995; Risau, 1997), and matrix (Figure 1.2). Cellular markers used to identify 
peri-ECs include α smooth muscle actin (α-SMA), NG2 chondroitin sulphate 
proteoglycan, 
- 7 -  
PDGF receptor-β (PDGFR-β) and desmin (Bergers and Song, 2005). α-SMA is 
an isoform of the cytoskeletal protein actin family normally restricted to SMCs, 
It is suggested as a marker of differentiated PCs. α-SMA expression has been 
detected in the peri-ECs of most intermediate sized vessels, but not in capillaries. 
Therefore, not all PCs can be identified solely based on α-SMA. In contrast, 
desmin, another contractile filament, as well as NG2 chondroitin sulfate 
proteoglycan, PDGFR-β, and a tyrosine kinase receptor, are also expressed in the 
immature peri-ECs of developing micro-vasculature (Ozerdem et al., 2001; 
McDonald and Choyke, 2003; Bergers and Song, 2005). 
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Figure 1 .2 Blood vessel morphology 
A blood vessel consists of an EC monolayer, arranged in a mosaic model. a) Large 
vessel. b) Capillary, (adapted from Jekunen and Kairemo, 2003). 
1.3.3 Function and structure of the lymphatic vasculature: 
The lymphatic system consists of lymphatic vessels and lymphoid organs, which 
include lymph nodes, thymus, tonsils, spleen and Peyer’s patches. It is a one-way 
system; collecting proteins and fluid from body tissues and transporting them 
back into the subclavian veins of the blood vasculature (Karkkainen and Alitalo, 
2002; Nguyen et al., 2001). A major part of the transportation of the fat absorbed 
by the gut is performed by lymphatics. Foreign particles, such as bacteria and 
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viruses, are transported to the phagocytes in the lymph nodes, as part of the host 
defense (Alitalo and Carmeliet, 2002; Karkkainen and Alitalo, 2002). The lumen 
of the lymphatic vessels is lined with a discontinuous layer of EC, sitting on an 
irregular layer of the basement membrane. The lymphatic EC have a valve-like 
arrangement that permits influx of the tissue fluid into vessels, but blocks reverse 
transport, and are anchored by filaments into surrounding tissue (Figure 1.3). In 
addition, initial lymph sacs can arise from primitive precursors 
(lymphangioblasts), independent of the veins, and, subsequently, from lymphatic 
vessels that connect to the veins (Alitalo and Carmeliet, 2002; Nagy et al., 2002) 
 
Figure 1 -3 Schematic drawing of a lymphatic vessel 
(Taken from Nguyen et al., 2001) 
 
 
 
 
 
1.3.4 Types of Angiogenesis: 
Angiogenesis is only switched on under specific conditions. (Figure 1.4). 
Physiological angiogenesis is activated during embryogenesis and in the female 
reproductive system, for example. Pathological vascular remodelling is found in 
tumour growth, atherosclerosis and diabetes, as prime examples. There are 
thought to be major differences between the blood vessels associated with 
tumours and those associated with physiological angiogenesis with the former 
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being described as more leaky and less well organised compared to the normal 
vasculature (Liekens et al., 2001). 
1.3.4.1 Sprouting angiogenesis: 
There are three described mechanisms of angiogenic growth, the main difference 
being the mode of stimulation for the production of new vessels. The classical 
form of angiogenesis is sprouting angiogenesis, which occurs when a stimulus 
from the abluminal side of the vessel, for example muscle overload (extirpation), 
initiates the release  of cytokines and growth factors from skeletal muscle. 
Proteolytic degradation of the ECM occurs following an increase in the 
permeability or integrity of the basement membrane (BM), a barrier made of 
structural proteins that provide support to the capillaries. Disruption of the BM 
allows the growth and migration of the EC into new vessel architecture (Haas et 
al., 2000). The BM breakdown is mediated by matrix mettaloproteinases 
(MMPs) activated by vascular endothelial growth factor VEGF (Folkman, 1971). 
1.3.4.2 Splitting angiogenesis: 
Splitting angiogenesis can also occur due to a luminal-triggered stimulus, for 
example, an increase in blood flow, increasing shear stress and up regulated nitric 
oxide (NO) production. There are two forms of splitting angiogenesis: 
intussusception occurs when a single capillary splits into two capillaries from 
within by the formation of a longitudinal divide on the luminal side of the 
capillary (Prior et al., 2004), and involves abluminal activation of mural cells for 
example fibroblasts. The other form of splitting angiogenesis occurs whereby 
endothelial cells, as opposed to interstitial cells, send filopodial processes into 
the capillary lumen, which then join to form a separate branch, and this 
subsequently propogates down the capillary (Zhou et al., 1998). The main 
difference between the described mechanisms is that sprouting angiogenesis 
requires BM and extracellular matrix degradation, allowing migration and 
proliferation of ECs, and thus the development of the sprouting tube. Work by 
Egginton et al., (2001) supports the notion that BM degradation is not a pre- 
requisite for splitting capillary growth. 
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Figure 1 .4 Schematic outlines of angiogenesis by two different mechanisms. 
Intussusception and sprouting. (Jain, 2003) 
 
 
 
1.4 Mechanisms of blood vessel growth: 
The sprouting growth of new capillaries is initiated via degradation of the BM. 
The increased vascular permeability due to a combination of VEGF and the 
MMPs enables extravasation of plasma proteins that lay down a provisional 
scaffold for migrating cells (Carmeliet, 2003). This also results in the release of 
other growth factors involved in stimulating angiogenesis and up-regulating 
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VEGF mRNA expression, including insulin-like growth factor-1 (IGF-1), 
transforming growth factor Β (TGF-Β), platelet-derived- growth-factor (PDGF) 
and basic fibroblast growth factor (bFGF). ECs and vascular smooth muscle, 
initiating the establishment of paracrine and autocrine loops for EC activation 
and proliferation (Dunn et al., 2000). The formation of properly patterned and 
structurally stable microvascular networks requires the coordinated recruitment 
of pericytes to microvessels (Ponce and Price, 2003) and it has been suggested 
that pericytes lead capillary sprouts into tissues (Figure 1.5). 
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Figure 1 .5 Mechanisms of blood vessel growth 
BM degradation, EC migration, differentiation and reformation into tubes that form new capillaries 
(Taken from Collinson and Donnelly, 2004). 
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Table 1 .1 Summary of the molecular basis underlying new blood vessel 
growth (Receptors are indicated in brackets) (Christopher and Peter, 2003). 
 
Steps in angiogenesis Stimulatory factors Inhibitory factors 
Vasodilatation Nitric oxide synthesis  
1.4.1 
Increased vascular 
permeability 
VEGF 
(Flt-1, Kdr) 
Ang-1 (Tie-2) 
Extravasation of plasma 
proteins 
VEGF Ang-1 (Tie-2) 
Endothelial sprouting Ang-2 
Tie 2 
VEGF (Flk-1) 
1.4.2 
Degradation of 
extracellular matrix 
MMPs  &  TIMPs  (tissue 
inhibitors) Collagen 
prolyl-4-hydroxylase 
PAI-1 
Liberation of growth 
factors 
uPA receptor Thrombospondin-1 
PAI-1 
Endothelial cell 
proliferation & migration 
VEGF, Ang 1&2, FGFs, 
PDGF 
1.4.3 
Pericyte and smooth 
muscle recruitment 
PDGF 1.4.4 
Endothelial  assembly  and 
lumen acquisition 
VEGF, Ang-1 (Tie-2) 
Integrins 
Thrombospondin 
Stablilisation of nascent 
vessels 
PAI-1 1.4.5 
Maintenance of 
differentiation and 
remodelling 
Ang-1 (Tie-2) Ang-2 (Tie-2) 
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A number of factors contribute to the dissociation and movement of ECs through 
the matrix. The Tie-2 receptor is a signalling system involved in vessel 
maintenance, growth and stabilisation. Tie-2 is a membrane bound receptor tyrosine 
kinase that binds angiopoietins 1 and 2 (Ang1 and Ang2). To enable ECs to 
dissociate from each other, competitive inhibition of Tie-2 by Ang2 occurs, 
initiating the  loosening of matrix contacts and  support cell interactions, thus 
allowing access for the above-mentioned growth factors and other angiogenic 
inducers (Douglas, 1997). Redistribution of intercellular adhesion molecules 
platelet endothelial cell adhesion molecule (PECAM-1) and vascular endothelial 
VE-cadherin also contributes to the dissociation of ECs from their neighbouring 
cells, causing them to undertake mitosis, and, due to loss of contact inhibition, start 
migrating throughout the matrix. Proteinases also expose new epitopes in ECM 
proteins that induce migration, along with a matrix of fibronectin and fibrin, and 
another group of adhesion molecules called the integrins αvβ3 and αvβ5 (Eliceiri 
and Cheresh, 1999). These all aid in migration the ECs towards their objective sites 
(Carmeliet, 2003). During the migration of the ECs to distant sites, there is a 
complex interaction and redundancy between VEGF, bFGF and angiopoietins. Via 
phosphorylation of Tie2, Ang1 stimulates interactions between pericytes and ECs 
and induces sprouting of new capillaries (Conway et al., 2001), solidifying and 
stabilising a newly formed blood vessel. Initial breakages in the BM are repaired 
rapidly as an intact BM was initiated around various EC sprouts (Egginton et al., 
2001). 
 
1.5 Formation of blood vessels 
The formation of new vessels occurs mainly throughout two processes, 
vasculogenesis and angiogenesis (Conway et al., 2001). Vasculogenesis occurs 
during early embryonic development starting with the formation of 
hamangioblasts from the mesodermal germ layer (Risau and Flamme, 1995). 
Blood vessels are formed within an aggregation of multipotent cells derived from 
the mesoderm called blood islands. These de novo blood vessels develop inside 
the embryo providing support to the heart, the first primitive vascular plexus and 
in its surrounding membranes as the yolk sac circulation. This primitive network 
originate from vasculogenesis is formed by angiogenesis, which is a strongly 
regulated process of amplification of pre-existing vessels by sprouting, bridging, 
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as well as branching. This angiogenic method occurs in the development of adult 
tissues (i.e. osteogenesis, menstrual cycle) but moreover in patho-physiological 
situations such as wound healing along with pathological situations such as 
atherosclerosis and tumour growth and spread through metastasis (Ozerdem et 
al., 2001;McDonald and Choyke, 2003;Bergers and Song, 2005). Figure 1.6. 
 
 
Figure 1 .6 Outline of the vasculogenic process 
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1.6 Stabilisation of general networks. 
Blood vessel development is dependent on the activity of VEGF on its receptor 
tyrosine kinases, VEGFR-1 / Flt-1 and VEGFR-2 / vascular endothelial cells 
growth factor receptor 2 antibody (Flk-1), in endothelial cells (Fong et al., 1995; 
Shalaby et al., 1995; Carmeliet et al., 1996; Ferrara et al., 1996). Deletion 
VEGFR-2 cause an arrest in vasculogenesis during the angioblasts differentiation 
state (Shalaby et al.,1995), while deletion of VEGFR-1 causes embryonic 
lethality from edema following initial formation of definitive blood vessels (Fong 
et al., 1995). 
The receptor tyrosine kinases (Tie1 and Tie2) are expressed in embryonic 
angioblasts, vascular endothelium and  endocardium, and in adults. Tie1 is 
expressed in endocardium and lung blood vessels and Tie2 is shown in 
endocardium and general endothelium (Dumont et al., 1994; Korhonen et al., 
1994). The signalling through angiopoiens and Tie1 and Tie2 essential in the 
stabilisation of immature vascular networks. The importance of the Tie receptor 
system was outlined with genetic studies carried out with Tie1 deficient mice 
where vascular integrity is compromised leading to embryonic lethality. Tie2 
deficient mice showed vascular network formation lacking normal sprouting, 
branching, and remodelling of vessels also leading to embryonic lethality. Ang- 
1 in pericytes is involved in vessel creation by promoting endothelial cells to 
generate the bordering mesenchyme into pericytes or smooth muscular tissue 
cells (Suri et al., 1996). Conversely, mice over-expressing Ang-1 exhibit 
increased vascularisation (Suri et al., 1998). In the absence of VEGF, Ang-2 acts 
as a antagonist of Ang-1 and destabilises blood vessels, leading to vessels 
regression, whereas in the existence of VEGF, Ang-2 facilitates growth and 
branching by blocking Ang-1 signalling (Maisonpierre et al., 1997). 
 
 
1.7 Remodelling of general networks by angiogenesis. 
New vessels divisions could grow to a collection of cells in the bordering 
mesenchyme that generates the angiogenic stimulation. Already existing vessels 
could split in to specific little daughter vessels by the formation of 
transendothelial    cell    bridges    or    the    vessels    could    branch    through 
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intussusceptions, based after installation of interstitial cells pillars in to the lumen 
of pre-existing vessels (Figure 1.7) (Djonov et al., 2000) 
 
 
 
 
Figure 1 .7 Schematic layouts standing for the progress of the angiogenic 
response various systems where angiogenesis takes place in the establishing 
vasculature. (Adapted from Patterson et al., 2000). 
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Angiogenesis features have already been very well characterised, by real-time 
image resolution in the zebra fish (Lawson and Weinstein, 2002) and by studying 
the establishing retina (Uemura et al., 2006). In growing angiogenesis, ECs that 
are included in the vessel wall surface become loosened and begin to move after 
stimulation by development signals, controlled by VEGF (Habeck et al., 2002; 
Leung et al., 1989; Tischer et al., 1989). Intersegment vessels development in 
zebra fish, comprises intracellular vacuoles, which link to vacuoles of nearby 
ECs to develop a continual lumen (Kamei et al., 2006) (Figure 1.8). 
 
 
 
 
 
Figure 1 .8 Vacuoles compartments and lumen 
Start with pinocytic vesicle, intracellular vesicle formation, intracellular vesicle 
fusion, and finally intercellular merging of vacuoles compartments and lumen 
formation (Kamei et al., 2006). 
 
 
As the tip cell encounters a new sprout or vessel it bunds and circulation is 
created, for example in the retina, protruding endothelial tip cells generate the 
majority of PDGF, which in turn entices pericytes by activation of PDGF 
receptor (Gerhardt et al., 2003; Hammes et al., 2002). Endothelial cell motion 
within the ECM is a firmly controlled procedure that requires the polarisation of 
the molecular components matrix decline to the accelerate side of the relocating 
cell. The pattern of retinal blood vessels has been revealed to depend on the 
equilibrium between two features of extracellular VEGF-A. The slope and the 
stimulation, which is essential for the appropriate support of filopodial expansion 
from specialized endothelial cells at the tips of the vascular sprouts, and 
endothelial cell development takes place in the grow stalks in response to 
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VEGFA stimulation. VEGFR-1 was revealed to promote grow formation by 
detrimentally regulating the number of VEGF-A signalling to endothelial cells 
using soluble VEGFR-1 as the primary mediator of the effect (Kearney et al., 
2004). Hence, the local presence of VEGF signal is essential to effectively 
promote morphogenesis and growth (Gerhardt et al., 2003; Kearney et al., 2004). 
 
 
1.8 Angiogenic stimuli 
Many factors have the effect of the initiation of angiogenesis, there is a very fine 
balance between pro- and anti-angiogenic factors, and disruption of this balance 
provides the driving force for the development of new vessels for example 
metabolic stress, cytokines, hypoxia, pH, and hypoxlyceamia. Up-regulation of 
angiogenic inhibitors and/or down-regulation of angiogenic activators may be 
linked to reduced neovascularization capacity (Figure 1.9). 
 
 
1.9 The key process of angiogenesis 
Endothelial cells that form the inner blood vessel surfaces differentiate in 
response to angiogenic signalling and also secrete matrix metalloprotease 
(MMP) which enable migration toward the source of the angiogenic stimuli 
(Folkman, 1985). The EC processes inside the sprout become vacuolated and 
subsequently the vacuole will become the extracellular tube, encased by a thin 
wall membrane on the EC cytoplasm (Folkman, 1985). Once the sprout forms 
and elongates, EC proliferation occurs, to complete the elongating vessel. The 
EC processes within the sprout become vacuolated and later the vacuole becomes 
an extracellular tube, surrounded by thin wall of the EC cytoplasm (Folkman, 
1985). The lumen is formed, either through the tubular wall of one cell 
connecting to the tubular wall of another cell, or the EC within the sprout changes 
shape, becoming curved to form a lumen (Folkman, 1985). 
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Angiogenic balance 
 
 
 
 
Activator 
E.g.VEGF/bFGF 
 
Inhibitors 
E.g. Endostatin 
 
 
 
 
 
 
 
  
 
 
Figure 1 .9 The angiogenic balance between angiogenic activators and 
 
angiogenic inhibitors regulate vascular homeostasis. Angiogenesis under 
physiological and pathological conditions is associated with up-regulation of 
angiogenic factors and/or down-regulation of angiogenic inhibitors. 
Off 
On 
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Once the growing sprouts are formed by leading migrating cells, they converge 
and anastomose to form a capillary loop (Folkman, 1985), where in blood, flow 
may initiate and subsequently the basement membrane is synthesised by ECs 
(Figure 1.10). 
 
Figure 1.10 Key steps in angiogenesis 
The angiogenesis cascade occurs as an orderly series of events. Angiogenic 
endothelial cells must proliferate, avoid apoptosis, migrate, and produce 
molecules able to degrade the extracellular matrix and, finally, differentiates into 
new vascular tubes. 
http://www.angio.org/understanding/understanding.html. 
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1.10 Notch signaling 
The Notch signaling pathway is an evolutionarily conserved, intercellular 
signaling mechanism essential for proper embryonic development in organisms 
as diverse as insects, nematodes, echinoderms and mammals (Gridley, 2007). 
Notch receptors initiate a highly conserved signaling pathway that influences cell 
fate decisions within multiple tissues and regulate the ability of precursor cells 
to respond to other developmental signals. In mammals, Notch signaling 
regulates neurogenesis, myogenesis, vasculogenesis, hematopoiesis, skin 
development, and other aspects of organogenesis. In addition, Notch signaling is 
involved in other critical cellular processes such as apoptosis, differentiation, 
migration, and proliferation. Notch proteins are cell surface transmembrane- 
spanning receptors, which mediate critically important cellular functions through 
direct cell-cell contact. Interaction between Notch and its proposed ligands 
initiates a signaling cascade that governs cell fate decisions such as 
differentiation, proliferation, and apoptosis in numerous tissue types. (Mumm et 
al., 2000; Radtke et al., 2002). Expression analysis of the Notch signalling 
pathway in human cancer samples provides encouraging evidence of a role for 
Notch signalling in human disease. Expression of the Notch ligand Delta-like-4 
(DLL-4) is up regulated in human breast cancer but not found in normal breast 
tissue (Li et al., 2009). 
 
 
1.11 Angiogenesis in Disease and treatment 
The fundamental role of angiogenesis is in embryogenesis/vasculogenesis. 
Number diseases are connected with dysfunctional capillary development, 
including diabetic retinopathy, rheumatoid arthritis, skin psoriasis, myocardial 
anaemia, and coronary artery disease (Folkman et al., 1995; Isner, 1999). The 
formation of new blood vessels is vital for the development of the majority of 
expanding tumours. Tumor angiogenesis refers to the ability of a tumor to 
stimulate new blood vessel formation (Hicklin and Ellis, 2005). This critical step 
in development enables tumor expansion, local invasion, and dissemination 
through; Delivery of oxygen, nutrients, and survival factors, production of 
growth factors that benefit tumor cells, and formation of a route for tumor cell 
egress. As a result, each part of the angiogenesis process is a potential target for 
new cancer treatments. (Hanahan and Weinberg, 2011). 
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The tumour is dependent on diffusion for the exchanges of four medicines that 
target VEGF have been authorized by the government medicine management in 
the USA to be utilized scientifically. 
 
1. Bevacizumab (Avastin™; a VEGF neutralising antibody) is a monoclonal 
VEGFA-antibody. It has been approved mainly to treat of metastatic colon 
cancer, but is broadly used off-label for ocular angiogenesis and has shown 
promising effects on corneal angiogenesis (Dastjerdi et al., 2009; Koening et al., 
2009; Zaki and Farid, 2010). 
2. Pegaptanib, (Macugen™; an oligonucleotide that expecteds VEGF) is the 
common therapy for most age-related macular deterioration (AMD), by 
intravitreal injection (Gragoudas et al., 2004). 
3. Ranibizumab (Lucentis™; an antibody that detects all VEGF isoforms) for 
treating of damp AMD. (Jain et al., 2006). 
4. Aflibercept (VEGFTrap) is a soluble decoy receptor, which binds to all 
isoforms of VEGFA and placental growth factor (PlGF). A recent study by 
Oliveira showed a promising effect of VEGFTrap on FGF2-induced corneal 
neovascularization in a murine model (Oliveira et al., 2010). 
Several particles having anti-angiogenic properties detected in human cells. They 
are signified endogenous obstacle, most of them usually are proteolytic pieces of 
ECM proteins or plasma proteins, shown by endostatin (a piece of collagen 
XVIII), endorepellin (the C-terminal component of perlecan), angiostatin (a 
piece of plasminogen) and tumstatin (a piece of the IV alpha3 chain) (Bix and 
Iozzo, 2005). 
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1.12 Blood vessels cells 
 
1.12.1 Endothelial cells 
In vivo and in vitro, endothelial cells is just one cell layer often identified as 
"cobblestone" in appearance, that could be a criterion for identification, although 
it is not a solid identification marker (Haudenschild., 1984;Manconi et al., 
2000).(Figure 1.11). Endothelial cells are the only cells in the body that are 
exposed to a moving fluid under pressure (blood) and a solid substrate (blood 
vessel wall) (Haudenschild., 1984; Manconi et al., 2000). Within regular 
circumstances, endothelial tissues keep a quantity epithelioid geometry that 
really helps to prevent unstable blood circulation within blood vessels and 
produces an antithrombotic area (Cines et al., 1998). 
 
 
and lean on a cellar membrane layer. 
Figure 1.11 Schematic cross section of a capillary. ECs are bounded by pericytes 
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The endothelial cell consists of a variety of frameworks, composed of a round 
ellipsoid. An organelle that is restricted to endothelial cells is the Weibel-Palade 
body (Weibel and Palade, 1964), which has been identified in human, pig, rat, 
and mouse endothelium (Jaffe, 1987). Weibel-Palade bodies are therefore 
markers for endothelial cells (McNiff et al., 1983; Wanger et al., 1982), however 
usually are not present in all endothelial tissues. (Johnson et al., 2002). 
There are three considerations widely used to positively identify cultured 
endothelial cells: 1) contact inhibition resulting in a monolayer of endothelial 
cells; 2) immunocytochemical staining with vWF (elements VIII associated 
antibody); and 3) particular uptake of acetylated low-density lipoprotein. Other 
qualities associated with cultured endothelial cells include CD31+ and CD34+ 
markers, angiotensin changing enzyme (ACE), endothelial nitric oxide synthase 
(eNOS) secretion, prostacyclin secretion, cobblestone appearance, and "tube" 
development in Matrigel (a synthetic extracellular area including laminin and 
collagen to which endothelial cells could stick) (Manconi et al., 2000; Scott et 
al., 1993). Endothelial cells are associated with a number of physiological 
processes.These includ capillary obstacle feature and leaks in the structure, 
coagulation, fibrinolysis, blood circulation requirement, and angiogenesis 
(Ausprunk et al., 1977; Mombouli et al., 1999; Shimokawa et al., 1999; Taddei 
et al., 2000). The endothelium is first element to be facing to the blood and its 
numerous components, including hormones, development elements, different 
other elements secreted by cells throughout the body, and various other elements 
presented in to the blood (Mombouli et al., 1999). 
1.12.2 Endothelial cell differentiation 
In the embryo, endothelial cells arise from haemangioblast (Choi et al., 1998) 
present in different organs (Jiang et al., 2002) and in the adult, from endothelial 
parent cells, mesoangioblasts, multipotent mature parent cells or side population 
cells in the bone marrow (Reyes et al., 2002). Endothelial cells interact in 
between bordering endothelial cells, periendothelial cells/mural cells (such as 
smooth muscular tissue cells and pericytes) and cells inside the vessels lumen, 
and dynamically connect with these cells and their bordering extracellular 
matrix. 
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Endothelial cells can differentiate to either arterial or venous endothelial cells 
throughout embryonic development, neonatal retina and even in the heart of an 
adult (Stalmans et al., 2002; Visconti et al., 2002). Growth factor generated 
endothelial cells have the intrinsic capacity to develop a network of blood vessels 
(Flamme and Risau, 1992). Many of growth factors and developmental stimuli 
affect the phenotype of endothelial cell with the signalling of their receptors on 
the cell membrane consisting of VEGFs, ang-1 and ang-2, TGF- β1 and Ephrin 
B2. It is very clear that endothelial cells interact with various other endothelial 
cells and periendothelial cells/mural cells with adherent and void joints, whereas 
and with strict joints exist in brain and retinal blood vessels. VE-cadherin 
mediates the adherent endothelial-endothelial cell joints in blood vessels 
(Lampugnani et al., 1992) and mediates an endothelial cell survival path via its 
intracellular communications with β-catenin (Carmeliet et al., 1999). The 
communications and interactions between endothelial cells and the matrix 
bordering controlled by cell surface integrins. 
1.12.3 Mural cells (MCs) 
The main function of Peri-ECs, PCs and Vascular SMC (vSMCs), are to stabilise 
the blood vessels and give physiological support. Without the backing of 
periECs, vessels become leaky, hyper-dilated, dysfunctional and regressive 
(Benjamin et al., 1998; Bergers and Song, 2005). Mutal cells subdivided into 
vSMCs as well as PCs according to their density, morphology, location and the 
expression of specific protein markers. Human venous malformation 
characterised by a complete lack of vSMCs around certain veins, is mainly 
caused by mutations in the  tyrosine  kinase with immunoglobulin (Ig) and 
Epidermal growth factor (EGF) homology domains-2 (Tie-2) gene (Vikkula et 
al., 1996). In two independent families, the responsible mutation was found to 
activate the Tie-2 kinase. Both inactivation (mouse knockout) and constitutive 
activation of Tie-2 (human venous malformation) results in MCs loss (Hall, 
2006). The ligand/receptor pair plateletderived growth factor (PDGF) receptor-β 
(PDGFRβ) axis forms paracrine endothelium to MC signalling loop. The 
angiopoietins-Tie receptor axis represents generally a signalling loop of the 
opposite orientation from MCs to the endothelium (Armulik et al., 2005; Hall, 
2006). 
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1.12.4 Pericytes 
Pericytes (historically known as Rouget cells) and share a basal membrane with 
the endothelium. Pericytes are either singly connected with the EC tube or form 
a single, often discontinuous, cell layer around it. Pericytes morphology and the 
degree to which they cover the endothelium vary substantially between different 
tissues. In some tissues, PCs have acquired specialised functions, for example, 
mesangial cells in kidney glomeruli, as well as peri-sinusoidal fat storing cells 
(Ito-cells) in the liver (Hall, 2006). Usually, fully developed PCs form intimate, 
umbrella-like contacts with the ECs in capillaries, pre-capillary arterioles, 
collecting venules and post-capillary venules. ECs and PCs together synthesise 
and share a common basement membrane (Mandarino et al., 1993). Pericytes are 
embedded in the basement membrane and are immediately in contact with the 
ECs through peg-and-socket junctions that extend through a discontinuous 
basement membrane (Cuevas et al., 1984). These junctions consist of membrane 
evaginations, which are rich in tight and gap junctions. Pericytes-endothelial 
adhesion, recognition and signalling are maintained by neural (N)-cadherin 
adhesion junctions (Gerhardt et al., 2000) also with fibronectin-rich dense 
plaques (Courtoy and Boyles, 1983). Pericytes support vessel stability via 
physical and chemical signalling with the endothelium and can directly regulate 
EC-SMC communication (Armulik et al., 2005). Moreover, PCs have been 
suggested to play an essential role throughout angiogenesis, which are 
recognised at angiogenic sprouts (Morikawa et al., 2002) and are a source of 
VEGF-A(Darland et al., 2004). Pericytes also play a role in the regulation of 
capillary diameter and EC differentiation (Hellstrom et al., 2001). Endothelial 
cells and PCs share a common progenitor cell in the embryonic mesoderm, the 
VEGFR-2-positive angioblasts. This progenitor cell can differentiate into ECs 
upon stimulation by VEGF-A, and into PCs upon stimulation by platelet-derived 
growth factor-BB (PDGF-BB) (Yamashita et al., 2000).Pericyte contraction 
could control microvascular blood flow and permeability. At the blood brain 
barrier, several reports suggest that PCs are able to act as brain phagocytes and 
can be converting to tissue macrophages (Balabanov et al., 1996; Thomas, 1999). 
In an ovarian model of angiogenesis, pericytes were the first angiogenic cells to 
invade the normally avascular Graafian follicle and precede the sprouting 
vascular tip (Amselgruber et al., 1999). 
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1.12.5 Smooth muscle cells 
Vascular SMCs are present in arteries and veins and form multiple concentric 
layers (Hall, 2006). Here, they create many of the ECM components include 
collagens, which provide solidity, and elastin, which confers properties of elastic 
recoil. They also produce proteoglycans, which regulate permeability, 
viscoelasticity, cell adhesion and migration (Wight, 1989), and regulating short- 
term vascular tone myogenically. SMCs play a part in vascular remodelling by 
synthesising and secreting matrix-degradative enzymes that include both 
plasminogen-dependent as well as plasminogen-independent proteinases (Galis 
et al., 1994), growth factors and other cytokines. 
 
 
1.13 Extracellular matrix 
The extracellular matrix (ECM) is non-cellular meshwork bordering nearly the 
most of cells in multicellular microorganisms. The ECM is an architectural 
structure and provides cells with positional and environmental information, 
however additionally provides specialised components such as cartilage material, 
ligaments, bone marrows (BMs), bone and teeth. The macromolecules of the 
ECM usually excreted by neighbouring cells such as fibroblasts. The most rich 
proteins of the ECM are collagens specified as structurally connected ECM 
proteins offering mechanical constancy for tissue. A quality of all collagens is 
the presence of a minimum of one triple-helical domain name consisting of three 
polypeptides, called α-chains, comprised of a duplicated (Gly-X-Y) amino acid 
series with glycine (Gly) as every thirth amino acid deposit, and regularly 
hydroxyl proline and hydroxyl lysine in the X and Y placements (Figure 1.12). 
This enables α- chains to develop stable triple-helical collagen particles. The 
triple helix is stiff and in many collagens, it is disrupted by globular particles that 
make the particle more flexible and functional in a range of macromolecular 
organic tasks (Bateman et al., 1996; Prockop and Kivirikko, 1995; Myllyharju 
and Kivirikko 2001). 
 
Some collagen types are formed by three identical α-chains, yet some (kinds I, 
IV, V, VI, VIII, IX and XI) consist of even more, and are coded by different 
genes (Prockop and Kivirikko, 1995; Bateman et al., 1996; Myllyharju and 
Kivirikko, 
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2001). The collagens are divided into subgroups based on their structural features, 
as shown in figure 1.12: fibril-forming collagens (types I-III, V and XI, Figure. 1. 
12, A), fibril associated collagens with interrupted triple helices, i.e. the FACIT 
collagens (types IX, XII, XIV, XVI and XIX, Fig. 1.12, B), hexagonal 
networkforming collagens (types VIII and X, Fig. 1.12, C), basement membrane 
collagen (type-IV, Fig. 1.12, D), beaded filament-forming collagen (type VI, Fig. 
1.12, E), collagen forming anchoring fibrils of basement membranes (type VII, Fig. 
1.12, F), collagens with transmembrane domains (types XIII and XVII, Fig. 1.12, 
G), and the family of collagen types XV and XVIII, Figure. 1. 12 (Prockop and 
Kivirikko 1995; Myllyharju and Kivirikko, 2001). 
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Figure  1  .12  The  members  of  the  collagen  family  of  proteins  and  their 
molecular assemblies. 
The rods show triple helical collagenous domains in each molecule, solid circles 
N and C terminal non-collagenous domains and open circles interruptions in the 
collagen triple helix. GAG, glycosaminoglycan; PM, plasma membrane. 
(Myllyharju and Kivirikko, 2001). 
1.14 Basement membrane layers 
Basement membranes (BM) or know as basal lamina are thick sheets of 
extracellular matrices that work as architectural barriers separating epithelial and 
endothelial cells as well as outer nerve axons, fat deposits, cells and muscular 
tissues, from the underlying cells stroma. BMs offer structural support, separate 
tissues into compartments, and regulate cell behaviour (Timpl and Brown, 1994). 
All cell types produce components of BMs, which include type-IV collagen, 
laminin, heparan sulfate proteoglycans and nidogen/entactin. Minor components 
include agrin, SPARC, fibulins, type XV collagen and type XVIII collagen. 
Fibronectin  is  present  in  fetal  BMs  (Erickson  and  Couchman,  2000).  The 
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molecular composition of the BM varies among different tissues. The differences 
are supposed to funding tissue specificity, which is important for defining the 
specialised functions of epithelial and endothelial cells in different organs. The 
collagen network/scaffold but another scaffold the laminin scaffold forms 
independently interacting with the collagen scaffold through nidogen (Aumailley 
et al., 1989; Timpl and Brown, 1994), makes the basic structure of the basement 
membrane. Additional adhesive glycoproteins, such as tenascin, as well as 
proteoglycans, adhere to the scaffold and interact with cells in or adjacent to the 
matrix. Microcellular proteins offer indispens able role in modulating cell-matrix 
connections. Basement membranes and other ECMs undergo regular dynamic 
changes in response to a huge number of cellular stimuli, and the altering of the 
vascular basement membrane is a vital aspect of angiogenesis. After endothelial 
cells and mural cells migrate to form new blood vessels, the ECM network is not 
only degraded, but its structure is also reformed. New cryptic epitopes of the 
ECM proteins show to facilitate the migration of endothelial and mural cells. The 
basement membrane considered as the main source of angiogenic growth factors 
such as FGF-2, VEGF, PDGF-B and TGF-β, also angiogenesis inhibitors, such 
as thrombospondin-1 (TSP-1), canstatin, tumstatin, platelet factor-4 and 
endostatin. The cells responsbale for production of proteinases are essential for 
the liberation of these factors from the matrix (Egeblad and Werb, 2002; Kalluri, 
2003). ECMbound VEGF can also stimulate endothelial cell adhesion, migration, 
and survival through integrin ligation. It is very important that the degradation 
and remodelling of the ECM should occur in a balanced manner, thus, it is a 
highly regulated process. Deficient breakdown of the ECM will discontinue 
endothelial and mural cells from leaving their original position, in the opposite 
site; too much breakdown of the ECM removes critical support and guidance 
signs for migrating endothelial and mural cells inhibiting the formation of new 
blood vessels. When endothelial cells and mural cells move to develop brand- 
new blood vessels, the ECM network is not just abject, yet its make-up is 
additionally changed and brand-new puzzling epitopes of the ECM proteins are 
subjected to assist in the migration of endothelial and mural cells. Growth factors 
stimulation leads to the secretion of ECM absorbing enzymes from endothelial 
cells, and in some times from the bordering stromal cells and growth cells 
(Kalluri, 2003). 
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1.15 Degradation of cellar membrane layers 
Proteolyic decline of sub-endothelial BM is crucial for endothelial cell migration 
into the underlying ECM. Furthermore, proteases stimulate endothelial cell 
migration by activation of pro-angiogenic growth factors and with their release 
from the ECM. Proteolytic cleavage of the ECM unmasks cryptic adhesion sites 
and liberates bioactive destruction merchandise (Pepper et al., 1996; Werb et al., 
1999; Kalluri, 2003). Physiological angiogenesis require a balance in proteolysis. 
Extreme proteolysis brings about inhibition of angiogenesis because of 
exploitation of the matrix scaffold that is necessary for endothelial cellular 
migration and tubular constructions and formation of endogenous angiogenetic 
inhibitors. Insufficient proteolysis, conversely, prevents migration and tubular 
morphogenesis because of restricted destruction of ECM and generates propose 
proangiogenic progress variables (Bergers and Benjamin, 2003). One of the most 
important protease systems associated with angiogenesis are the plasminogen 
activators as well as the matrix metalloproteinases. Urokinase-type plasminogen 
activator (uPA), Urokinase-type plasminogen activator receptor (uPAR), as well 
as plasminogen activator inhibitor (PAI-1) are not detectable in the quiescent 
endothelium, but can be detected in the course of effective angiogenesis 
(Bacharach et al., 1992; Larsson et al., 1984). In vitro, the particular expression 
of these proteins can be controlled by angiogenic expansion components for 
instance FGF-2, as well as VEGF (Mignatti and Rifkin, 1994). 
Urokinase-type plasminogen activator has the ability to degrade fibrin, lamanin, 
fibronectin, and proteoglycans although native collagens are generally resistant to 
uPA proteolysis. In addition, uPAR as well as PAI-1 are generally upregulated by 
hypoxia, a known inducer of angiogenesis (Kroon et al., 2000; Uchiyama et al., 
2000). 
Matrix mettaloproteinases undoubtedly are a large class of MMPs that break 
down the various protein components of the ECM and BM. Matrix 
mettaloproteinases participate are implicated in wound healing, angiogenesis, 
embryogenesis and within pathological conditions including tumour invasion 
and metastasis. MMPs (Table 1, 2) are divided into four groups; collagenases, 
gelatinases, stromeolysins and matrilysins, according to their ECM substrate 
specificity however now are divided into unique structural groups (Egeblad and 
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Werb, 2002; Stamenkovic, 2003). Matrix mettaloproteinases activity controlled 
by the activation in transcription, proteolytic activation from the zymogen; they 
contain a pro-peptide, whose cleavage is required for MMP activation, and by 
the inhibitory activity of various endogenous MMP inhibitors (Egeblad and 
Werb, 2002; Stamenkovic, 2003). Many MMPs are stimulated by the proteolytic 
activity of other MMPs and range of serine proteases. α2- macroglobulin is the 
main MMP inhibitor inside tissues fluids leading to this clearance of MMP-α2- 
macroglobulin by scavenger receptors (Sottrup-Jensen and Birkedal-Hansen, 
1989). Since cells have receptors, such as integrins for structural ECM 
components, degradation of ECM components affects cell signalling through 
most of these receptors. Cleavage of insulin-like growth factor-binding protein 
and perlecan releases insulin-like growth factor. 
Another example is the cleavage of SPARC, a matricellular protein of the ECM, 
by MMP-3. Produced peptides can regulate EC proliferation and/or migration 
and angiogenesis (Sage et al., 2003). Moreover, the proteolytic degradation of 
ECM molecules, recent data has extended the substrate specificity of MMPs to 
include enzyme inhibitors, cell-bound precursors of cytokines and active 
cytokines, cell adhesion molecules and growth factor receptors (Monika, 2010). 
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Table 1 .2 Members of the MMP family. 
 
 
Subgroup 
 
MMP 
 
Name 
 
Substrate 
 
1. Collagenases 
 
MMP 1 
 
Collagenase-1 
 
Collagen I, II, III, VII, VIII, 
X, gelatin 
  
MMP 8 
 
Collagenase-2 
 
Collagen I, II, III, VII, VIII, 
X, aggrecan, gelatin 
  
MMP 13 
 
Collagenase-3 
 
Collagen I, II, III, IV, IX, X, 
XIV, gelatin 
 
2. Gelatinases 
 
MMP 2 
 
Gelatinase A 
 
Gelatin, Col I, II, III, IV, VII, 
X 
  
MMP 9 
 
Gelatinase B 
 
Gelatin, Col IV, V 
 
 
 
 
1.16 Integrins and cell-matrix communications 
 
Integrins are found in all multicellular animals, but not in prokaryotes, plants, or 
fungi. The number of different integrin α and β subunits varies in different species. 
Mammals have 24 different heterodimeric integrins composed of eight different β 
subunits and eighteen different α subunits. Though some subunits appear only in a 
single heterodimer, 12 integrins contain a β1 subunit and five have α V. The 
occurrence of integrins in all multicellular animals suggests that integrins are 
essential for the development of multicellular organs and tissues (Hynes, 2002; Kim 
et al., 2011). 
Integrins are bidirectionally signalling transmembrane receptors composed of 
two different subunits, α and β (Hynes, 1992). They integrate the intracellular 
cytoskeleton, the contractile actin microfilament system and signalling pathways 
to the network of extracellular matrix (ECM) proteins (Brakebusch and Fässler, 
2003; Humphries et al., 2004; Kinashi, 2005). In vertebrates, specific integrins 
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are also involved in cell-cell interactions with other transmembrane proteins of 
the nearby cells. To facilitate proper function it is important that integrins 
become active and thus capable of binding their ECM ligands only under specific 
conditions (Hynes, 2002; Kim and Ginsberg, 2011). Bidirectional signalling and 
the regulation of integrin activity are mediated via large conformational changes 
(Hynes, 2004; Mould and Humphries, 2004; Arnaout et al., 2005; Gahmberg et 
al., 2009; Shattil et al., 2010; Springer and Dustin, 2012) (Figure 1.13). 
Amongst others, integrins, cadherins, selectins, syndecans and the 
immunoglobulin superfamily-related cell adhesion molecules (IgCAMs) are 
suggested as a factor in these situations (Juliano, 2002). Integrins form important 
family of adhesion molecules of which the main receptors for ECM proteins for 
example fibronectin, vitronectin, collagen, or even Laminin (Hynes, 1992). 
These integrin molecules integrate the intracellular cytoskeleton with the ECM- 
rich extracellular environment by binding to intracellular protein complexes 
(Critchley, 2000). Signalling molecules, initialized in an adhesion dependent 
fashion, also recruited into most of these complexes. As a result, ECM proteins, 
integrins, cytoskeletal proteins along with signalling molecules make into 
aggregates either side of the cellular membrane. Integrins connect to cell surface 
receptors, for example, the intracellular adhesion molecule-1 (ICAM-1), the 
vascular cell adhesion molecule-1 (VCAM-1), some other growth factor 
receptors such as FGF-2R (Meredith et al., 1996) and also bind to co-receptors 
present on other cells, bacterial polysaccharides, or viral coat proteins (Danen 
and Sonnenberg,  2003). Integrins perform diverse cellular functions  which 
includes cell adhesion, migration (Hynes, 1992), design, polarity (Schwartz and 
Ginsberg, 2002), spreading (Lauffenburger and Horwitz, 1996), apoptosis 
(Assoian and Marcantonio, 1997), survival (Schaller, 2001), angiogenesis 
(Luscinskas and Lawler, 1994), cell differentiation (Hynes, 1992), homeostasis 
connected with multicellular microorganisms (Schwartz et al., 1995) 
organogenesis. 
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Figure 1.13 Integrin signalling. αβ subunits have head region and leg region α 
subunit domain head region include; α domain, propeller domain, and thigh domain, 
leg reigion include: calf1, calf2, trns-membrane and cytoplasmic domain. β sub unit 
head region include; βI domain, Hybrid domain, and PSI domain, leg region include 
FGFI receptor, β-tail domain, trans-membrane domain, and cytoblasmic domain. 
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Integrins are not just involved with typical cellular processes but also 
pathological disorders such as atherosclerosis, tumorigenesis, metastasis and a 
number of inflammatory disorders (Schwartz et al., 1995; Simon et al., 1997). 
Integrin cues can be divided into (A) inside-out and (B) outside-in signalling 
pathways. Based on recent studies, an emerging class of integrin signals can be 
considered eliciting from (C) intracellularly active integrins that localized to 
endosome (Luo et al., 2007). 
Data around the functions of integrins, specificity in cell development has been 
obtained from integrin-deficient mice. The loss of any kind of integrin, α or, β, 
leads to severe abnormalities, including lethality in embryonic stage or soon after 
birth. Particularly, the β1 subunit could bind to one of many distinct α subunits, 
lack of the β1 integrin subunit ends up with embryonic lethality (Ratnikov I, et 
al. 2005) 
Structurally, integrins are usually glycosylated, heterodimeric, transmembrane 
receptors including non-covalently associated α (120 kDa to 180 kDa) and β 
subunits (90 to 110 kDa) (Giancotti and Ruoslahti, 1999; Hynes et al., 1987). 
Nearly 24 different integrins have been reported to be expressed as combinations 
of the 18 α and 8 β subunits already described and splice variant isoforms of 
individual subunits produce additional complexity (Burkin and Kaufman, 1999; 
de Melker and Sonnenberg, 1999). Study survey of the human genome has 
identified 6 novel α and 1 novel β subunit, however, their cellular expression has 
not been defined yet (Venter et al., 2001). Every single subunit consist of a large 
extracellular domain (700 to 1100 aa), one particular transmembrane section 
along with a short intracellular cytoplasmic tail (ranging via 20 to 60 aa) that 
interacts with various proteins essential for regulations connected with integrin 
affinity as well as cytoskel et al integrity (Aplin et al., 1998; Hynes, 1999). They 
were initially described as cell matrix adhesion molecules (Tamkun et al., 1986), 
but later it was found they are additionally crucial signal transducers (Clarkand 
Brugge, 1995; Giancotti and Ruoslahti, 1999). Characteristically, while specific 
ligands like ECM components bind to a particular integrin to form a cluster, the 
integrin induces a cascade of intracellular events termed outside in signalling. 
Reciprocally, signals from inside of the cell modulate the integrin-binding 
affinity to ligands, which convert the integrin from a low-affinity or resting state 
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to a high-affinity or primed (also known as activated) state (inside-out-signalling; 
Giancotti and Ruoslahti, 1999). Additionally, divalent cations such as Ca2+, 
Mg2+and Mn2+ modulate integrin-ligand binding; Ca2+ inhibits these interactions 
and stabilises a low-affinity conformation, while Mn2+ stabilises a high-affinity 
conformation (Mould et al., 1995). An additional essential feature can be that a 
single integrin binds to one or various ligands and that a single ligand interacts 
with various heterodimers of integrin subunits, one example is, that many of 
integrin could recognise a specific ECM component in the competing or 
cooperative manner alone and at the same time; one particular integrin can 
recognize various ECM components (Stupack and Cheresh, 2002). Various 
integrins strongly bind the tripeptide Arg-Gly-Asp (RGD) inside particular ECM 
proteins like vitronectin, fibronectin and other proteins. Moreover, RGD 
presenting receptor subfamilies, Laminin receptors, collagen receptors and a set 
of leukocyte particular integrins may also be present in vertebrates (Hynes, 2002) 
(Figure 1.14). 
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Figure 1 .14 The integrin receptor family. Integrins are made of α and β 
subunits. 18 α subunits and 8 β subunits associate together in different 
combinations resulting in at least 24 integrins. These can be subdivided into 
subfamilies based on evolutionary relationship, ligand specificity and restricted 
expression pattern such as β2 and β7, which are specifically expressed in white 
blood cells. Vertebrates have a set of collagen receptors with I/A domains (α1, 
α2, α10 and α11) and a pair of related integrins (α4β1, α9β1), which are restricted 
to chordates. Laminin receptors (purple) and RGD binding receptors (blue) are 
present throughout the metazoa. Asterisks (Adapted from Hynes, 2002) denoted 
splice variants in cytoplasmic domains. 
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1.17 Cytoskeletal proteins 
The internal framework of a cell composed of a network of protein filaments and 
extending throughout the cytosol. The cytoskeleton contains mainly of actin 
filaments and microtubules and plays vital role in cell movement, shape, growth, 
division, and differentiation, as well as in the movement of organelles within the 
cell. All eukaryotic cells have a cytoskeleton. 
1.17.1 Vinculin 
Vinculin is a 1066 amino acids cytoskeletal protein that has a molecular weight 
of 117-kDa, that is localized on the cytoplasmic face of integrin-mediated cell– 
extracellular matrix junctions (focal adhesions) and cadherin-mediated cell–cell 
junctions; all the evidence suggested that vinculin is required to maintain the 
integrity of adherens junctions. The interaction of vinculin with the LD1 and LD2 
motifs of paxillin regulate cell survival (Turner et al., 1999, Humphries et al., 
2007). It has been proposed that the tail domain of vinculin competes with FAK 
for paxillin binding and thereby promotes ERK signalling through FAK or 
paxillin to inhibit apoptosis (Subauste et al., 2004). 
1.17.2 Paxillin 
Paxillin a multi-domain 68-kD protein (Glenney and Zokas, 1989) is a 
cytoskeletal component that localizes to the focal adhesions at the ends of actin 
stress fibres in chicken embryo fibroblasts. Paxillin is phosphotyrosine- 
containing protein that may play a role in several signalling pathways (Schaller, 
2001). Paxillin binds to many proteins that are involved in changes the 
organization of the actin cytoskeleton, which are necessary for cell motility 
associated with embryonic development, wound repair and tumor metastasis 
(Legate et al., 2009). 
1.17.3 Talin 
Talin, a 270-kDa cytoskel et al protein is thought to be a key player in the 
formation of focal adhesions, implicated in integrin-mediated cellular 
interactions with the extracellular matrix.Talin is a ubiquitous cytosolic protein 
that is found in high concentrations in focal adhesions. It is capable of linking 
integrins to the actin cytoskeleton either directly or indirectly by interacting with 
vinculin and alpha-actin (Alan, 2006). 
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1.18 Collagen receptor integrins 
The collagen receptor integrins initiate several processes within normal and 
pathological states. Collagen receptor integrins are usually structurally different 
in comparison to the other ECM binding integrins. They have a particular 
‘inserted’ site as well as and I domain inside the β-propeller domain on the N- 
terminus as part of α subunit which usually mediates ligand binding. Belonging 
to this group is α1β1, α2β1, α10β1 and α11β1 (Briesewitz et al., 1993; Camper 
et al., 1998; Velling et al., 1996). On top of the αI domain is a cation-binding site 
(MIDAS) that is formed by three loops of the domain coordination a metal ion. 
MIDAS is the major ligand-binding site in integrins possessing a αI domain 
(Michishita et al., 1993). Also specific to collagen binding integrin αI domains 
is the existence of an additional α helix, the αC-helix located on the top face of 
the domain. It is responsible for developing a groove on the leading area of the 
domain name that increases communications with collagen (Emsley et al., 2000; 
Emsley et al., 2004). Collagen-integrin interactions include essential 
physiological functions such as, proliferation, migration, differentiation, ECM 
assembly,  angiogenesis,  and  pathological  ailments  such  as  thrombosis  and 
tumour metastasis (Hynes, 1992; Senger et al., 1997). Integrins α1β1, α2β1 show 
the broadest tissue expression during embryonic development (Gardner et al., 
1996). 
The α2β1 integrin is also expressed on endothelial cells and fibroblasts as well as 
epithelial cells (Camper et al., 2001). 
 
1.18.1 Modulation of integrin mission by conformational modification 
There is a necessity for integrin activation to occur under the best orders for 
physical response as well as a system in position for keeping them less active 
when  they  are  not  required.  This  sort  of  regulation  is  accomplished  by 
conformational adjustments that circulate with the domain from cytoplasmic 
components to extracellular ones (inside-out) or ligand binding can induce 
changes to the αI domain that cause the separation of transmembrane and 
cytoplasmic parts and initiate a signalling cascade inside the cells (outside-in). 
Two conformations of αI domain are now understood the shut or open kind that 
varies by the existence of the metalion (Lee et al., 1995). 
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1.18.2 Crosstalk in between integrin and growth factor receptors 
Integrins co-operate with several growth factor receptors, which include EGFR, 
PDGFR, and fibroblast increase component receptor (FGFR) and induce 
different cell signalling activities (Giancotti and Ruoslahti, 1999; Huynh-Do et 
al., 1999). 
For example, αvβ3 integrin clusters with PDGF receptor or insulin receptor and 
form complexes (Bartfeld et al., 1993; Schneller et al., 1997). 
These complexes, established upon the integrin clustering, lead to crosstalk 
between two different receptors (Miyamoto et al., 1996; Plopper et al., 1995). 
Due to the fact, several mechanisms between integrin and growth factor 
stimulation are identical; there is an opportunity for cross talk between these two 
pathways. One of the main converging levels with both of these pathways is 
usually focal adhesion kinase. While FAK phosphorylation stimulated by growth 
factors contributes to an increase in cell migration. FAK knockout cells do not 
migrate towards chemotactic response against PDGF that indicates FAK function 
is required and essential for PDGF stimulated migration (Sieg et al., 2000). This 
kind of impaired motility could be rescued through re-expressing FAK cells. 
Integrins promote signalling pathways such as MAP kinase pathway even in the 
absence of growth factor, the integrin binding to ECM protein trigger the MAP 
kinase pathway (Moro et al., 1998; Schlaepfer et al., 1994). Interestingly, growth 
factors do not stimulate those pathways in suspension cells underlying the 
importance of cell adherence to ECM proteins via integrins (Aplin and Juliano, 
1999; Aplin et al., 2001; Assoian and Schwartz, 2001; Howe et al., 2002; 
Schwartz and Assoian, 2001). 
It is an established fact that growth factors such as PDGF modulate the 
expression of a variety of proteinases including MMPs. Interruption of these 
kinds of signalling pathways by anti-PDGF prevent VSMC migration by 
controlling MMPs. These kinds of observations proposed that integrin initiated 
FAK signalling and growth factor cooperative signalling may have an important 
influence on cell migration (Howe et al., 2002). 
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1.19 Growth Factors 
 
1.19.1 Vascular endothelial growth factor 
VEGF-A is an essential regulator of physical angiogenesis and belongs to a gene 
family that includes placental growth factor (PIGF), VEGF-B, VEGF-C, VEGF- 
D and VEGF-E. At least six different VEGF-A isoforms have been identified 
through alternate splicing of exons including VEGF121, VEGF145, VEGF165, 
VEGF183, VEGF189 and VEGF206. VEGF121, VEGF165 and VEGF189 are 
the major isoforms detected in most cells whereas VEGF145 and VEGF206 are 
rare. VEGF expression is up regulated by hypoxia (Minchenko et al., 1994, and 
Ferrara N., et al., 2003), which increases hypoxia inducible factor-1 (HIF-1) 
(Jiang et al., 1996, and Brahimi-Horn et al., 2005) and induces the binding of 
HIF-1 to the hypoxia response element in the VEGF gene promoter region (Liu 
et al., 1995). Numerous growth factors and cytokines such as EGF, FGF-2, 
PDGF, TGF-α, TGF-β, FGF-4, keratinocyte growth factor (KGF/FGF-7), 
insulin-like growth factor 1(IGF-1), IL-1α, IL-1β, IL-6 also increase expression 
of VEGF mRNA or induce VEGF release (Brogi et al., 1994,and Nina, et al., 
2009 ). 
VEGF121, VEGF165 and VEGF189 are widely expressed, whereas VEGF145 
and VEGF206 are uncommon. VEGF binds to two receptor tyrosine kinase 
VEGFR-1 (Flt-1) and VEGFR-2 (Flk1/KDR). Both receptors have seven 
extracellular immunoglobulin (Ig)-like domains followed by a transmembrane 
region and a cytoplasmic tyrosine kinase domain (Ferrara, 2001; Petrova et al., 
1999). Growth factors including VEGF and FGF-2 increase VEGF receptor 
expression (Wilting et al., 1996; Shen et al., 1998, and Narita et al., 2009). As 
for other receptor tyrosine kinases (RTKs), ligand binding induces 
homodimerisation of VEGF receptors and phosphorylation of their intracellular 
domain. VEGFR-1 has a higher affinity for VEGF than VEGFR- 2. However, no 
apparent proliferation, migration or cytoskeletal effects mediated by VEGFR-1 
were observed in ECs. It has been suggested that VEGFR-1 may not function as 
a signalling receptor, but rather as a decoy receptor to negatively regulate VEGF 
activity on the endothelium by sequestering the ligand (Seetharam et al., 1995, 
and  Presta,  et  al.,  2005).  In  ECs,  VEGFR-1  is  involved  in  up-regulated 
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expression of tissue factor, urokinase-type plasminogen activator and 
plasminogen activator inhibitor 1 (Clauss et al., 1996). 
VEGFR-2 is phosphorylated more efficiently upon ligand binding and is thought 
to be the key receptor to transmit VEGF signalling. VEGF-dependent association 
and/or activation of a number of signalling proteins have been reported, including 
Grb2, Nck, PLCγ, Ras GAP, PI3 kinase, Src family tyrosine kinases, PKB/Akt, 
FAK, SHP1 and SHP2 (Matsumoto and Claosson-Welsh, 2001). Activation of 
different signalling pathways such as PI3 kinase/Akt, p38 mitogen-activated 
protein kinase or ERK, transmits functions of VEGF in endothelial survival, 
proliferation, migration, vascular permeability and gene expression. Heparan 
sulphate proteoglycans (HSPG) may act as co-receptors for VEGF to facilitate 
its receptor binding and bioactivity (Cohen et al., 1995; Gengrinovitch et al., 
1999). 
 
1.19.2 Fibroblast growth factor 
In the early 1970s, Gospodarowicz purified a protein from bovine pituitary gland, 
which was able of inducing proliferation and phenotypic transformation of 
BALB/c 3T3 fibroblast (Gospodarowicz, 1975). This protein was named “basic 
fibroblast growth factor” (bFGF). Human FGFs are 18-25 KDa polypeptides and 
have a 120 amino acid residue core, is a strong promoter of fibroblast 
proliferation (Pey et al., 2007). This has been isolated from various neural tissues 
including the pituitary, adrenal cortex, corpus luteum and placenta (Omar et al., 
2004). FGF-2, a ubiquitous angiogenic and heparin-binding growth factor 
(HBGF), plays important roles in angiogenesis and tumour growth, (Beenken 
and Mohammadi, 2009) FGFs play major roles in normal development; wound 
healing, tumour development and progression. The 23 members of the FGFs 
family have been identified and characterised (Itoh, and Ornitz, 2004). They all 
have high affinity for heparin, heparan sulfate proteoglycans (HSPG) which are 
thought to facilitate dimerisation, and activation of FGFRs. FGF-2 has four 
isoforms derived from alternative translation initiation (Florkiewicz et al., 1989) 
and does not contain a signal sequence for secretion. While the 18-kDa form of 
FGF-2 is secreted by an unknown mechanism, the higher molecular weight forms 
are predominately localised to the nucleus. FGF-2 exerts its biological functions 
by binding to and activating the transmembrane receptor tyrosine kinases. FGF- 
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2 is found in storage form in ECM. Heparin sulphate proteoglycans present in 
the ECM protect the FGF-2 from activation within the matrix. Therefore, if ever 
there is an ECM breakdown FGF-2 can be released by soluble heparin. The FGF- 
2 receptors are integral membrane proteins with a single trans-membrane helix. 
The FGFR intracellular domain is largely composed of a tyrosine kinase domain, 
and is classified as a classical tyrosine kinase receptor (Harmer et al., 2004). Four 
FGF receptors nominated as FGFR-1 to FGFR-4, which share 55% to 72% 
homology (Johnson et al., 1993). FGF binding leads to receptor dimerisation and 
tyrosine phosphorylation. The FGFR-1 has been studied in detail and several 
potential tyrosine phosphorylation sites in the cytoplasmic part have been 
described (Klint and Claesson-Welsh, 1999). FGF-2 induces proliferation, 
migration, proteinases production and expression of specific integrins in cultured 
endothelial cells (Klein et al., 1996). FGF-2 plays key roles in development, 
remodelling and disease states in almost every organ system (Bikfalvi et al., 
1997). The various effects displayed by FGF-2 indicate the importance of the 
growth factor in regulation of developmental and physiological activities. 
Unexpectedly, the bFGF knockout mice lacking all isoforms are viable, fertile 
and are phenotypically similar to the wild type mice. However, the knockout 
animals have some mild defects including delayed wound healing, decreased 
neuronal density in the motor cortex and reduced blood pressure (Ortega et al., 
1998; Miller et al., 2000). 
1.19.3 Other growth factors 
Several other factors take part in vascular development and growth. 
Plateletderived growth factor (PDGF) plays a role in embryonic development, 
cell proliferation, cell migration, and angiogenesis. It had been initially identified 
in platlets but has since been found in many other cell types, including 
fibroblasts, keratinocytes, myoblasts, epithelial cells, macrophages and 
endothelial cells (Heldin and Westermark, 1999; Hoffmann et al., 2005). 
 
Transforming growth factor-β (TGF-β) as well as its receptor is also expressed 
in endothelial cells as well as pericytes (Massague, 1990). TGF-β is chemotactic 
for many cells and establishes structural integrity of newly formed vessels during 
angiogenesis through synthesis of ECM components and proteases (Wahl et al., 
1987).  Angiopoietins,  a  family  member  of  4  secreted  proteins  and  their 
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Tiereceptors, play a crucial role in angiogenesis. Angiopoietin-1 (Ang-1) binding 
to receptor Tie2 on endothelial cells is an anti-permiability elements as well as 
functions as a chemoattractant. Ang1 stimulates Tie2 receptor 
autophosphorylation, while Ang2 has been reported that Ang2 may function as 
an endogenous antagonist of Ang1. However, it is both Ang1 and Ang2 
potentiated VEGF-induced angiogenesis in vivo (Maisonpierre et al., 1997; 
Koblizek et al., 1998; Wakui et al., 2006). 
Ephrin ligands are divided into an A and a B class according to their sequence, 
and they stimulate Eph RTKs. Many ephrins and Eph receptors are upregulated 
in tumours, especially in the more aggressive stages of tumour progression. 
Ephrins and the Eph-receptors are understood to play roles in neural and vascular 
development; ephrin-A1 was revealed to be upregulated throughout in vitro 
capillary tube development and induce angiogenesis (Holzman et al., 1990; 
Pandey et al., 1995). Ephrin-B2 marks arterial endothelial cells and Eph-B4, the 
receptor, marks veins (Wang et al., 1998; Iso et al., 2006).. 
 
 
1.20 Endothelial cell migration 
During the first steps of angiogenesis, ECs need to reduce inter-EC contacts and 
detach peri-EC support, to destabilise mature vessels. Vascular permeability 
increases and the blood clotting protein fibrinogen leaks out of the vascular bed 
and forms a fibrin gel. For invasion into the underlying interstitium, ECs need to 
degrade and invade through insoluble fibrin, the underlying basement membrane 
as well as the interstitial matrix. 
The basement membrane degradation results in the release of cytokines and 
growth factors from ECs and other cell types (Plank et al, 2003). As the gap 
between ECs increases, they form finger-like projections known as EC cords, 
which initially travel as a solid cord followed by lumen formation (Folkman and 
Haudenschild, 1980). The EC sprout elongates and fusion of microvilli at the end 
of the sprout forms a vascular network. Studies have shown that adhesion 
molecules of the select in, integrin, and cadherin families play an important role 
in capillary morphogenesis (Brooks et al., 1994; Stromblad and Cheresh, 1996). 
Despite the ability of the endothelium alone to form capillary networks in vitro, 
capillary  morphogenesis  is  a  complex  process  of  interaction  between  EC 
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response and the paracrine effects of blood constituents, stromal cells and PCs 
(Gerhardt and Betsholtz, 2003; Bergers and Song, 2005). The following step is 
the migration and proliferation of the now in situ ECs. As the ECs leave the 
original place they become activated ECs and exhibit numerous changes. The 
ECs experience alterations in the expression of cell-cell and cell-matrix adhesion 
molecules, reorganisation of cytoskeletal elements, and express cell surface 
adhesion molecules such as integrins, members of the Ig supergene family, 
selectins, and components of the ECM (Polverini, 1995; Polverini, 1997). 
Integrins are expressed by ECs, which in turn bind to ECM proteins. One integrin 
of particular importance in angiogenesis is integrin αv-β3, which binds to MMP- 
2. Integrin αv-β3 causes MMP-2 matrix degradation of the EC surface (Brooks 
et al., 1994). Generation of proteolytic enzymes occurs due to the activation of 
the ECs, which in turn degrade the ECM and migrate away from the original 
vessel. Because of this in angiogenesis, capillary buds are produced. In addition, 
growth factors sequestered in the basal lamina and surrounding ECM are released 
to stimulate further angiogenesis steps. Furthermore, there is also induction of 
EC-derived cytokines and growth factors that play an important role in the later 
stages of the angiogenic response (Polverini, 1995; Polverini, 1997). 
 
1.21 Endothelial cell filopodia 
Endothelial cell motility is a critical aspect of angiogenesis, but only a limited 
number of molecules have been identified as specific regulators of endothelial 
cell. The regulated polymerization of actin filaments result in two 
morphologically distinct protrusive structures, lamellipodia and filopodia, at the 
leading edge of motile cells. (Nambiar et al., 2010). The lamellipodia are thin 
(thickness 0.1–0.2 µm) fan-like projections composed of a branched network of 
actin. (Pollard and Borisy 2003). In contrast, filopodia are slender, finger-like 
extensions (diameter 0.1–0.3 µm), often emanating from lamellipodia, made up of tight 
bundles of actin filaments. (Faix and Rottner 2006; Mattila and Lappalainen 2008). 
With respect to directed cell migration, filopodia are particularly important, probing and 
sensing the pericellular environment for chemotactic and other molecular cues in the 
ECM that guide the direction and movement of the cell. They also act as points of 
attachment to the ECM for the cell, generating tension that may act to pull the cell 
forward and/or stabilize the cell as it moves. Given these roles, it is not surprising that 
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filopodia contain diverse receptors for ECM proteins and an array of signaling 
molecules. 
 
 
1.22 Endothelial cell proliferation 
When there is a ‘disturbance’ between the various cell types previously 
mentioned in section 1.17, ECs degrade and travel through their basement 
membrane and ECM. The release of growth factors (which include angiogenic 
growth factors) causes the activation of further ‘proliferating’ ECs to migrate 
behind the degraded ECs (Polverini, 1995; Polverini and Nickoloff, 1995). 
Angiogenic factors first target post-capillary venules and small terminal venules. 
It is contain ECs that are flattened and rest upon a basal lamina. The flattened 
ECs are bounded by a sporadic layer of PCs and SMCs and are invested into the 
matrix (Polverini, 1995; Polverini and Nickoloff, 1995). There are a number of 
angiogenic growth factors that act specifically on ECs. These include VEGF and 
angiopoietins. The production of cytokines and growth factors has been 
suggested for efficient functioning of ECs, such as control of EC growth, 
elongation, orientation and mutation of ECs as they organise into functioning 
vessels (Polverini, 1995). 
 
 
1.23 Protein phosphorylation in cell signalling 
Intracellular signalling controls cell survival, proliferation, differentiation and 
apoptosis. The importance of protein phosphorylation for cell signalling started 
to emerge with the findings that reversible phosphorylation can alter the activity 
of glycogen phosphorylase (Hunter et al., 1995; Hunter et al., 2000). It has been 
approximated that human genome consists of at least 518 protein kinases genes, 
representing about 1.7% of all human genes (Manning et al., 2002). In a typical 
vertebrate cell, around 90% of the proteins are serine phosphorylated compared 
to tyrosine phosphorylation of only approximately 0.05% of the proteins. 
Consequently, tyrosine phosphorylation enables a high degree of specificity in 
cell signalling through regulation of the activity of tyrosine kinases, and the 
counteracting tyrosine phosphatases, which remove phosphate groups from 
target tyrosine residues (Fischer, 1999). 
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1.23.1 Phosphorylation by tyrosine kinases 
A tyrosine kinase is an enzyme that can transfer a phosphate group from ATP to 
a protein in a cell. It functions as an "on" or "off" switch in many cellular 
functions. Tyrosine kinases are a subclass of kinase. The phosphate group is 
attached to the amino acid tyrosine on the protein. Tyrosine kinases are a 
subgroup of the larger class of protein kinases, which attach phosphate groups to 
other amino acids (serine and threonine). Phosphorylation of proteins by kinases 
is an important mechanism in communicating signals within a cell (signal 
transduction) and regulating cellular activity, such as cell division. 
Approximately 2000 kinases are known, and more than 90 Protein Tyrosine 
Kinases (PTKs) genes have been found in the human genome. They are divided 
into two classes, receptor and nonreceptor PTKs. At present, 58 receptor tyrosine 
kinases (RTKs) are known, grouped into 20 subfamilies, controlling developing 
cell growth and differentiation, as well as remodelling and regeneration of adult 
tissues, are moderated by polypeptide growth factors and their transmembrane 
receptors, numerous of which are RTKs (Mustonen and Alitalo, 1995; van der 
Geer et al., 1994). Several families of receptor tyrosine kinases are characterised 
and some of them are strictly endothelial cell-specific. Growth factor receptors 
with protein tyrosine kinase activity have a similar molecular topology. They 
consist of a large glycosylated extracellular domain defining the receptor binding 
characteristics, with a hydrophobic transmembrane region anchoring the receptor 
in the plane of the plasma membrane. 
The kinase domain of subclass III RTKs is divided into two halves by insertions 
of hydrophilic amino acid residues. The role of this kinase insert region is to 
modulate receptor interactions with certain cellular substrates. Lastly, they 
contain the carboxy-terminal tail, which interacts with the substrate binding sites 
of the protein tyrosine kinase region, modulating the capacity of the tyrosine 
kinase (TK) region to interact with exogenous substrates (Ullrich and 
Schlessinger, 1990). RTKs are activated by polypeptide ligands commonly 
known as growth factors or cytokines. Signalling involves ligand binding, which 
induces a conformational change in the external domain of the receptor resulting 
in its dimerisation (Ullrich and Schlessinger, 1990). This event results in receptor 
transphosphorylation at specific tyrosine residues and activation of the catalytic 
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domains for the phosphorylation of cytoplasmic substrates. These 
phosphorylated tyrosine residues may serve to control the kinase activity of the 
receptor, and to create docking sites for the cytoplasmic signalling molecules, 
which are often substrates for the kinase. These molecules are adapters or 
enzymes themselves, linking RTKs to different signalling pathways. The 
interaction of these proteins with the activated RTKs can initiate signalling 
pathways leading to the nucleus or other cellular targets (Heldin, 1995). 
Following ligand binding and dimerisation, receptors are internalised for 
degradation or recycling in order to attenuate signalling (Cadena and Gill, 1992). 
1.23.2 FGF-2 signalling pathways 
After binding to its receptor, FGF-2 activates a number of intracellular pathways 
(Nugent and Iozzo, 2000). The proteins FGF receptor substrate 2 (FRS2) and 
SHC bind to the phosphotyrosine deposit of the bFGF receptor and feature as 
docking protein for the GRB2-SOS complex, which can activate RAS and 
subsequently initiate the Raf-MEK-MAPK cascade (Pintucci et al., 2002). The 
MAPK translocates to the nucleus, where it activates transcription factors by 
phosphorylation. Moreover, PLCγ binds also to the phosphotyrosine residue and 
activated during FGF-2 receptor binding. By activation it initiates a signalling 
cascade via hydrolysis of phosphatidylinositol to inositol-3-phosphate and 
diacylglycerol (DAG) leading to calcium release and activation of protein kinase 
C (PKC), which is implicated in a variety of cell functions. Moreover, FGF-2 has 
also been shown to be internalised via the cell surface receptors and subsequently 
translocated and accumulated in the nucleolus, where it is, among others, thought 
to stimulate the transcription of ribosomal genes during G0→G1 transition in the 
cell cycle (Chen et al., 2004). The binding of FGF-2 to its receptor as well as 
internalisation of the growth factors is significantly reliant after binding to 
HSPG. 
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1.24 The optical system 
 
1.24.1 The eye 
The eye is composed of three different layers: exterior layer (cornea and sclera), 
intermediate layer (iris-ciliary physical body and choroid), and interior layer 
(retina) (Duvvuri et al., 2003) and is filled of two sorts of fluids: liquid humor 
between the cornea and the iris and vitreous humor between the lens and retina 
(Figure 1.15). 
 
 
Figure 1 .15 The human eye.(A) Shows the anatomical structure of Cross 
section of eye, (B) The black rectangle indicates the central cornea where all 
analyses were carried out, (C) The corneal stroma from the central cornea 
(Shoujun et al., 2014). 
 
 
This cornea is an optically transparent tissue that enables light to reach the retina. 
This tissue is non-vascular, and nutrients and oxygen are supplied by diffusion 
from lachrimal fluid and aqueous humour as well as from blood vessels located 
at the junction between the cornea and the sclera. The cornea is composed of five 
layers: epithelium, Bowman’s membrane, stroma, Decement’s membrane, and 
endothelium (Duvvuri et al., 2003). The epithelium has tight junctions and is a 
A 
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hydrophobic layer that makes it a crucial barrier to medicine distribution. The 
Bowman’s membrane separates the epithelium and the stroma. The stroma 
comprises 90% of the corneal thickness. This region is hydrophilic because 85% 
of the stroma is water. The Decement’s membrane lies between the stroma and 
the endothelium. The endothelium contacts the aqueous humour and is 
responsible for controlling corneal hydration. The sclera forms about five-sixth 
area of the outer envelope of the eye (Boubriak et al., 2000). The sclera is a 
fibrous tissue extending from the cornea to the optic nerve. It is a protective layer 
usually referred to as the “white of the eye”. Nearly 70 % of the sclera is water, 
and the remaining components are mostly fibrillar collagen (predominately 
collagen typeI) and proteoglycans containing glycosamino glycan side chain 
(Boubriak et al., 2000). 
The coloured part of the eye is the Iris and controls light entering eye, and divides 
the anterior humour chamber from the posterior humour chamber. The ciliary 
body produces the aqueous humour at rate of 2.2 × 10-3 ml/min (Friedrich et al., 
1997). 1-2% of aqueous humour production flows in the posterior direction into 
the vitreous (Maurice et al., 1987) and the remaining flows in the anterior 
direction and drains through the Schlemm’s canal. The choroid is vascular and 
pigmented tissue between the retina and the sclera. 
The retinal pigment epithelium (RPE) is located between the choroid and the 
retina and the superchoroidal space is between the choroid and the sclera. The 
choroid is composed of layers of blood vessels that nourish the sub retinal region. 
The retina is a multi-layered membrane occupying the internal space of the 
posterior portion of the eye wall. One side of the retina contains the rod, cones, 
and is adjacent to the retinal pigment epithelium and the choroid; the other side 
of the retina faces the vitreous. Photoreceptor cells are located in the sub retinal 
region near to the choroid. The macula is the central of retina that serves fine 
central vision and colour perception. The fovea is a depression at the centre of 
macula. The vitreous is a transparent substance that fills the centre of the eye 
between the lens and the retina. It is composed of hyaluronic acid and collagen 
(Huges et al., 1972) in 98% water. Aqueous humour is the fluid that fills the 
space between the cornea and the iris and nourishes the cornea and the lens. 
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1.24.2 Vitreous balance 
That vitreous is now considered an important ocular structure with respect to 
both normal physiology (Foulds et al., 1987) and several important pathologic 
conditions of the posterior segment (Sebag et al., 1989). Vitreous hormone 
balance has actually been thoroughly evaluated by (Sebag, 1998; Bishop, 2000) 
(Figure.1.16). A.Hyaluronan: is a main macromolecule of vitreous. It is found 
throughout the body and was initially separated from bovine vitreous in 1934 by 
Meyer and Palmer. Hyaluronan is a long, unbranched polymer of repeating 
disaccharide (glucuronic acid β (1, 3)-N-acetylglucosamine) moieties linked by 
β 1– 4 bonds (Balaz, 1984). The sodium salt of hyaluronan has a molecular 
weight of 3 to 4.5 × 106 in normal human vitreous. Hyaluronan is not normally a 
free polymer in vivo, but it is covalently linked to a protein core, called a 
proteoglycan. 
B.Collagen: the vitreous contains collagen type-II, is a hybrid of types V/XI, and 
type-IX collagen in a molar ratio of 75:10:15, respectively (Bishop, 2000). In the 
whole body, only cartilage material has as higher a percentage of type-II collagen 
as vitreous,  explaining why certain  inherited mutations  of type-II collagen 
metabolism affect vitreous as well as joints. Vitreous collagens are organised into 
fibrils with type V/XI residing in the core, type-II collagen surrounding the core, 
and type-IX collagen on the surface of the fibril. The fibrils are 7 to 28 nm in 
diameter (Seery et al., 1991). 
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Figure 1 .16 The structure of the vitreous, maintained by a dilute dispersion of 
unbranched collagen fibrils with hyaluronan filling the space in between. 
 
 
 
1.24.3 Vitreous supramolecular organisation 
The vitreous has been described as a dilute meshwork of collagen fibrils 
interspersed with extensive arrays of hyaluronan molecules (Mayne, 2002). If 
collagen is removed, the remaining hyaluronan forms a viscous solution; if 
hyaluronan is removed, the gel shrinks but is not destroyed. Comper and Laurent 
proposed that electrostatic binding occurs between the negatively charged 
hyaluronan and the positively charged collagen in vitreous (Comper et al., 1996). 
Bishop has proposed that to appreciate how vitreous is organised and stabilised 
requires an understanding of what prevents collagen fibrils from aggregating and 
by what means the collagen fibrils are connected to maintain a stable gel structure 
(Bishop, 2000). Some studies indicated the chondroitin sulfate chains of type-IX 
collagen  bridge  located  between  adjacent  collagen  fibrils  in  a  ladder-like 
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configuration spacing them apart (Scott et al., 1992), this type of spacing 
essential for vitreous transparency, so can keeping vitreous collagen fibrils 
separated by as a minimum one wavelength of incident light minimises light 
scattering, allowing the unhindered transmission of light to the retina for 
photoreception. Bishop proposed that the leucine-rich repeat protein opticin is 
the predominant structural protein responsible for short-range spacing of 
collagen fibrils (Bishop, 2000). Concerning long-range spacing, it has been 
suggested that hyaluronan plays a pivotal role in stabilising the vitreous (Scott et 
al., 1992; Mayne et al., 1997). 
1.24.4 Inhibition of general cell development by the vitreous humor 
 
The vitreous body is resistant to endothelial cell invasion and the disturbing 
consequences of neovascularisation that may occur under pathological 
conditions (Neely and Gardner 1998; Campocchiaro, 2000). The regression and 
prevention of vessel invasion may partly be due to the influence of angiogenic 
inhibitors (Lutty et al. 1985), as several studies have assigned anti-angiogenic 
properties to the vitreous humour. Tumour vascularisation and development 
within the vitreous physical body is prevented (Brem et al., 1976), draws out 
from it hinder endothelial cell expansion and stability in vitro (Lutty et al., 1985; 
Zhu et al., 1997) and suppress tumour-induced neovascularisation (Felton et al. 
1979) and angiogenesis in the chick CAM assay in vivo (Lutty et al., 1985). 
Putative antiangiogenic molecules present in the vitreous humour have been 
described in some studies and these inhibitory factors are thought to derive from 
hyalocytes (Raymond and Jacobson 1982; Zhu et al., 1997), such as 
chondromodulin-1 (Funaki et al., 2001), thrombospondin-1 (Sheibani et al., 
2000), a pigment epithelial-derived element (Dawson et al., 1999), and changing 
growth factors (Eisenstein and Grant-Bertacchini, 1991). 
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1.25 Ocular conditions 
 
Table 1.3 shows data concerning the patients suffering from eye disease (Clark 
et al., 2003). Among ocular diseases, the posterior segment ocular diseases, 
agerelated macular degeneration, diabetic retinopathy, and glaucoma, are the 
main causes of irreversible blindness in developed countries. 
Table 1 .3 Leading causes of visual impairment and ocular discomfort (Clark et al., 
2003) 
 
Disease Number of patients 
Cataract 6-19 % of patients over 43 years of age 
Age-related macular degeneration  
11-28 % of patients over 65 years of age 
 
Glaucoma 
 
1-4 % of patients over 65 years of age 
Diabetic retinopathy  
71-90 % of patients over 10 years of age 
Dry eye (US)  
50-60  million (~10-15% of 
US population) 
Ocular allergy ~25 % of US population 
Retinitis pigmentosa 1 in 3000-5000 people 
 
 
 
 
1.26 Glycation General Introduction 
Glycation is a non-enzymatic reaction that adds carbohydrates, especially 
glucose, to proteins, lipids and nucleic acids througha series of parallel and 
sequential reactions (often termed the Maillard reaction). Louis Maillard (1912) 
(Chichester, 1986), who observed browning of amino acids when they were 
heated with sugars. The 'Maillard reaction' was not shown to be important outside 
the food industry for many decades. The first protein demonstrated to be glycated 
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in vivo was haemoglobin Bookchin and Gallop, (1968) showed that there was a 
hexose molecule linked to the protein N-terminal. Their further rearrangement, 
gives rise to a stable Amadori product. These products degrade into a variety of 
compounds that are much more reactive than the sugars from which they were 
derived (Wautier and Schmidt, 2004). These propagators again form yellow- 
brown, often fluorescent, irreversible compounds, usually called Advanced 
Glycation EndProducts (AGEs). 
 
 
1.27 Diabetes mellitus 
 
Diabetes mellitus (DM) is a complex and heterogeneous disease characterized 
by chronic hyperglycaemia with instabilities in carbohydrate, fat and protein 
metabolism due to a deficiency of insulin secretion and/ or reduction in the 
biological effectiveness of insulin (Michael et al., 2004). The most common 
symptoms of hyperglycaemia are polydipsia, polyuria, weight loss, blurred 
vision and polyphagia (Sharma and McGowan, 2000). Diabetic patients suffer 
from many complications leading to increased morbidity and mortality (Ahmad 
and Ahmed, 2006), including micro and macro vascular complications which 
involve renal failure, nerve damage, blindness, increased atherosclerosis, 
embryopathy and many others (Ahmed and Furth, 1990). The majority of 
diabetic complications are due to chronic hyperglycaemia (Browniee, 2001). It 
affects not only quality of life, but also poses a great burden upon healthcare 
authorities in both developed and developing nations (Goh and Coopr, 2008). 
Although the etiology of this disease is not clear, autoimmunity, viral infection, 
environmental and genetic factors all appears to play a crucial role in the 
pathogenesis of diabetes mellitus (Notkins and Lernmark, 2001). The current 
classification tries to include both etiology and clinical stages of the disease and 
is useful clinically. It includes four main kinds or classes. The two main types 
are, type 1, which accounts for 5–10% of all cases, and type 2, consider; 90-95% 
of all individuals with diabetes. The third group contains of other less common 
types of diabetes that are caused or linked with assured specific conditions and/or 
syndromes. The last group comprises diabetes diagnosed during pregnancy, 
called gestational diabetes mellitus (GDM). Besides; there is an intermediate 
group of individuals whose glucose level, although not meeting standards for 
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diabetes are still too high to be considered normal. This group comprises of 
individuals that have impaired fasting glucose (IFG) and/or impaired glucose 
tolerance (IGT) and is stated to as “pre-diabetes” as progression to overt diabetes 
is common, particularly when therapeutic interventions such as lifestyle changes 
or medications are not provided (Gavin et al., 2003). 
 
1.28 Diabetes mellitus types: 
 
1.28.1 Type 1 diabetes mellitus: 
Type1, IDDM or Juvenile diabetes this type of diabetes usually develops in 
children or young people, but may occur in any age. Type1 diabetes usually 
develops when the immune system destroys the insulin-producing cells (beta 
cells in the pancreas). This is called an autoimmune response. Type-I diabetes 
can develop in people with a family history of type1 diabetes, but it also develops 
in people with no family history of diabetes. This process occurs over many 
months or years, and there may be no initial symptoms of diabetes. 
1.28.2 Type 2 diabetes mellitus: 
Formerly called non insulin dependent diabetes mellitus (NIDDM, type-II or 
adult-onset); is characterized by insulin resistance in peripheral tissue and an 
insulin secretory defect of the beta cell. Characterised by insulin resistance, and 
considered most common type, also known as non-insulin dependent in which 
the cells fail to use the insulin properly. This type quite common in adult over 40 
years of age (Roglic, 2005). 
 
 
1.29 Diabetic complications 
All forms of diabetes are characterized by chronic hyperglycaemia and the 
development of diabetes-specific microvascular pathology in the retina, skin, 
renal glomerulus and peripheral nerves. The global prevalence of diabetes is 
rapidly rising at an alarming rate (Rolo and Palmira, 2006; Anitha et al., 2008). 
Patients with diabetes mellitus are prone to developing diabetic complications, 
which ultimately represent a major cause of morbidity and mortality.The 
biochemical pathways linking chronic hyperglycaemia and tissue damage are not 
completely understood. 
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Virtually every major organ system in the body is damaged by diabetes such as: 
 
1.29.1 Short term complications 
Hyperglycemia, Diabetic ketoacidosis (DKA), Hyperosmolar Non-ketotic (HONK) 
state, Lactic Acidosis, Infections etc. 
 
 
1.29.2 Long Term Complications 
Eye disorders, Diabetic  retinopathy, Cataracts, Diabetic neuropathy, Macro 
vascular Disease, Heart disease, High blood pressure, Stroke, Kidney Disease 
(End stage renal disease), Feet problem and Amputation of extremities, Early 
loss of teeth, Impotence, Pregnancy complication, Congenital malformations in 
babies, Death of the newborn etc. 
1.29.3 Diabetic cataract 
Cataracts are the main cause of visual destruction and blindness worldwide, and 
are characterised by pacification of the lens. Chronic hyperglycaemia represents 
a risk factor for cataract genesis (Crabbe, 1998). However, the main mechanism 
responsible for diabetic cataract formation is unknown. Currently, the glycation 
theory is widely accepted as playing a key role in cataract development in the 
lens, and numerous studies report that the accumulation of AGEs on lens 
crystalline may lead to protein cross-linking, oxidation and formation of high 
molecular weight aggregates responsible for cataract formation (Truscott, 
2005;Yamagishi et al., 2007). 
1.29.4 Diabetic nephropathy 
Diabetic nephropathy is the most common cause of end-stage renal disease in the 
world (Yamagishi et al., 2007). It develops in 40–50% of all diabetic patients 
(Berger et al., 2003; Wolf, 2004), and is characterised by glomerular and tubular 
basement membrane thickening and mesangial expansion, which eventually 
results in vascular occlusion, microvascular damage, and fibrotic changes, 
thereby leading to glomerulosclerosis. Significantly, the accumulation of AGEs 
in patients with nephropathy may be due to decreased clearance in the kidney, 
rather than increased production by glycation. More evidence suggests that the 
interaction of AGEs with RAGE is involved in nerve dysfunction, which may 
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play an inflammatory role in peripheral nerve damage, although their precise role 
remains unknown (Huijberts et al., 2008; Rong, 2005). 
 
 
 
 
1.30 Advanced glycation endproducts and macrovascular complications 
The term ‘‘macrovascular complications’’ in diabetes involves a broad spectrum 
of pathological changes affecting major blood vessels and leading to structural 
and functional abnormalities. Structural changes result mainly from glycation of 
wall  components  and  functional  changes  which  originate  in  endothelial 
dysfunction, and which increase stiffness of the arterial wall or reduce vascular 
compliance. Macrovascular disease in diabetes comprises an accelerated form of 
atherosclerosis, which is believed to be fundamentally responsible for several 
vascular diseases, namely stroke, myocardial infarction and peripheral vascular 
diseases (Laakso, 1999; Rahman, 2007). 
1.31 Diabetes and atherosclerosis 
Atherosclerosis is a complex multifactorial disease caused by excessive 
accumulation of lipids in the vascular wall, and eventually limits blood flow 
(Mallika et al., 2007). Atherosclerotic arterial disease may be clinically 
manifested as cardiovascular disease (CVD), where more risk in diabetic people. 
Several studies report that AGEs may play a role in the development of 
atherosclerosis in diabetic patients (Bierhaus et al., 1998; Jandeleit-Dahm, 2008). 
Advanced glycation endproducts may accelerate atherosclerosis through several 
mechanisms, including the cross-linking of proteins, the modification of matrix 
components and abnormal lipoprotein metabolism (Goh and Cooper, 2008). 
 
 
1.32 Obesity metabolic syndrome and insulin resistance. 
One of the obesity-associated health risks is development of metabolic 
syndrome. According to the WHO, metabolic syndrome is characterized by the 
presence of central obesity, dyslipidemia (elevated triglycerides and decreased 
HDL cholesterol), impaired glucose  tolerance or insulin resistance, type 2 
diabetes and high blood pressure. Randle proposed that fatty acid (FA) compete 
with glucose as anenergy substrate in rat heart and diaphragm muscle, and 
speculated that increased fatty acidoxidation was responsible for the obesity- 
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induced insulin resistance (Randl et al 1965). It has been shown that an increase 
in the intracellular concentration of FA metabolites (diacylglycerol, fatty acyl 
CoA) leads to activation of PKC, c-Jun N-terminal kinase (JNK) and inhibitory 
kappaB kinase (IKK), which ultimately block the insulin signaling pathway 
through functional inhibition of insulin receptor substrate-1 (IRS-1), (Blaschke 
F et al 2005). Therefore a person with severe untreated diabetes mellitus suffers 
rapid weight loss and asthenia (lack of energy) despite eating large amounts of 
food (polyphagia).It accounts for 80–85 per cent of the overall risk of developing 
Type2 diabetes and underlies the current global spread of the condition (Hanuer 
H, 2010). Almost two in every three people in the UK are overweight or obese 
(62 per cent of women and 66 percent of men). 
 
1.33 Introduction of Diabetic retinopathy 
Diabetic retinopathy occurs when diabetic complications lead to destruction of 
the very small blood vessels in the retina. In earlist stage of diabetic retinopathy, 
called non-proliferative retinopathy, where blood vessels become leaky and 
weak. This is followed by proliferative retinopathy, where fragile new blood 
vessels increase around the retina and in the vitreous humor. Retinal oedema, 
haemorrhage, anemia, microaneurysms, and neovascularization are 
characteristics of diabetic retinopathy. The Diabetes Control and Complications 
Trial (DCCT) determined hyperglycaemia as a significant threat for the 
progression and development of retinopathy; however, the pathogenic 
mechanisms of DR are not fully understood. Basement membrane thickening and 
pericyte loss have been recognised as the histological hallmarks of early DR 
(Kohner, 1989). Mainly, DR consider as disease of the retinal capillary 
endothelial cells (ECs) (Kohner, 1993; Archer, 1999). Since the retina is one of 
the few tissues that do not require insulin to transport glucose into the cell, 
hyperglycaemia leads to high intracellular glucose levels. In hyperglycaemia, 
ECs respond to abnormally high blood glucose values, and with rapid 
normalisation of blood glucose, ECs undergo apoptosis (Li et al., 1996; 
Mizuntani et al., 1996; Joussen et al., 2001) leading to eventual blood-retinal 
barrier breakdown (Poulaki et al., 2002). The consequences of retinal 
microvascular cell apoptosis can account for various features of DR (Lorenzi and 
Gerhardinger   2001).   It   has   been   shown   that   prolonged   exposure   to 
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hyperglycaemia leads to progressive dysfunction of the endothelium through a 
number of potential pathways (Barnett, 1993; Funatsu and Yamashita, 2002). 
These biochemical mechanisms include sorbitol (polyol) pathway, nonenzymatic 
protein glycation (advanced glycation end products, AGEs), oxidative stress 
(generation of reactive oxygen species, free radicals, and impaired antioxidant 
mechanisms), protein kinase C beta (PKC-β) and the rennin-angiotensin system 
(RAS) (see figure 1.17) these abnormal pathways work in a network may 
influence various vasoactive factors and cytokines to mediate functional and 
structural changes of DR (Candido and Allen, 2002). For instance, AGEs cause 
increased oxidative stress and leading to cell death. Moreover, retinal ECs are 
much more disposed to oxidative stress and increased vascular permeability 
when compared by brain-derived ECs (Grammas and Rideen, 2003). It has being 
found not only the pathogenesis of DR does not only affect retinal vessels. In 
addition, other cell types in the retina are affected early by diabetes (Lorenzi and 
Gerhardinger, 2001). 
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Figure 1 .17 Schematic diagram of the pathogenesis of diabetic retinopathy. 
NPOR start with microcaneusm formation to retinal ischemia. PDR; sever visual 
loss due to retinal detachment, and neovascular glaucoma, mild to sever visual loss 
due to vitreous haemorrhage. 
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1.34 Epidemiology 
International epidemiological studies indicate that over the last 50 years there has 
been progressive raise in diabetes incidence. Diabetes mellitus has becoming 
increasingly widespread in recent years. While Diabetes consider as common 
chronic disease, which consider to be the fifth leading cause of death in 2000. 
Additionally, it became the 3rd most common killer of mankind, after cancer, 
and cardiovascular and cerebrovascular diseases (Li, 2004). World Diabetes Day 
2013 marks the release of the International Diabetes Federation's 6th edition of 
the Diabetes Atlas.According to the new studies, the number of people living 
with diabetes is expected to increase from 382 million in 2013 to 592 million by 
2035.The highest number of people with diabetes is from 40 to 59 years of age, 
in main time 175 million people with diabetes are undiagnosed due to many 
reason. 80% of people with diabetes belong to low and middle-income countries 
North America have highest prevalence of diabetes is in where it reached 10.2% 
of adult population while in Europe the prevalence is 6.9% of population aged 
20 to 79 years. Mainly worrying is continuous increase in diabetes incidence of 
both type 1 as well as type 2 in developmental age population. (Jarosz-Chobot et 
al., 2011; D'Adamo and Caprio, 2011). Since of increase in diabetes, prevalence 
there is higher number of patients will have microangiopathic complications 
including DRin children and youth and in adults (Cho et al., 2011; Rosenson et 
al., 2011). Chronic complications decrease the quality of life and are a main 
cause of disability. DR has become a most important reason for blindness and 
visual impairment in developed countries and is continually increasing (Fong et 
al., 2004). Near all patients with type 1 diabetes will develop some appearance 
of DR, whereas in type 2 diabetic patients 80% of insulin- dependent patients 
and 50% of patients not requiring insulin therapy will have DR within 20 to 25 
years following disease onset (Lamoureux and Wong, 2011). The prevalence of 
any retinopathy was 8% at 3 years, 25% at 5 years, 60% at 10 years, and 80% at 
15 years. The prevalence of PDR was 0% at 3 years and increased to 25% at 15 
years. The prevalence of proliferative diabetic retinopathy (PDR) was 0% at 3 
years and increased to 25% at 15 years (National Health and Nutrition 
Examination Survey, 2006). It is predictably estimated that 20% of all diabetes 
cases are undiagnosed, so the actual prevalence is likely significantly higher 
(Philip Hooper et al., 2012). 
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1.35 Eipdemiology of Diabetes in UK. 
2.6 million People have been diagnosed with diabetes in the UK (2009). By 2025, 
there will be more than four million people with diabetes in the UK. In 2008, 
145,000 people were diagnosed with diabetes in the UK. Diabetes is the leading 
cause of blindness in people of working age in the UK. It is estimated that there 
are 4,200 people in England who are blind due to diabetic retinopathy.This 
increases by 1,280 each year. (Scanlon, 2008), within 20 years of diagnosis 
nearly all people with Type 1 and almost two thirds of people with Type 2 
diabetes (60 percent) have some degree of retinopathy. (Scanlon, 2008). People 
with diabetes are twice as likely to suffer from cataracts or glaucoma as the 
general population. (Petit and Adamec 2002). More than one in ten (11.6 per 
cent) deaths among 20 to 79-year-olds in England can be attributed to diabetes. 
If current trends continue, one in eight (12.2 per cent) deaths among 20 to 79- 
yearolds will be attributable to the condition by 2010. (Yorkshire and Humber 
Public Health Authority 2008). Life expectancy is reduced, on average, by more 
than 20 years in people with Type 1 diabetes up to 10 years in people with Type 
2 diabetes. 
1.35.1 Background Diabetic Retinopathy (BDR) 
This condition appears in people who have had diabetes for a long time, two 
types of diabetic retinopathy, which can damage the sight. Both involve the fine 
network of blood vessels in the retina. 
1.35.2 Proliferative diabetic retinopathy (PDR) 
 
This condition is growth of new vessels from the retina or optic nerve,mainly 
occurs when many of the blood vessels in the retina become obstructed, stopping 
blood flow, to repair the damage to the area where the original vessels closed, 
and the retina responds by growing new blood vessels. This is called 
neovascularisation. However, these new blood vessels are often very weak and 
do not supply the retina with sufficient blood flow, growing in the wrong place 
on the surface of the retina and inside the the vitreous. The new vessels are also 
often accompanied by scar tissue that could cause the retina to wrinkle or detach. 
PDR is a major cause of blindness, and its earliest signs include damage to the 
blood vessels and the formation of lesions in the retina. Automated detection and 
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grading of hard exudates from the fundus imaging is a critical step in the 
automated screening system for diabetic retinopathy (Bala and Vijayachitra, 
2012). Small bulges, known as microaneurysms, leave behind metabolic waste 
products known as exudateslead capillaries to leak. The fluid causes the retina to 
swell (edema) and on top ofthat leave behind metabolic waste products known 
as exudates. Additionally, if the small retinal vessels block off (capillary closure 
or capillary drop out) the retina will become oxygen starved (ischemic). When 
this happens, white patches of oxygen-starved retina (cotton wool spots) appear. 
In addition, vessels can form scar tissue, which the vitreous can pull. This can 
cause bleeding into the vitreous and/or cause retinal detachment. 
 
 
1.36 Differences between the PDR and BDR 
Diabetes has an effect on circulatory method in the retina.The intial step of the 
disease is recognized as backdrop diabetic retinopathy (BDR). In this step, only 
the arteries inside the retina become weakned and leak, forming small, dot-like 
haemorrhages, which will lead to retinal detachment and blindness. These kinds 
of leaky often produce swelling as well as oedema in the retina and decreased 
vision. The following stage is recognized as proliferative diabetic retinopathy 
(PDR). In this stage, circulation problems lead to areas of the retina to become 
oxygen-deprived or ischemic. New, fragile, vessels develop as in (Figure 1.18), 
formed (proliferative retinopathy). Haemorrhage from these vessels could cause 
acute loss of sight, which may obvious. 
Organisation   from   the   haemorrhage   leads   to   fibrosis   within   the   retina, 
(http://www.stlukeseye.com/Conditions/DiabeticRetinopathy.html). 
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Figure 1 -18 Diabetic retinopathy: New thin walled and fragile blood vessels 
are formed .Organisation of the haemorrhage causes fibrosis within the retina. 
(http://www.stlukeseye.com/Conditions/DiabeticRetinopathy.html). 
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Circulatory system attempts to maintain appropriate oxygen amounts nside the 
retina. This is called neovascularization. Unluckily, these types of new vessels 
are delicate, and haemorrhage easly. Blood may possibly leak in to the the retina 
and vitreous, producing spots or floaters, along with decreased visionIn the 
advanced phases of the disease, continued abnormal vessel growth and scar tissue 
formation may cause severe problems include ingretinal detachment and 
glaucoma. 
 
 
1.37 Pathophysiology of Diabetic Retinopathy 
The mechanism of DR is still unclear, but some studies suggest that chronic 
hyperglycemia is a major cause of damage to multiple organs. Complications of 
chronic hyperglycemia will lead to inadequate perfusion due to vascular organ 
tissue damage, including damage to the retina itself. There are four biochemical 
processes that occur in chronic hyperglycemia and are related to the onset of 
diabetic retinopathy, among others. 
1.37.1 Accumulation of Sorbitol 
Excessive production and accumulation of sorbitol because of the activation of 
the polyol pathway occurs due to increased activity of the enzyme aldose 
reductase that is present in nerve tissue, retina, lens, glomerulus, and the walls of 
blood vessels. Sorbitol is a sugar compound and alcohol, which cannot pass 
through the basal membrane and will accumulate in large amounts in the cell. 
Cell damage caused by the accumulation of sorbitol, which is hydrophilic, occurs 
when the cells become swollen due to osmotic process. In addition, sorbitol also 
increases the ratio of NADH / NAD+ thereby reducing the uptake mioinositol. 
Mioinositol serves as a precursor for the synthesis of phosphatidylinositol 
modulation of the enzyme Na-K-ATPase that regulates nerve conduction. In 
short, the accumulation of sorbitol can cause disruption of nerve conduction. 
Experiments on animals have shown the enzyme aldose reductase inhibitor 
(sorbinil) that inhibits the formation of sorbitol, can reduce or slow the onset of 
diabetic retinopatic. However, clinical trials in humans have not shown a slow 
down of progressive retinopathy (Susan, 1993; Nagoya, 1997). 
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1.37.2 Formation of protein kinase C (PKC) 
There are currently at least 13 known isoenzymes of the PKC family are expressed 
preferentially in different tissues of the body. The vascular, retinal and renal tissues 
express PKC- I and PKC- II more so than other isoenzymes (Nagpala et al., 1996). 
Under conditions connected with hyperglycaemia, PKC activity in the retina and 
the vascular endothelial cells is elevated because of increased de novo synthesis of 
diacylglycerol that is a regulator of glucose cyclic citrullinated peptide (CCP). PKC 
could have an influence on platelet aggregation, vascular permeability, synthesis of 
growth factors and vasoconstriction.Increase in CCP improves diabetic 
complications, simply by interfering with vascular permeability and retinal the 
circulation of blood flow (Helen and Christopher 2007). Increased vascular 
permeability will cause plasma extravasation, therefore increasing intravascular 
blood viscosity, and is accompanied with an increase in platelet aggregation causing 
thrombosis. Moreover, the growth factors formation will produce an increase in 
vascular smooth muscle cell proliferation and extracellular matrix including fibrous 
tissue; subsequently, there will be thickening of the vascular wall combined with 
the activation of endothelin-1, which is a vasoconstrictor that narrows vascular 
lumen. These effects combined will eventually cause retinal vascular occlusion 
(Lee et al., 1989; Daria et al., 2012). 
1.37.3 Formation of Advanced Glycation End Products (AGE) 
 
Glucose binds to the amino group in a non-enzymatic manner to form a covalent 
bond. The process will ultimately result in AGE compounds. The effects of AGE 
are mutually synergistic with the effects of PKC, causing increased vascular 
permeability, synthesis of growth factors and endothelin activation whilst, 
inhibiting the activation of nitric oxide by endothelial cells. The process will 
increase the risk of retinal vascular occlusion (Sho-ichi and Takanori, 2009). 
AGE contained inside and outside cells, correlated with glucose levels. AGE 
accumulation that precedes cell damage. The level of AGEs is 10-45X higher in 
DM than non-DM patients in 5-20 weeks. In patients with diabetes, the glucose 
rise induced AGE accumulation is substantial, and this accumulation is faster in 
the intracellular than extracellular compartment. (Sho-ichi and Takanori, 2009) 
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1.37.4 Formation of Reactive Oxygen Species 
Reactive Oxygen Species (ROS) is a phrase used to express a number of reactive 
molecules and free radicals derived from molecular oxygen. ROS formed from 
oxygen to the m et al ion catalyst or enzyme that produces hydrogen peroxide 
(H2O2), superoxide (O2-). Recent evidence has shown that ROS play a key role as 
a messenger in normal cell signal transduction and cell cycling. In case of 
Autooksidasi increased ROS generation through glucose on polyol pathway and 
degradation of AGE. ROS accumulation in tissues would lead to oxidative stress, 
which adds to cell damage (Hancock et al., 2001) 
 
 
1.38 AGE-driven angiogenesis in vitro 
Yamagishi et al. (1997) studied AGE-driven angiogenesis in vitro, and tested 
BSA- AGE on the growth and tube-formation of human microvascular 
endothelial cells. Moreover, Kim et al. (2008) suggested that AGE-induced 
proliferation of cells via binding of RAGE-AGE occurs through signalling 
pathways. During treatment of cells with AGE, cell proliferation was 
significantly increased compared to control cells in vitro, as shown in figure 1.19 
(Yamagishi et al., 1997; Kim et al., 2008). 
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Figure 1 .19 shows the probable mechanism of the development of diabetic 
microangiopathy. (Yamagishi et al., 1997) 
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1.39Pharmacologic Management of DR 
Although effective in stopping the progression of DR, a procedure for retinal 
photocoagulation surgery does not destroy tissue and improve vision. 
A. Corticosteroids: These agents possess anti-inflammatory properties and the 
ability to down regulate VEGF, thereby reducing leakage from damaged retinal 
capillaries. Safety studies are ongoing for this class of drugs. 
B. VEGF Inhibitors: VEGF is a suitable therapeutic target because it is 
upregulated in DR and contributes to neovascularization and capillary leakage in 
severe DR. Because VEGF inhibitors are administered intravitreally, adverse 
systemic effects are minimized (Simó and Hernández, 2009). C. Renin- 
Angiotensin System (RAS): 
Inhibitors: Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II 
receptor blockers (ARBs) reduce DR and VEGF levels in PDR (Leal et al., 
2005). 
D. Antiplatelet Drugs: 
 
Platelet aggregation contributes to capillary occlusion and microaneurysm 
formation in DR. The antiplatelet drug ticlopidine has an off-label indication to 
delay the rate of microaneurysm formation in NPDR (Knight, 2003). E. Protein 
Kinase C (PKC) Inhibitors: 
The beta isoform of PKC modulates and up regulates the expression of VEGF, 
which, in turn, contributes to microvascular DR complications (Shen, 2003). 
F. Advance Glycation End-Product (AGE) Inhibitors: 
Accumulation of AGEs in the  diabetic retina appears to contribute to the 
endorgan damage detected in DR. Pimagedine, also known asamino guanidine, 
is an oral AGE inhibitor under investigation for its ability to prevent end-organ 
complications. Adverse reactions and oral dosing have not been fully elucidated 
(Brownlee et al., 1986; Vasan et al., 2003). 
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1.40 Diabetic retinopathy treatment 
 
The best treatment for diabetic retinopathy is to prevent it, during the first three 
stages of diabetic retinopathy, no treatment is needed and before macular 
oedema; people with diabetes should control their levels of blood sugar, blood 
pressure, and blood cholesterol. Treatment usually will not cure diabetic 
retinopathy nor does it usually bring back normal vision, but it could slow the 
progression of vision loss. Without treatment, diabetic retinopathy progresses 
steadily from minimal to severe stages. 
 
1.40.1 Laser surgery 
The laser is traveling throughout the clear cornea, lens and vitreous without 
affecting them at all. Laser surgery minimizes abnormal new vessels and 
decreases macular swelling. Treatment is usually recommended for those who 
have macular edema, proliferative diabetic retinopathy (PDR) and neovascular 
glaucoma. However, it is nessary to understand the Laser surgery does not cure 
diabetic retinopathy and does not always prevent further loss of vision. 
1.40.2 Medication injection 
In many circumstances, medication can often help care for diabetic 
retinopathy.Occasionally a steroid medication can be used. In other cases 
antiVEGF medication used. This substance contributes to abnormal blood vessel 
growth in the eye. An anti-VEGF drug can help decrease the growth of these 
abnormal blood vessels. The medication reduces the swelling, leakage, and 
growth of unwanted blood vessel growth in the retina, and may improve the 
eyesight. Medication treatments may be given once or as a series of injections at 
regular intervals, usually around every four to six weeks. 
1.40.3 Vitrectomy surgery 
Vitrectomy is a surgery where in operating microscopes and smaller precise 
equipment areused to remove blood, and scar tissue that accompany abnormal 
vessels in the eye. By removing, the vitreous haemorrhage the obstacle will 
eliminate and allows light rays to focus on the retina again.Vitrectomy usually 
prevents further vitreous haemorrhage by removing the abnormal vessels that 
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caused the bleeding. Elimination of the scar tissue allows the retina go back to 
its normal location. 
1.41Small leucine-rich proteoglycans (SLRP) 
SLRPs are comprised of a small leucine-rich protein core approximately 40 KDa, 
consist of 17 members of secreted proteins divided in five classes based on their 
structural composition and chromosomal location (Figure 1.20).(Iozzo, 1999; 
Henry et al., 2001; Dellett et al., 2012). The core proteins contain a number of 
leucine-rich repeats (LRRS), which consist of the consensus sequence 
LXXLXLXXNXL, where X is any amino acid, L is leucine or valine, and N is 
asparagines, cysteine or threonine. The N-terminal domain contains the 
negatively charged and covalently attached glycosaminoglycan (GAG) chains, 
and the central domain of the protein comprises approximately 80 % of the 
molecule, composed of tandem repeats of leucine-rich regions. The first class 
includes decorin (Krusius and Ruoslahti, 1986). The second class includes 
lumican (Blochberger et al., 1992), fibromodulin (Oldberg et al., 1989), 
keratocan (Corpuz et al., 1996), praline, arginine-rich end leucine-rich repeat 
protein (PRELP) (Bengtsson et al., 1995), and osteoadherin/osteomodulin 
(Sommarin et al., 1998). The third class within the SLRP family comprises 
epiphycan/proteoglycan-Lb (shinomura and Kimata,  1992), 
mimican/osteoglycin (Madisen et al., 1990) and opticin/oculoglycan (Reardon et 
al., 2000; Friedman et al. 2000). 
The fourth class includes Chondroadherin, Nyctalopin and Tsukuhi (Ohta et al., 
2004), and fifith class includes Podocan (Ross et al., 2003), and Podocan-like 1 
Protein (Mochida et al., 2011). More recently, as a function of their various 
proteins cores and glycosaminoglycans side chains, SLRPs have ability to bind 
to various cell surface receptors, growth factors, cytokines and other ECM 
components resulting in the ability to influence various cellular function (Dellett 
et al., 2012). 
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Figure 1 .20 Dendrogram representing the evolutionary relationship between 
the members of the SLRP family (Dellett et al., 2012) 
Horizontal distances are proportional to the evolutionary distance and based on 
human protein sequences. This family is mainly subdivided into three main 
classes (Classes I, II, III, IV and V) based upon the genomic organisation, the 
number of LRRs and the spacing of the four cysteine cluster. 
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1.42 Opticin 
Reardon and colleagues discovered opticin in an eye-specific molecule (Reardon 
et al., 2000, Pattwella et al., 2010) by using a 4 M guanidine hydrochloride 
extract from bovine vitreous collagen fibrils to prepare peptides as a starting 
point for molecular cloning. Another group of researchers discovered an iris 
specific molecule, which they termed oculoglycan (Friedman et al., 2002), and 
was later on found to be identical with opticin. Opticin expression is believed to 
be mostly specific to the eye since human opticin sequence can be found in only 
eye specific EST libraries (Hobby et al., 2000; Wistow et al., 2002). Using in- 
situ hybridisation and immunohistochemical studies they showed opticin was 
especially immunolocalised to the vitreous humor where labelling was most 
intense in the basal and cortical vitreous gel and less intense in the central 
vitreous. The findings suggested that opticin is secreted by the non-pigmented 
ciliary epithelium into the vitreous cavity where it associates with vitreous 
collagen and adjacent basement membranes (Ramesh et al., 2004).Furthermore, 
opticin was found in various ocular tissues, mainly the ciliary body, the iris, and 
the anterior vitreous close to the pars plana. 
Fovola et al., isolated a chicken homologue of opticin (cOptc), using in situ 
hybridisation, cOptc was found to be expressed in the brain and neural tube from 
developmental stage 9 onwards. At later stages, cOptc expression was found 
strongly in the non-pigmented ciliary epithelium. Expression of cOptc was 
analysed from stages 4–26 with opticin mRNA been detected in not only the 
ciliary epithelium but optic stalk, neural tube, brain including Rathke’s pouch, 
pharyngeal pouches, nasal pit and optic vesicle (Fovola et al., 2004). 
Opticin is a proteoglycan of the small leucine rich repeat (LRR) family located 
in the ECM. The sequence of opticin and glycation target amino acids is shown 
in Figure1.21. 
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Figure 1.21 The amino acid sequence of opticin chain,taken from the 
Q9UBM4 entry in Swiss-Prot/TrEMBL protein database. It consists of 332 
amino acid residues.48 leucine amino acids (L), and 13 valine amino acids 
(V).Glycated target amino acids are26 arginine amino acids (R), 8 lysine amino 
acids (K), and 6 cysteine(C),(Adapted from;Swiss-Prot/TrEMBL protein 
database). 
 
 
Opticin has been shown bind to glycosaminoglycans (GAGs) including heparin 
and chondroitin sulphates (Hindson et al., 2005), suggesting a role in stabilising 
vitreous structure and maintaining vitreoretinal adhesion. Bishop first suggested 
a function in maintaining gel stability and structure (Bishop, 2000). The vitreous 
is composed mainly of a type-II collagen scaffold full with a matrix of 
hyaluronan. Other non-collagenous proteoglycans and proteins for instance 
versican and fibulin could be involved in stabilisation of this delicate structural 
network (Bishop, 2000). It is suggested that opticin is bound to the surface of 
chondroitin sulphate proteoglycan type-IX collagen and is covalently linked to 
their surface. Chondroitin sulphate chains of the type-IX collagen on one fibril 
could link to opticin on the surface of adjacent fibrils explaining the ladder like 
conformations of chondroitin sulphate GAG chains seen bridging adjacent fibrils 
observed in ultra-structural studies of the vitreous using cationic dyes like 
Cupromeronic Blue (Le Goff and Bishop, 2006). 
Opticin is the only member of the LRR family of proteins present in the vitreous 
binds to heterotypic vitreous collagen fibrils. One of the proposed functions of 
- 79 -  
this family of proteins is the prevention of lateral association, or aggregation, of 
collagen fibrils, and its abundance in the vitreous may be important to the 
determination of appropriate short-range spacing of the thin collagen fibrils of 
the vitreous essential to permit light transmission. In this sense then, these 
proteins are regulators of supramolecular organisation of tissues and include 
other proteins such as decorin and lumican. These have importance to spacing of 
other critical collagenous matrices for example the corneal stroma (lumican 
knockout mice have opaque corneas) and skin matrix. 
Coating of vitreous collagen fibrils with molecules for instance opticin and 
typeIX collagen through its chondroitin sulphate chains could thus have a dual 
purpose: first allow structural integrity of the vitreous give link to form a 
contiguous collagen network; second, these molecules also might avoid 
aggregation of the vitreous fibrils, which would destabilise the gel. During ageing 
or disease, mainly after cellular infiltration of the gel, these molecules are likely 
to be damaged or degraded and thus lead to collagen fibril aggregation and gel 
condensation, clinically known as vitreous syneresis. The vitreous is normally 
anti-angiogenic, but becomes pro-angiogenic in many diseases for instance 
proliferative diabetic retinopathy, however the vitreous maybe has multiple 
mechanisms for avoiding angiogenesis because they are essential for vision and 
hence survival. Opticin continues to secrete into the vitreous cavity throughout 
life, therefore unlikely to be purely structural. Another role for opticin has been 
suggested, namely, as a repository for growth factors (Sanders et al., 2003). 
Binding of growth factors by matrix molecules is well recognised. For example, 
vitreous type-II collagen binds TGF-β and BMP-2 (Zhu et al., 1999; Fukui et al., 
2003). Fibroblast growth factor among many other factors is stored 
extracellularly in basement membranes bounce to a heparan sulphate 
proteoglycan (syndecan) (Li et al., 2003). Opticin also appears to bind growth 
hormone (Sanders et al., 2003). Growth hormone has been implicated in new 
vessel growth either directly or through its mediator insulin-like growth factor 1 
(IGF-1), mainly during development, and matrix molecules for instance opticin 
may have a role in ensuring an enough supply of growth hormone for ocular 
vasculogenesis. This could beapplying to the retina and other ocular tissues since 
opticin appears to be widely distributed in the eye. Thus, it may have more 
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functions besides promoting the development of the hyaloid vascular system 
during embryogenesis. 
1.43 Methylglyoxal 
 
1.43.1 Functionality involving methyalglyoxal 
Methylglyoxal (MG) research started late in the 19th century with the research 
focus being synthesis, and understanding the reactions of MG (Kalapos, 1999). 
MG, often known as pyruvaldehyde, is remarkably reactive aldehyde compound 
with carbonyl groups and occurs as a yellowish fluid with a strong odour. 
Methylglyoxal production has been discovered in all mammalian cells and it is 
essentially generate from glucose metabolism through the glycolytic pathway 
(Phillips and Thornalley, 1993). In this pathway, the usual of MG is thought to 
be formed by the non-enzymatic and / or enzymatic elimination of phosphate 
from dihydroxyacetone phosphate (DHAP) and glyceraldehyde 3-phosphate (G- 
3-P) 
 
 
 
1.43.2 MG and AGEs 
AGEs, a group of brown colored compounds with intra- or inter-molecular 
crosslinking, are formed by the Maillard reaction of aldehydes and ketones with 
amino groups of proteins (Singh et al., 2001). The formation of AGEs is age- 
correlated (Li et al., 1996) and they are found to accumulate slowly in vascular 
and renal tissues. However, the accumulation of AGEs is accelerated in 
conditions such as complications of diabetes (Brownlee et al., 1988). As the most 
active AGE precursor, MG reacts with residues of different proteins including 
arginine, lysine and cysteine and therefore forms different AGEs, such as 
argpyrimidine, (Dhar et al., 2008). Many studies, both in vivo and in vitro have 
proved that increased MG leads to an increase in AGEs formation. In cultured 
VSMCs, CEL and CML production detected using immunohistochemistry 
increased significantly after treatment with MG for 3 hours (Dhar et al., 2008). 
In the spontaneously hypertensive rat (SHR) kidney, immunoreactivity to CEL 
and CML increased at 8, 13 and 20 weeks groups compared to age-matched 
Wistar-Kyoto (WKY) rats, but not in the 5 week group, following the same 
pattern as MG levels in the plasma (Wang et al., 2004; Wang et al., 2005). 
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Medical information indicates that plasma MG concentrations are 5-6 folds 
higher in patients with Type 1 diabetes mellitus and 2-3 fold in those with type 2 
diabetes mellitus (McLellan et al., 1994). 
 
 
 
1.44 Protein glycation 
 
1.44.1 Chemistry of protein glycation 
Nonenzymatic glycation, in which reducing sugars are covalently attached to free 
amino groups and ultimately form AGEs, has been found to occur during the 
normal aging and at accelerated rate in diabetes mellitus. They preferentially 
occur on lysine and arginine amino acids. Oxidation, accompanying glycation in 
vivo, further supports chemical modifications. AGE formation and protein 
crosslinking are irremediable processes that modify the structural and functional 
properties of proteins, lipid components and nucleic acids. Moreover: A general 
pattern of the chemistry involved in the glycation reaction is outlined in Figure 
1.22. Protein glycation divided into three different steps: 
 
1. Early stage, Protein glycation: This ends in Amadori products. 
 
2. Intermediate stage, after the occurrence of Amadori products. Over a period 
of time, this rearrangement results in more reactive products, such as dicarbonyl 
compounds including glyoxal, MOG and deoxyglucosones. 
3. An advanced stage, which ends with the formation of heterogeneous 
compounds known advanced glycation end products or (AGEs). 
- 82 -  
 
 
 
 
 
Figure 1.22 Formation of advanced glycation products 
(Harding and Ganea, 2006) 
 
 
 
1.44.2 Advanced Glycation end products 
They interact with nearby proteins to produce pathological cross-linkages that 
harden the tissue. According to the glycation hypothesis, accumulation of AGEs 
alters the structural properties of tissue protein and reduces their receptiveness to 
metabolism (Peppa and Vlassara 2005). 
1.44.3 AGEs groups: 
 
a. Fluorescent cross-linkingAGEs. 
 
b. Non-Fluorescent cross-linking AGEs. 
 
c. Non-Cross-linking AGEs. 
 
Metabolic intermediates and intracellular reducing sugars other than glucose are 
largely responsible for the formation of AGEs. One of the most reactive 
metabolic  intermediates  is  MOG.  Alternatively,  AGEs  can  enter  the  body 
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exogenously through diet and smoking. One of most common AGEs found in 
tissues is Necarboxymethyllysine (CML). Another pathway of protein 
modification by glucose involves the auto oxidation of glucose or the Schiff base 
to form low weight carbonyl compounds such as glyoxal (GO), MOG, and 
glycolaldehyde (GLA), which can modify lysine as well as arginine residues. 
1.44.4 RAGE (receptor for advanced glycation end products) 
RAGE was first identified as a cell surface receptor for the products of 
nonenzymatic glycation and oxidation of proteins, the advanced glycation 
products (AGEs). Several AGE receptors have been characterized on the surface 
membranes of monocytes, macrophage, endothelial, neuronal, mesangial and 
hepatic cells including macrophage scavenger receptor type-I and type-II, 
oligosaccharyl transferase-48 (AGE-R1), 80 K-H phosphoprotein (AGE-R2) and 
Galectin-3 (AGE-R3) and RAGE, a member of the immunoglobulin superfamily 
which has been found to have a wide distribution in tissues(Li et al., 1996). The 
RAGE gene was first cloned and characterized from mouse lung in 1992.The 
principal means through which AGEs influence cellular actions is by binding to 
specific receptors. (Christiane et al., 2014). 
Moreover, RAGE is a transmembrane receptor comprising 394 amino acids with 
a single hydrophobic transmembrane domain of 19 amino acids, and a short 
cytoplasmic tail of 43 amino acids, which is essential for intracellular signalling 
as figure1.23. 
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Figure 1 .23 Schematic representation of RAGE. 
Schematic representation of RAGE and the generation of some of its isoforms. 
RAGE is composed of an intracellular tail, a transmembrane domain, and an 
extracellular domain consisting of three immunoglobulin-like domains, one 
Vtype followed by two C-type (C1 and C2) domains. The V-type domain is 
essential for ligand binding, and deletion of this domain results in an N-truncated 
form. The C-truncated, circulating soluble RAGE corresponds to the 
extracellular domain of RAGE lacking the intracellular tail and transmembrane 
domains. It may derive via proteolytic cleavage of full-length RAGE from the 
cell surface (cRAGE) or via alternative splicing of RAGE mRNA (esRAGE). C: 
constant; V: variable. (Yaw Kuang et al., 2013). 
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1.45 Sources of AGEs 
 
1.45.1 Exogenous sources of AGEs 
The formation of AGEs is usually endogenous, but can be derivative from 
exogenous sources (Figure 1.24), such as tobacco smoke and food (Nicoll ID, 
1998). Numerous studies propose that introducing exogenous AGEs into the 
biological systems may have significant impacts in terms of the progression of 
disease processes. Although it is well recognised that cigarettes can lead to 
vascular disease, Tobecco derived AGE have been observed in the lens crystallin 
and conary artery walls (Nicoll, 1998), what role exogenous AGE have in 
contributing to this process, especially in diabetes, is not known. Heat treatment 
of food results in non-enzymatic browning; it has been proposed that the 
accumulation of food derived AGE in cause glomerus damage. (Ross, 1993). 
Evidence has accumulated that dietary AGEs are partially absorbed (Forster et 
al., 2005) and either retained in the body or excreted in the urine (Erbersdobler 
and Faist, 2001). These dietary AGEs represent an important source for 
circulating AGEs under in vivo conditions (Vlassara, 2002; Uribarri et al., 2003). 
 
 
 
 
Figure 1 .24 The cycle of endogenous and exogenous AGEs. Adapted from (Ali 
et al., 2014). 
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1.45.2 AGEs inhibitors 
Attempts have been made to pharmacologically manipulate the process of 
nonenzymatic glycation in order to prevent or slow down the formation of 
glycation products. AGE inhibitors can be classified into six categories or types. 
Pyridoxamine (PM) is an in vitro inhibitor of the formation of AGEs by blocking 
the reaction at the Amadori intermediate. The exact mechanism of how PM 
functions as a post-Amadori inhibitor is unknown. However, it has been 
determined that PM scavenges reactive carbonyl products of glucose degradation 
along with interfering with the catalytic role of redox metal ions in glycoxidative 
reactions. Guanidine compounds have the capacity to trap -dicarbonyl 
compounds, which can subsequently stop reactions from occurring with protein 
amino groups. Noteworthy, a guanidine compound was presented as being a 
nucleophilic hydrazine compound concerned with entrapping those carbonyls 
created during the process of the glycation reaction particularly Amadori 
products; thereby hindering the formation of AGEs. 
 
1.45.3 RAGE blockers 
Moreover, the inhibition of glycation reactions, another approach to reduce 
AGEmediated damage may be adopted by preventing cellular actions of AGEs. 
These compounds exert their actions via several different mechanisms, such as 
blocking the interaction between AGEs and RAGE, or inactivating either AGEs 
or RAGE and thereby preventing their interaction, or by the inhibition of the 
intracellular signalling transduction mediated by the AGEs-RAGE interaction. 
The prototype agent for the trapping of AGE ligands is soluble RAGE (sRAGE), 
which is the extracellular ligand-binding domain of RAGE. The use of sRAGE 
to interfere with the binding of RAGE in diabetic animals has been reported to 
prevent several effects of hyperglycaemia, such as diabetic nephropathy and 
macrovascular injury. It is also known to restore effective wound-healing and 
decreased levels of cytokines, such as TNF-α, IL-6 and of metalloproteinases. 
Recently, a novel splice variant coding for a soluble RAGE protein, called 
endogenous secretory RAGE (esRAGE) (Shigeru et al., 2003), has been 
identified in human vascular cells. It neutralises AGEs and exerts protection 
against AGEinduced endothelial cell injury. 
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1.45.4 Measurement of glycation reaction products 
Determination of protein modification has always been a challenge for 
biochemists. Due to the AGEs are found as a mixture of different structures, their 
measurement has always been difficult to achieve, the absence of internal 
standards leaves assays open to error, which requires a high degree of accuracy 
and reproducibility of each sample. So far, a measure of AGEs measurement is 
limited to laboratory investigation, and there is no commonly accepted method 
for estimating AGE, or any commercially available kit. 
Several tests have been employed both qualitatively and quantitatively to 
determine the level of active AGE. Predictably, AGEs have specific fluorescence 
characteristics and the detection of AGEs by fluorescence spectroscopy one of 
the main methods of measuring in vitro and in vivo are used. 
Assay methods of separation such as SDS-PAGE, were also used during the 
search of glycation. In addition, immunochemical methods, using mainly ELISA 
monoclonal and polyclonal antibodies specific for defined age structures, enable 
highly sensitive and quantitative measures of AGE. Recently, mass spectrometric 
techniques have been widely introduced in the search for glycation. It was 
reported that the use of matrix-assisted laser desorption ionization-time mapping 
of flight mass spectrometry of peptides (MALDI-TOF-MS) is a valuable tool for 
the determination of specific protein glycation products, the both in vitro and in 
vivo. 
Moreover, the measurement of the reaction products of glycation can be divided 
in to three different samples and experiment all largely biological, and includes 
the measurement of early glycation products, the measurement of intermediate 
glycation products, and measurement advanced glycation products. 
1.45.4.1 Measurement of early glycation products 
The measurement of early-stage glycation products (Amadori products) is 
generally used to evaluate metabolic controls in diabetic patients. The two 
parameters regularly used are glycated haemoglobin (HbA1c) and glycated 
serum proteins. 
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1.45.4.2 Measurement of intermediate glycation products 
Advanced glycation endproduct accumulation is enhanced in diabetes, with 
concomitant increases in the concentration of dicarbonyl compounds, such as 
glyoxal, MOG and 3-deoxyglucosone. Estimation of dicarbonyl compound 
levels is one of interest in terms of evaluating oxidation processes occurring in 
glycated proteins. Such compounds may be quantitatively determined using mass 
spectrometric techniques of diabetic patients. 
1.45.4.3 Measurement of advanced glycation products 
Advanced glycation endproducts were initially measured by spectroscopic and 
fluorimetric methods. However, these methods are not very specific, and can 
only provide mere indications on the general trend of the glycation process. More 
recently, however, various investigators have developed ELISA methods using 
poly-and monoclonal antibodies. The limitation of this current methodology is, 
however, that there is no absolute AGE standard for quantitative analysis. 
Advanced glycation endproducts are currently being identified as biomarkers for 
specific disease processes. Amongst those found in vivo, are CML and 
pentosidine. 
1.45.5 Methylglyoxal reacts with proteins to form AGEs 
MOG is an α-dicarbonyl compound that reacts with lysine, arginine and histidine 
residues in proteins to form AGEs, such as hydroimidazolone, argpyrimidine and 
MOG lysine dimer (MOLD). MOG is derived mostly from triose phosphate 
intermediates of glycolysis by non-enzymatic mechanisms in vivo. AGE 
formation from MOG occurs predominantly in arginine residues of proteins. 
Examples of arginine-derived AGEs caused by MOG glycation are 
argpyrimidine and hydroimidazolone. 
1.45.6 Reactive carbonyl species 
Carbonyl species are compounds containing the (C=O) carbonyl functional 
group. As the oxygen atom in the carbonyl group is more electronegative than 
the carbon atom, it pulls the electrons from the carbon atom and thereby increases 
the polarity of the carbonyl group. The carbonyl carbon is electrophilic in nature 
and  readily  reacts  with  nucleophiles.  The  carbonyls  methylglyoxal  (MG), 
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glyoxal, acrolein, hydroxyhexenal, hydroxynonenal (HNE) are highly reactive 
compared to other carbonyls produced in the biological system (Ellis, 2007). 
These carbonyls are collectively called reactive carbonyl species (RCS). RCS are 
more stable than the free radicals, and can diffuse over long distances to reach its 
target molecules (Lesgards et al., 2011). 
 
 
1.46 Carbonyls in pathological conditions 
Persistent hyperglycaemia in  diabetic patients causes  metabolic alterations, 
leading to over production of a variety of intermediary metabolites. One of the 
metabolites is the reactive αβ-dicarbonyl, MG, which are both an aldehyde and 
a ketone. MG has been attributed to be responsible for the development and 
progression of diabetes and diabetes associated vascular complications 
(Bourajjaj et al., 2003) including atherosclerosis, ischaemia, hypertension, 
retinopathy and nephropathy (Brownlee, 2001). All of the diabetes associated 
vascular complications are characterized by a variety of changes in the micro and 
macro vasculatures. Most of these changes are due the impairment of the 
appropriate response of the vasculatures to vascoactive substances, hormones, 
neurotransmitters, cytokines 2 etc. The changes in the vasculature can be one of 
the following or a consortium of many abnormal functions of the vasculature and 
high potential for thrombosis can lead to atherosclerosis. Inflammation, presence 
of high levels of oxidants and stiffening of the vasculature and improper 
expression of surface markers are also markers for vascular complications 
(Creager et al., 2003). In Alzheimer’s disease an increase in the levels of 
acrolein, HNE and acrolein, modified proteins have been identified (Lovell et al., 
2001). Increased levels of HNE and HNE modified proteins have also been 
identified in hypertension (Asselin et al., 2006) and HNE have  also been 
identified in atherosclerotic plaques (Leonarduzzi et al., 2005). MG is also 
thought to be present in the amyloid plaques (Kuhla et al., 2005). 
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Aims 
Protein glycation is a feature of chronic diabetes and can result in modified 
cellular function. It was before shown that opticin is an important constituent of 
the eye and may be liked to modulation of vascular growth and subsequent PDR 
in diabetic patient. Therefor in this project aim to: 
1-  Identify the characteristics and glycation pattern of opticin. 
2-  Measure the effect of opticin glycation on: 
A-Modulation angiogenesis in vitro. 
B-Signal transduction capacity. 
3-  Demonstrat its potential important in determining vascularization 
associated with PDR. 
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2 Material and Methods 
All the reagents and chemical used in this thesis were of cell culture grade as 
appropriate. 
2.1 Material 
2-Mercaptoethanol (Sigma, UK) 
ABTS   peroxidase   substrate:   2,   2-Azino-bis   (3-ethylbenz-thiazoline- 
6sulphonic acid) (Vector, UK). 
Acrodisc 32mm syringe filter with 0.2 µm membrane (Pall Corporation). 
Acrylamide/Bis-acrylamide solution 40% (Bio-Rad Laboratories, 
Germany). 
Alexa fluor green fluorescence dye (Sigma. 
Ammonium persulphate (Sigma, UK). 
Anti- fibroblast growth factor antibody (Santa Cruz Biotechnology) 
Antiactin (α-actin), rabbit polyclonal antibody (Sigma) Anti-AGE (Abcam).  
Antibiotics: L-glutamine, pencilline, and streptomycin solution in 
0.9%NaCl (Sigma). 
Anti-human VLA-2integrin (Millipore). 
Anti-mouse polyclonal IgGperoxidase conjugate (Sigma). 
Anti-Opticin (Abcam). 
Anti-Paxillin (Millipore). 
Anti-Talin (Millipore). 
Anti-Vinculin (Millipore). 
Basic fibroblast growth factor; bovine (R & D systems). 
Blotting papers (Whatman). 
Bovine aortic endothelial cells, secondary cell line. 
Bovine serum albumin (Sigma). 
Bromophenol blue (Serva, Germany). 
Coomassie brilliant blue (Sigma, UK). 
ECL and ECL + kits (Amersham Biosciences, Buckinghamshire, UK). 
Flk-1 (C-20): VEGFR-2 antibody (Santa Cruz Biotechnology, Inc). 
Fo et al bovine serum (Cambrex Bioscience). 
Gelatine, 0.1% w/v (Sigma). 
Glacial acetic acid (Fisher Scientific International, UK). 
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Glycerol (BDH, UK). 
Glycine (BDH, UK). 
Horse-radish peroxidase conjugated goat anti-rabbit IgG, whole molecule 
(Sigma). 
Hydrochloric acid (HCl) (BDH, UK). 
Isopropanol (Sigma, UK). 
Lysozyme (Sigma, UK). 
Matrigel TM basement membrane reduced (Becton Dickinson). 
Methanol (Fisher Scientific International, UK). 
MOGMG (Sigma, UK). 
N, N, N′, N′-tetramethylethylenediamine (TEMED) (Sigma, UK). 
Nitrocellulose membrane, protan nitrocellulose (Schleicher & Schuell). 
Opticin (Manchester University). 
Para formaldehyde (Sigma). 
Peroxidase conjugated rabbit anti-mouse immunoglobulin (DAKO). 
Protein molecular weight marker for SDS-PAGE (Sigma, UK). 
Recombinant human FGF-2 (R & D System). 
Silver stain (sigma, UK). 
Six-well, 24-well, 48-well and 96-well plates, 96-well EIA/RIA plates 
(Nunc corporation). 
Sodium azide (Sigma, UK). 
Sodium bicarbonate (NaHCO3) (Sigma, UK). 
Sodium dodecyl sulphate (SDS) (BDH, UK). 
Sodium hydroxide (NaOH) (BDH, UK). 
Staining solutions: methylene blue, giemsa (Sigma). 
Sterile needle (Terumo). 
Thermanox plastic cover slips, 13mm diameter (Nunc Corporation). 
Thymidine (Sigma). 
Tissue culture flasks; T-25, and T-75 (Nunc). 
Tris (hydroxymethyl) methylamine (BDH, UK). 
Trypan blue (Sigma). 
Trypsin-10X (Sigma), trypsin-EDTA solution, trypsin blocking solution, 
buffered saline rinsing solution (TCS Cell Works). 
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Tween 20, glycine, sodium dodecylsulphate, NaCl (Sigma). 
 
 
2.2 Solutions 
Acrylamide/bisacrylamide solution (Bio-Rad Laboratories). 
Antibody dilution buffer: primary and secondary antibody diluted 1XX 
bloking solution. 
APS (10%): 100mg was dissolved in 1mL dH2O. 
Bicarbonate/carbonate coating buffer (100mM): 3.03g Na2CO3, 6.0g. 
NaHCO3 and 1 L dH2O PH 9.6. 
Blocking solution: 1%BSA in PBS. 
Bovine serum albumin (1%): 1g BSA to 100 mL TBS-tween. The pH 
adjusted to 7.4. The buffer was stored at 4°C for one week. 
Destianing solution: Methanol (250 ml) was mixed with 70 ml of acetic 
acid and the volume was made up to 1 L with dH2O. 
Electrophoresis buffer: 12.02g Tris-base, 4g SDS and 57.68g glycine were 
dissolved in 2 L dH2O. The buffer was kept at RT. 
Milk (5%): 5g milk to 100ml TBS-tween. The pH was adjusted to 7.4 and 
the buffer stored at 4°C for one week. 
Phosphate buffer solution (0.1 M) (pH 7.4): the acid component of the 
buffer (sodium dihydrogen phosphate) and the basic component (sodium were 
weighed out in a certain ratio according to the Henderson). 
Hasselbalch equation. The desired volume was then accordingly adjusted 
with distilled water and the solution was mixed. The pH of sodium phosphate 
buffer was adjusted to 7.4. Sodium azide was added to the mixture to prevent 
any bacterial growth. Then stored at 4 °C. 
Phosphate buffered saline (PBS): one tablet of PBS was dissolved in 100 
ml H2O and autoclaved at 121°C for 15 min. 
Radioimmunoprecipitation assay (RIPA) buffer: contain 50mM Tris- HCL, 
0.25%  SDS,  1%  Triton  X-100,  0.15M  NaCl,  1mM  EDTA,  1%  sodium 
Deoxycholat 1 mM sodium orthovanadate, 1g/mL pepstatin and 0.5 mM 
PMSF, pH 7.2. 
Running buffer: Tris-base (1.5 g), glycine (7.2 g) and (0.5 g) of SDS were 
dissolved in 500 ml distilled water. 
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Sample treatment buffer: Sodium dodecyl sulphate (0.1 g) and 0.1 ml of 2 
mercaptoethanol were added to 1 ml of solution C (what is solution C) and 2ml 
of glycerine and the volume was made up to 10 ml with distilled water. 
Separation gel: In a universal tube; 2.5 ml of separating solution was added 
to 6.1 ml of distilled water and mixed with 1.45 ml of 40% cold acrylamide 
solution, 100 µl of APS was added to the mixture. Gel polymerization was 
initiated by adding 10 µl of room temperature TEMED and allowed to 
polymerize for 10-15 min. 
Stacking gel: 2.5 ml of separating solution in 4.2 ml of distilled water was 
mixed with 3.3 ml of 40% cold acrylamide solution. 100 µl of APS was added 
to the mixture. Polymerization was initiated by adding 10 µl of TEMED. The 
gel was allowed to polymerize for 7-10 min, the solution was stored at 4 °C. 
Towbin buffer: 1.51g Tris-base, 7.2g glycine and 0.167g SDS were 
dissolved in 400 mL distilled water and 75mL methanol. The pH adjusted to 
8.3 and adjusted to 500 ml with distilled water. Moreover, the buffer kept at 
room temperature. 
Wash solution: PBS containing 0.05% Tween 20 (TBST). 
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2.3 Equipments 
 Blotter (Semi-Phor, Hoefer Scientific Instruments) 
 Centrifuges (Eppendorf and Laborzentrifugen 3K10, Sigma) 
 CO2 incubator (Lab Impex Research) 
 Cross power 500 for electrophoresis (Scientific laboratory Supplies Ltd, 
England). 
 Cryo vials (Nunc) 
 De-ionizer (Millipore) 
 Digital multi channel pipits (Eppendorf) 
 Dual gel casting electrophoresis chambers (Scientific Laboratory Supplies 
Ltd, England) 
 Fluorescence microscope 
 Freezer (-80oC) (Juan Quality Systems) 
 Ice maker (Borolab Ltd) 
 Immunofluorescence microscope (Zeiss Axo imager Z1) 
 Inverted phase contrast microscope 
 Laminar flow hood or safety cabinet: tissue culture grade (Walker Safety 
Cabinet Ltd) 
 Luminescence spectrometer model LS 30 (Perkin Elmer). 
 Magnetic stirrer hotplate (Stuart Scientific Co, England). 
 Media card reader (MISCO, UK) 
 Microplate reader, 96-well (Spectramax) 
 Orbital shaker (Denley) 
 Single threshold coulter counter (Beckman Coulter) 
 Sonicator 
 Universal model 200 laboratory, pH meter (Medical scientific instruments, 
England). 
 Vortex (Chiltern) 
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2.4 Methods 
 
2.4.1 Dialysis procedure 
To remove unbound MG before protein assay, MG-treated opticin were 
subjected to extensive dialysis against distilled water by using dialysis cassette. 
Cassette was placed in warm water for 5 minutes. The Protein samples were 
delivered into dialysis cassette after the air was removed by pressing on the 
membrane. Dialysis cassette was placed into 2L beaker containing distilled 
water. A few drops of chloroform were added to prevent any contamination. 
Dialysis was carried out by stirring the samples at 4 ºC for 4 – 5 changes over 1 
to 2 days. At the end of dialysis, the dialysed samples were transferred into clean 
tube and stored in freezer until used. (Figure 2.1). 
 
Figure 2.1The dialysis process by using the dialysis cassette 
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2.4.1.1 Coomassie brilliant blue 
The stain dissolved in 500 ml of methanol and 100 ml of acetic acid. The volume 
was made up to 1 L with distilled water and then filtered. The staining solution 
was stored at room temperature. The colloidal Coomassie brilliant blue staining 
of polyacrylamide gels was performed with the Roti-Blue kit (Carl Roth GmbH). 
After SDS-PAGE, the gels were incubated with Roti-Blue staining solution for 
215 h with constant agitation. The gels were then incubated in destining solution 
until the background of the gels appeared nearly transparent. Then the gels were 
washed with dH2O several times. 
2.4.2 MALDI TOF Mass Spectrometry 
This work has done by Kratos Analytical Limited Company, Manchester.UK. 
All samples were supplied in PBS buffer at 2.5mg/ml concentration but PBS 
buffer should be removed from the samples because of the damaging effect of 
this buffer on the MALDI ionisation process. Therefore, there are two methods 
to clean up the samples including drop-dialysis using 0.025 μm VSWP 
membrane and C18 ZipTip (both are from Millipore corp. USA). However, in 
this test just one of the clean up methods was successfully utilised, which was 
the ZipTip method. The next stage, 5uL of each of the samples was dialyzed 
against millipore H2O using drop dialysis disks (millipore) for 60 minutes. The 
samples (1ul) were then spotted directly on to the MALDI plate with Sinapinic 
acid matrix (1uL) and left to dry. Each sample was analyzed in linear mode using 
an Axima Confidence MALDI-TOF instrument (Shimadzu/Kratos) with a 
standard raster containing 121 points. 
2.4.3 Sliver staining of polyacrylamide gels 
Silver staining is a highly sensitive method for detecting proteins and nucleic 
acids in polyacrylamide slab gels. The Bio-Rad Silver Stain, derived from the 
method of Merril, 1 is 10-50 fold more sensitive than Coomassie brilliant blue, 
and we used Modified Silver Stain Protocol as in (Bio-Rad Laboratories 
protocols). This modified protocol, optimized for mini gels (~7 cm x 8 cm x 0.75 
mm), gives clear backgrounds and consistent results in less time than the standard 
protocol. 
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2.4.4 Silver Stain Protocol 
Fixative: 40% methanoland 10% acetic acid (v/v). 
Oxidizer: 10 ml of oxidizer and 90-deionizer water. 
Silver Reagent: 10 ml of reagent and 90 deionised water. 
Developer: 32 grams of developer per litre of deionised water. 
Stop: 1% acetic acid (v/v):200 ml of acetic acid and 800ml deionised water. 
The protocol for mini-gels (up to 1.0 mm thick). When gel removed from glass 
and place in several gel volumes of milli-Q water shake it for 30 minutes. Then, 
discard water and add Fixing Solution (approx. 100 mls for a small gel). Shake 
for 10minutes. After replace fixing solution with Rinse Solution. Shake for 
5minutes.Replace rinse solution with Sensitizer. Shake for 2 minutes, and discard 
sensitizing solution and replace with dH2O. Shake for 2minutes, and wash with 
dH2O three times for 5 minutes. After second wash, add developers shake for 
1minute and repeat it until the bands visualized. Last step discard developer and 
add Stop Solution. Shake for at least 5 minutes. Wash gel with dH2O. 
2.4.5 Image analysis of SDS-PAGE gels 
The gels were analyzed using either  laser densitometer 2202 Ultroscan or 
photographed using Gene snap programme from G Box Chem HR16. Bands 
were compared within the same gel. 
 
 
2.5 Preparations of samples 
 
2.5.1 Preparation of MG-treated opticin 
Opticin (1mg/ml) was incubated with MG (0.1M) in 0.1M sodium phosphate 
buffer containing 3mM sodium azide, pH 7.4 at 37 °C for 0, ½ hour and, 1, 3, 6, 
days at 37 ºC. After incubation, un-reacted MG was removed by dialysis against 
distilled water for 2 days at 4 ºC and samples were stored at -20 °C. Control 
opticin was incubated under the same conditions without the addition of MG. 
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2.5.2 Detection of AGE using MALDI/TOF. 
Bruker Autoflex MALDI-TOF-MS (Bruker Daltonik, Germany). All samples 
were supplied in PBS buffer at 2.5mg/ml concentration but PBS buffer should 
be removed from the samples because of the damaging effect of this buffer on 
the MALDI ionisation process. Therefore, there are two methods to clean up the 
samples including drop-dialysis using 0.025 μm VSWP membrane and C18 Zip 
Tip that both are from (Millipore corp. USA). However, in this test just one of 
the clean-up methods was successfully utilised, which was the ZipTip method. 
For MALDI analysis, 1 uL of sample was loaded onto the sample plate with 
0.5uL of sinapinic acid matrix (saturated sinapinic acid in 50% Acetonitrile/50% 
0.1% TFA) and allowed to co-crystallize on the sample target. The mass 
spectrometer is equipped with a nitrogen laser (337 nm, 3ns pulse width). All 
measurements were performed in positive ion linear mode using delayed ion 
extraction. The delay time was adjusted according to the mass of the protein. The 
ion acceleration voltage was set to 20 kV. In all MS/MS experiments, helium was 
used as the collision gas. 
 
 
2.5.3 Cell culture 
All tissue culture experiments and procedures were carried out in a sterile 
environment in a class II biological safety cabinet. Ethanol [70% volume/ volume 
(v/v)] was used for cleaning all surfaces before commencing work. Only sterile 
plastics were used and all media were pre-warmed by placing in a water bath at 
37ºC for 30 minutes before use. 
2.5.3.1 Routine culture of bovine aortic endothelial cells 
Bovine Aortic Endothelial Cells (BAEC) characterized by the presence of von 
Willebrand factor and the uptake of Di-labeled acetylated low density lipoprotein 
were previously isolated at Manchester Metropolitan University by Dr Slevin. 
They were routinely cultured in Dulbecco’s modified Eagle’s medium containing 
15 % foetal Bovine serum (FBS) (DMEM/FBS), 1.5 mM glutamine, 100 IU/ml 
penicillin, and 50 ng/ml streptomycin (complete medium). Culture flasks were 
maintained at 37 °C in a humidified incubator (5 % CO2 and 95 % air). Cells 
were passaged once per week at a ratio of 1:3 and used within ten passages in all 
experiments. Cells at concentration of 1.5 x 105 and 5 x 105 in 10 to 15 ml of 
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complete medium were seeded into T-25 and T-75 flasks, pre-coated with 0.1% 
gelatine (Sigma, UK) and cultured in DMEM (Lonza, UK) supplemented with 
15% fo et al bovine serum (FBS, Cambrex, UK), 2 mM glutamine and 1% 
antibiotics (100 µg/ml streptomycin, 100 U/ml penicillin). Cells were put in 
saturated air humidity 5% CO2-incubator at 37°C. Growth medium was changed 
every 2-3 days, when the cells were confluence; they were sub-cultured by 
enzymatic digestion with 0.05% trypsin / 0.02% EDTA and split at a ratio of 1:3. 
 
 
 
2.5.3.2 Sub-culturing of endothelial cells 
Medium was discarded from the flasks, and the cells washed twice with 10-15 
ml sterile PBS at 37 ºC and incubated with 5-10 ml of 1 % (v/v). Trypsin / 
Ethylene Diamine Tetra Acetic acid (Trypsin/EDTA; 4 ml) solution for 2 to 5 
min. Detachment of cells was checked by phase contrast inverted microscope. 
Upon cell detachment, 5-10 ml of complete medium was added immediately to 
the flask to neutralise the trypsin. The cell suspension was transferred to a 25 ml 
centrifuged tube, and centrifuged at 1500 rpm for 5 min. The supernatant was 
discarded and the pellet was resuspended in 1 ml fresh medium at 37 ºC. For a 
T75 culture flask, it was pre-coated with 2 ml of 0.1% gelatin. 
 
 
 
2.5.3.3 Trypsinization 
Medium from the flask was discarded and washed twice with 10 ml sterile PBS 
and incubated with 5 to 10 ml of 1 × trypsin solution for 2 to 5 minutes. 8-10 ml 
of complete media was added immediately to the flask to neutralize the trypsin. 
The resulting cell centrifuged at 1500 rpm for 5 minutes. The supernatant was 
discarded and the pellet was suspended in 1 ml fresh medium, and the cell 
number was determined. 
 
 
2.6 Storage of cells in liquid nitrogen 
Cell pellets were resuspended in freezing medium composed of 10 % DMSO in 
FBS. Approximately 3.5 × 105 cells in cold freezing medium were transferred to 
labeled cryotubes on ice and placed at -20 for 1 h, then transfer into the upper 
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level of the gaseous phase of liquid nitrogen for another 1 h and 30 min after that 
transferred to the liquid nitrogen for long term storage. 
2.7 Thawing Frozen Cells 
The vial was removed from liquid nitrogen, thawed immediately in a water bath 
at 37°C, and transferred to an empty sterile 15mL Falcon tube. DMEM media 
containing 15% was added drop wise to a volume of 10mL. The tube was 
centrifuged at 1500 rpm for 5 minutes at room temperature. The Pellets were then 
resuspended in fresh complete medium and seeded in T75 cm2 culture flasks. 
 
2.8 Cell counting 
Under experimental conditions medium was aspirated and the cells were rinsed 
in PBS and detached using a 1 % trypsin (v/v) solution. 0.1 ml of cell suspension 
was added to 20 ml Isoton solution and transferred to a counting chamber; and 
was mixed and counted at least three times using a Beckman Coulter counter. 
The following equation was used when 0.5 ml of trypsinzed cell suspension was 
added to 20 ml of isotonic solution and cells were counted as cells/ml: 
 
X (cell number) × (20/0.5) = X × 40 (dilution factor) 
 
 
2.9 Preparations of medium 
 
2.9.1 Preparation of complete medium (15% FBS); 
Pre-warmed sterile FBS was denatured at 65-70 ºC for approximately 30min and 
other reagents were mixed as described below (Table 2.1) 
Table 2.1 Preparation of 15% FBS culture medium 
 
 
Reagents 
Volume of Medium 
(100ml) 
Volume of Medium 
(500ml) 
 
DMEM 
 
84 ml 
 
420 ml 
 
 
FBS 
 
 
15 ml 
 
 
80 ml 
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2.9.2 Preparation of 2.5 % FBS and 0.1% FBS 
 
Serum-poor medium containing 2.5% or 0.1% FBS was prepared by diluting 15% 
FBS with DMEM as indicated in (Table 2.2) 
Table 2 .2 Preparation of 2.5% and 0.1% FBS culture medium 
 
 
Reagents 
 
0.1% FBS (120 ml) 
 
2.5% FBS (120 ml) 
 
DMEM 
 
118.2 ml 
 
99 ml 
 
15%FBS 
 
0.8 ml 
 
20 ml 
 
PSG 
 
1.0 ml 
 
1.0 ml 
 
2.10 Proliferation assay 
BAEC cells (3×104 cells/ml) in 0.5 ml of culture medium (15% FBS) were 
seeded in 24-well plates and allowed to adhere for approximately 4 hours. The 
complete medium was discarded and the cells were washed gently with PBS 
twice. Fresh media supplemented with 2.5% FBS was added to each well. 
Compounds at various concentrations, were incubated with and without growth 
factors, FGF-2 (25 ng /ml), opticin (25µg/ml) and FGF-2 + opticin (native or 
glycated), or opticin (native or glycated) controls wells were prepared 
appropriately. The contents of the plate were gently mixed to avoid possible 
dislodging of cells and incubated for a further 72 hours. Cells were washed twice 
with PBS and 250µl of trypsin was added to each well. The number of cells was 
counted using a Coulter counter. Experiments were carried out in triplicate wells, 
and repeated three times independently. The statistical analysis was carried out. 
All results are represented by means ± S.D. analysed t test between two groups, 
(*), (p<0.05) statistically significant. 
 
 
- 105 -  
Equation for determination of % change; Percentage change in the presence of 
growth factors was calculated using the above equation. 
 
2.11 Wound healing assay 
Thermanox plastic coverslips were placed in a 24-well plate. BAECs at a 
concentration of 2.4 × 105/ml were added to each well in complete medium and 
incubated for 24-48 hours. When confluent, the medium was replaced with (0.1% 
FBS, DMEM) and cells were incubated for a further 24 hours. Cells were washed 
with PBS (3-4 times) and wounded with a sterile razor blade producing uniform 
and straight edged cuts. The wounded cell monolayer was washed with PBS to 
remove cellular debris or dislodged cells and placed in a fresh 24-well plate 
containing serum poor medium (SPM) (0.1% FBS). Factors pre-incubated with 
FGF-2 (25ng/ml), opticin (native or glycated) were added to the test wells. For 
each experimental condition, cells were treated in triplicate. Plates were 
incubated in 5% CO2 incubator at 37 °C for 24 hours. Pilot studies demonstrated 
that BAEC wounded under these conditions underwent negligible proliferation 
up to 24 hours; however, cell movement resulting in wound closure was 
statistically significant in cells treated with growth factor after 24 hours. The 
coverslips were rinsed 3 times in PBS, fixed in 100% ethanol for 5 minutes, and 
allowed to air dry. Cells were stained with methylene blue for 30 seconds and 
excess stain was removed with distilled water. The plates were left to air dry. 
Pictures were taken using phase contrast microscopy (40×) for 10 random areas 
of each cover slip. Movement of cells into the denuded area was quantified by 
counting numbers of migrated cells in each field of view. For each coverslip, 10 
fields of view (each ~2 mm by 1.45 mm) were examined at random. To evaluate 
cell migration, two parameters were taken into account: the number of migrated 
cells counted under a light microscope (×40) into five random fields of denuded 
area and the distance of migration from the wound edge obtained by Image J, 
image analysis software (http:rsb.info.nih.gov//ij/). The number of migrated cells 
to the denuded area was determined by counting the number of cells in the injured 
area. Statistical significance was determined by one-way analysis of variance. 
Cell migration was examined from the “wound” edge by the aid of a microscope 
and photographed using a digital camera. Each photomicrograph was analysed 
with Image analysis software. A representative example is shown (Figure2.2). 
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Figure 2 .2 BAEC migration after 24 hours incubation. 
 
 
2.12 Boyden chamber 
BAEC migration was examined in vitro using TranswellCostar® porous 
membranes (Milian Laboratory Products, Gahanna, OH, USA; 8-mm pore filter) 
in a 24-well plate. Inserts were coated overnight with 100µl sterile 0.1% gelatine 
each insert and air-dried. BAEC were seeded at a concentration of (7.3×104 cells/ 
ml) in 100 mL of serum-poor medium, on the upper part of the filter and factors 
at different concentrations with and without chemo attractants; FGF-2 (25ng/ml), 
opticin (25ug/ml: native or glycated) and their combination were added. Basal 
medium was supplemented with 0.1% FBS. For each experimental condition, 
cells were treated in triplicate. Cells were incubated in 5% CO2 incubator at 37
oC 
for 24 hours. After incubation, the cells that did not migrate on the upper surface 
of the membrane were removed with a cotton swab soaked with PBS then wiped 
with a dried cotton swab. The cells that had migrated were fixed with 4% 
Paraformaldehyde, left to air-dry and stained with Giemsa stain and five 
microscopic fields from each membrane counted with an optical microscope. 
Cells migrations in triplicate wells were determined by counting the number of 
cells in the lower side of the filter using optical microscopy (10X objectives) 
A 
Wound edage 
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2.12. A. Expression and purification of recombinant bovine Opticin 
Opticin was provided by Professor Paul Bishop (Welcome trust centre for 
cellmatrix research, Manchester University, UK). Briefly, full-length 
recombinant bovine Opticin was expressed in 293-EBNA cells (human 
embryonic kidney cells, Invitrogen) using pCEP-pu expression vector. This 
expression vector is a modified version of the pCEP4 expression vector from 
Invitrogen. The expression and the purification of the recombinant protein were 
performed as previously described (Le Goff et al., 2003) using a combination of 
anion-exchange (DEAE) chromatography and Jacalin lectin affinity 
chromatography. 
 
 
2.13 Formation of tube-like structures in MatrigelTM 
EC/matrigel suspensions 1:1 (v/v) containing 1.5 × 106 cells/ml (BAEC and 
HUVEC) and 1.0 × 106 cells/ml (HREC) were prepared in triplicate and 
supplemented with (1) PBS, (2) Opticin (25 µg/ml), (3) FGF-2 (25 ng/ml), (4) 
FGF-2 (25 ng/ml) and Opticin (25 µg/ml), and spotted into 48-well plates and 
incubated for 1 hour at 37 ºC to allow the gel to polymerise. For BAEC and 
HREC, 0.5 ml of DMEM supplemented with 2 % (v/v) FCS and the appropriate 
treatments (1-4) listed above, and for HUVEC, 0.5 ml of large vessel basal 
growth medium (with growth supplements) supplemented with 2 % (v/v) FCS 
and appropriate treatments (1-5) were added to the wells. The gels were 
incubated for 24 h at 37 ºC to allow capillary morphogenesis. The Matrigel gels 
were then fixed with 4 % (v/v) PFA in PBS for 10 minutes at RT. The tube-like 
structures were examined and photographed using a phase contrast microscope 
(Nikon TMS and Nikon coolpix 4500 Digital camera). The total length of tube- 
like structures was measured in 5 fields of view for each experimental condition. 
Statistical significance was determined by student’s t-test. 
 
 
2.14 Formation of tube-like structures in type-I Collagen 
Prior to starting the experiment ECs were cultured in SPM containing 0.1 % FCS 
(v/v) (BAEC and HREC) and 2 % FCS (v/v) for 48 h. Cells suspensions at a 
concentration of 4.5 × 105 (HREC) and 7.5 × 105 (BAEC) cells/min in medium 
containing 0.1 % and 2 % FCS l were mixed with collagen at a concentration of 
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300 µg/ml and supplemented with (1) PBS (2) Opticin (25 µg/ml) (3) FGF-2 (25 
ng/ml), (4) FGF-2 (25 ng/ml) and opticin (25 µg/ml), and spotted in triplicate 
into 48-well plates and allow to polymerise for 1 hour at 37 ºC. After 
polymerisation, 0.5 ml of medium containing 0.1 % or 2 % FCS (v/v) 
supplemented with treatments 1-5 was added to the corresponding wells in the 
48-well plate and the gels incubated for 72 hours at 37 ºC to allow capillary 
morphogenesis. The gels were fixed with 4 % (v/v) PFA in PBS for 10 minutes 
at RT and dehydrated with 70 % ethanol for 30 minutes followed by 100 % 
ethanol for 5 minutes at -20°C. The collagen gels were allowed to dry overnight 
and stained with Giemsa. The total length of tube-like structures was examined 
using a phase contrast microscope (Nikon TMS) and photographed using a 
digital camera (Nikon coolpix 4500). The total lengths of the tube-like structures 
were measured in 5 fields of view for each experimental condition. Statistical 
significance was determined. 
2.15 SDS-PAGE 
Semi-confluent BAEC were cultured in 6 well plates in 2 % (v/v) FCS for 48 h 
then pre- before the addition of FGF-2 (25 ng/ml) ± Opticin (25µg/ml), and 
incubated at 37 ºC for 10 min and 24 h. Total cell lysates were collected in RIPA 
buffer, centrifuged at 10,000g for 15 min at 4oC to remove insoluble debris and 
stored at –70 oC until use. Protein concentration of cell lysates was determined 
using a modification of the Bradford assay (Bio-Rad, California, USA). Equal 
quantities of protein (10 ug) were mixed with 2 x Laemmli sample buffer, vortex 
mixed and boiled in a water bath for 15 minutes. SDS-PAGE was carried out 
using 4-12 % Bis-Tris gradient gels (Invitrogen). Samples were separated along 
with pre-stained molecular weight markers (20-200 kDa) or LI-COR’s pre- 
stained Western Blotting 
Proteins were transferred onto nitrocellulose filters for 1 hour 30 min and blocked 
for 1 hour at room temperature in TBS-Tween (50 mM Tris-HCl, pH 8.0, 0.15 
M NaCl containing 0.1 % (w/v) Tween-20/BSA). Filters were stained with the 
following primary antibodies diluted in blocking buffer overnight at 4oC on a 
rotating shaker; rabbit monoclonal antibody to ERK-1/2 (1:1000), mouse 
monoclonal antibody to phospho-ERK-12, rabbit monoclonal antibody to p38 
(1:500),  mouse  monoclonal  antibody  to  phospho-p38,  rabbit  monoclonal 
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antibody to JNK (1:500), mouse monoclonal antibody to phospho-JNK, rabbit 
monoclonal antibody to MEK-1/2 (1:1000), goat monoclonal antibody to 
phospho-MEK-1/2, rabbit monoclonal antibody to AKT-1, goat monoclonal 
antibody to phospho- 
AKT-1 and rabbit polyclonal α-Actin (1:1000). After washing 5 × 10 min in 
TBS-Tween at RT filters were stained with rabbit anti-goat, rabbit anti-rat, and 
goat anti-rabbit or rabbit anti-mouse horseradish peroxidase-conjugated to 
secondary antibodies diluted in TBS-Tween containing 5 % (w/v) de-fatted milk 
(1:2000) for 1 hour at RT with continuous shaking on an orbital mixer. After a 
further 5 washes in TBS-Tween, proteins were visualised using ECL 
chemiluminescent detection. 
 
 
 
2.16 Protein extraction for total proteins 
BAEC (1.5 × 105 cell/ml) were plated into a 6-well plate (Nunc), in 2 ml of 
complete culture medium (15% FBS) DEME. When they were confluent 
(8090%), medium was discarded, and cells were washed with PBS. Fresh SPM 
(2.5% FBS) was added to each well, according to the following experimental 
conditions:- Control, opticin(25ug/ml :native or glycated), FGF-2 (25ng/ml), and 
their combinations (FGF-2 + opticin [native or glycated]), and the cells were 
incubated for different periods of incubation time (10 minutes, 24, 48 and 72 
hours), in a 5% CO2 incubator at 37
oC. After 72 hours of incubation, the medium 
was discarded, and each well was rinsed with 500 μl of cold PBS. Ice cold 
radioimmuno precipitation buffer (RIPA) 400µl was added to wells and kept on 
ice. Gently the plate was shaken on ice for a few minutes, cells were scraped 
using a cell scraper. The total cells lysates were transferred to cold eppendorfs 
tubes on ice and stored at -20oC until used. 
 
2.17 Protein estimation for Western blotting 
Protein estimation was undertaken Bio-Rad protein assay: 1) 0.1% of bovine 
serum albumin (BSA) (1 mg/ml in distilled water) was prepared. 2) The Bio-Rad 
dye was diluted to 1:5 in distilled water. 3) A standard curve was prepared by 
measuring the absorbance at 570 nm. For Western blotting; the protein content 
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of each sample was normalised to 30µg then diluted half volume with the sample 
buffer, for a loading amount of 15µg (Table 2.3). Samples and sample buffer 
were mixed and boiled for 15 minutes, standard curve was calculated 
 
 
 
 
Table 2 .3 BSA dilution to establish the standard curve. 
 
BSA Standard ( μg) 
0 5 10 20 40 
 
BSA volume added (1μg/ µl) 
0 5 10 20 40 
 
Volume of dH2O(µl) 
 
100 
 
95 
 
90 
 
80 
 
60 
 
Volume of Bio-Rad (1:5)(ml) 
 
2 
 
 
2.17.1 Western blotting 
The acrylamide gel was prepared by mixing 3.3 ml of 40% bis-acrylamide with 
4.2 ml distilled water and 2.5 ml separating buffer in a universal tube. 100 µl of 
10% ammonium persulphate (APS) solution was added followed by 10µl 
TEMED solutions and the gel left to polymerise for 20 minutes. A few drops of 
isopropanol were added on top of the gel. Isopropanol was removed after 15 
minutes and rinsed with plenty of distilled water, for one minute. As much as 
possible, distilled water was removed by filter paper and then the stacking 
solution was prepared in a second universal tube, by combining 1.45 ml of 40% 
bis-acrylamide with 6.1 ml distilled water, and 2.5 ml stacking buffer. As before, 
100 µl APS was added followed by 10 µl TEMED solution and the gel left to 
polymerise for a minimum of 20 minutes. 
Slowly the combs, clamps, and gaskets were removed taking care not to damage 
the wells and the gel plates inserted into the electrophoresis chamber. The 
chamber was subsequently filled with reservoir buffer (25 mM tris, 192 mM 
glycine, 0.1% SDS, pH 8.3). A total of 500 ml-electrode buffer was used to fill 
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the tank, in the space between the two sets of glass plates. Take samples, sample 
buffers and molecular weight marker out of freezer and warm in room 
temperature. The protein concentration of each sample was determined by 
BioRad protein assay to facilitate equal protein loading/well. Equal parts of 
protein sample and sample buffer were mixed in eppendorfs tube, the tubes were 
placed in boiling water for 15 minutes, molecular weight marker 10 µl aliquots 
were boiled for one minute, and then sample buffer 20 µl, molecular weight 
marker 10 µl and the protein sample from plaques 20 µl were gently loaded. 
Sample buffer was added to the first and last well and in the second well 
molecular weight marker was added. The syringe was washed after loading the 
marker (Table 2.4). 
Samples containing 15 μg protein (up to 20 µl solution), along with pre-stained 
molecular weight markers, were separated by SDS-PAGE (10% w/v) for~45 
minutes at 60V (when samples were in stacking gel) and switched to 200V for 
separation until the dye, bromophenol blue, reached the bottom of the separation 
gel. 
 
 
 
Table 2 .4 Preparation of stacking and separating gels for Western blotting. 
 
 
dH2O 
Separating/Stacking 
buffer 
Acrylamide 
40% (4ºC) 
Ammonium 
persulphate 
TEM 
ED 
Separating 
solution 
4.2ml 2.5ml 3.3ml 100µl 10µl 
Stacking 
solution 
6.1ml 2.5ml 1.45ml 100µl 10µl 
 
 
2.17.2 Blotting 
Two nitrocellulose membranes (NCM) and 12 pieces of blotting paper were 
soaking for 2 minutes in tow bin’s buffer. Stacking gels were removed from the 
separation gels and discarded. The gels were sandwiched separately. The 
sandwich was assembled in an electro blotter for each gel as follows: Three 
pieces of blotting paper /NCM/gel/3 pieces of blotting paper. Any bubbles within 
the sandwiches were removed by rolling a clean 5 ml tip over the sandwich. 
Proteins were transferred to the membrane at 40 mA/gel for one hour. 
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2.17.3 Blocking 
Membranes were blocked with 1% BSA incubation for 1 hour at room 
temperature on rotating shaker. BSA was discarded and membranes were 
incubated separately in 10 ml of primary antibody solution (1:1000) dilution 
(rabbit polyclonal anti-ERK 1/2 and mouse monoclonal antibodies to pERK1/2 
at 4oC. After overnight incubation on a rotating shaker, primary antibody 
solutions were discarded (we can used another time), membranes were washed 
five times in tris buffered saline, and tween-20 (TBS-tween) for 10 minutes each 
at room temperature on rotating shaker. Membranes were incubated for 1 hour at 
room temperature in 10 ml of mouse anti-rabbit or rabbit anti-mouse horseradish 
peroxidase-conjugated secondary antibody diluted in TBS-tween containing 5% 
(w/v) de-fatted milk (1:1000) for ERK 1/2 and pERK1/2 respectively. After 
incubation, secondary antibody solutions were discarded and membranes were 
washed five times in TBS-tween for 10 minutes each at room temperature on a 
rotating shaker. 
2.17.4 Developing 
In a dark room, membranes were immersed in enhanced chemiluminescence 
(ECL) solution. To prepare the ECL solution, 1ml of solution-A was added to 
1ml of solution-B and kept in the dark room for five minutes. Once the ECL 
solution was prepared, it was then poured on to the membranes for one minute, 
left in the dark room excess reagent was drained off, and membranes were 
quickly wrapped in cellophane films and kept in a box. The box was taken to the 
G-Box and the sample was measured as a chemiluminescent sample the 
intensities of bands on the membranes were quantified by image analysis 
software. The results were semi-quantitative and compared to the loading 
control. 
2.18 .Binding assay opticin (native and glycated) binding to collagen type-I 
Binding assays were performed using ELISA-based techniques. Briefly, 96-well 
plates were coated with collagen type-I at 50 μg/ml in PBS or with Tris-buffered 
saline, pH 7.4 (TBS), containing 2 mM Mn2+ (TBS/Mn2+). Each experimental 
well was repeated in triplicate. After washing with TBS containing 0.1% Tween 
20 (TBS-T) or TBS-T/Mn2+, the wells were blocked with 5% BSA. Increasing 
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concentrations of recombinant opticin or biotinylated collagen type-I was 
prepared in blocking buffer. These ligands were added to wells for 2 hours. After 
washing, bound opticin was detected using an affinity-purified anti-rabbit opticin 
antibody followed by an HRP-conjugated anti-rabbit antibody. Bound 
biotinylated collagen type-I was detected using HRP-conjugated streptravidin. 
After extensive washing, TMB substrate was added to the wells, and the 
absorbance was measured at 620 nm using a Multiscan plate reader. Absorbance 
obtained from wells coated only with BSA wassubtracted from the experimental 
wells. All these experiments were performed in triplicate. 
 
 
 
2.19 .Binding assay with opticin and FGF-2/FGFR complex 
 
The 96 well plate coated with 100ul/well of capture antibody (goat anti-FGFR1) 
in coating buffer at a concentration of 2 µg/ml. the plate were sealed and 
incubated at 4oC overnight. Aspirate  well and wash 3 times with at least 
300ul/well wash buffer. Inverted the plate and bloted on absorbent paper to 
remove any residual buffer. Wells blocked with 200µl/well of 1% BSA in PBS. 
Incubate at room temperature for 2 hours. The well aspirated and washed 3 times 
with at least 300ul/well by wash buffer. Inverted the plate, blot on absorbent 
paper to remove any residual buffer, and stored at 4 C until use. 
 
Added FGFR 2µg/ml 100ul per well. Added 100 µl well of antigen (Opticin used 
as different concentration 0-5-10-25-50-100 µg/ml added to 2 µg /ml FGF-2 to 
the wells. Plate sealed and incubated at room temperature for 2 hours. Aspirated 
well and washed 3 times with at least 300ul/well by wash buffer. Inverted the 
plate and bloted on absorbent paper to remove any residual buffer. Added 
100ul/well of anti-FGF2 antibody diluted in blocking buffer at a concentration 
of 2 µg/ml. The plate sealed and incubated at room temperature for 1 hour. 
Aspirated well and washed 3 times with at least 300ul/well by wash buffer. 
Inverted the plate and bloted on absorbent paper to remove any residual buffer, 
than Add 100ul/well of secondary antibodies conjugated  to HRP anti-goat 
ANTIFGFR1 diluted blocking buffer at 1/500 dilution and incubate at room 
temperature for 45 minutes. After that well aspirated and washed 3 times with at 
least 300ul/well wash buffer. Inverted the plate and blot on absorbent paper to 
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remove any residual buffer. In this wash step, soak wells in wash buffer for 1 to 
2 minutes prior to aspiration. Repeated for a total of 7 washes. Meanwhile, DAB 
substrate prepare during plate washing. Add 8 drops of DAB stock 100ul/well of 
ABTS substrate solution to each well. Incubated plate at 37 C for 2 to 10 minutes. 
The color development can be stopped by adding 100ul of stop solution 
2MH2SO4, or use ABC Preoxidease staining kit lastly read plate at 405-450 nm. 
2.20 The frozen section 
The key instrument for cryosection is the cryostat, which is essentially a 
microtome inside a freezer. The mouse eyes was placed on a m et al tissue disc, 
which is then secured in a chuck, and frozen rapidly to about –20 to –30°C.The 
eyes was embedded in a gel like medium consisting of poly ethylene glycol and 
polyvinyl alcohol; this compound is known by many names and when frozen has 
the same density as frozen tissue. The sections cut at 4µm, each three sections 
placed on one slide, the slides saved in freezer until use. 
2.21 Immunocytochemistry 
Cover slides (treated in NaOH 1M for 30 min; wash H2O: Ethanol 100%) dry 
them than coated with and 0.1% gelatin in 24 well plate, BAEC were seeded at 
105cells/ml in DMEM on cover slip on each well, the conditions were added to 
each well, and left for1 to three hours in incubated at 37°C after that they were 
fixed with 4% Para formaldehyde for ten minutes. The cells were washed 3 
times/5 min in PBS and treated with 0.5% hydrogen peroxide for 30 minutes. 
Cells permeabilized with 0.1% Triton X100 (v/v in PBS) for 4 minute. Cells were 
washed again with PBS for 3 times/5 minutes. Nonspecific sites were saturated 
with blocking serum 1% BSA for 20 minutes at room temperature. cover slips 
were  incubated  with  primary  Antibody  150  µl  each  well  (  anti-  Paxillin, 
antiVinculin, and anti-VLA-2 (α2β1).for 2-3  hours at room temperature or 
overnight at 4C. wash the cells twice with PBS, for 5 mintes. Incubate the 
in the dark, with a 1:100 diluted of goat anti-mouse IgG fluorescein conjugated 
secondary antibody in 1% BSA in PBS for 1 hour at room temperature. Wash the 
cells three times with PBS, for 15 minutes. Examine the cells under a fluoresce 
microscope. 
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2.22 Immunohistochemistry 
Cut sections were selected carefully; drew around the section with hydrophobic 
pen and fellow these steps: A.Fixation: The slides were incubated in coplin jar 
containing 4% Paraformaldehyde in 1X PBS for 5minutes. The slides were 
Rinsed in 1× PBTS for 3× 3 minutes. B. Secondary Antibody Block: The 
sections were Incubated in diluted blocking serum (10 % BSA diluted with 
PBST) for 30 minutes (constantly). The slides were rinsed in 1× PBST for 1× 
5mins.C. Primary Antibody binding: The sectios were incubated with 
appropriately primary antibody (Anti-opticin 1:100 and Anti-AGE1:150). The 
slides were rinsed in 1×  PBST for 3× 3mins. D. Fluorescent  Secondary 
Antibody Binding: The sections were incubated with 1:100 diluted secondary 
antibodies in block buffer for 60 minutes. Rinse slides 1× PBS for 3× 3mins and 
dry off excessive liquid. E. Mounting (with DAPI counter stain for nuclei): 
Few drops were added of Vector Hard mount over sections. The slids were 
covered with cover slip, (taking care not to produce bubbles under the cover slip). 
The slides were kipet for 15minutes to dry than keepet them covered in fridge. 
The sectios were visualized with a Zeiss fluorescent microscope. 
 
2.23 Statistical analysis 
Statistical analysis was made through using Microsoft Excel 2007 program. Data 
were expressed at mean ± standard deviation (SD). Statistical significance was 
assessed by Student’s t-test. P-values below 0.05 were considered as statistically 
significant (*P ≤ .05, **P ≤ .01, ***P ≤ .001). Each experiment was repeated at 
least three times (n=3), and a representative example is shown. 
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3 Results 
3.1 Glycation 
 
3.1.1 Quantification and localisation of opticin glycation 
Under hyperglycaemic conditions in diabetes, the level of dicarbonyl compounds 
including MG is increased and lead to the formation of AGEs (Brownlee 2001; 
Vander-Jagt 2008). A 5-6 fold increase of MG levels in the blood samples of 
insulin dependent (type-1) diabetic patients and a 2-3 fold increase in blood 
samples of non-insulin dependent (type-2) diabetic patients has been reported ( 
McLellan et al., 1994). Preretinal neovascularisation is responsible for the start 
of diabetic retinopathy and ends in blindness. Collagen fibrils of vitreous humour 
offer a fundamental substrate for this process. These fibres are coated with 
opticin, a glycoprotein previously shown to be a potent endogenous inhibitor of 
angiogenesis (Le Goff et al., 2012). Here we show that exposure of opticin to 
MG produces glycation. 
3.1.2 Opticin detection by SDS-PAGE 
The opticin was donated by Manchester University following extraction from 
human vitreous collagen fibrils at 6.13mg/ml, following this opticin was diluted 
to 1mg/ml. The migration of opticin was visualized at 45 kDa as determinedby 
SDSPAGE following silver staining. This experiment was repeated three times 
and a representative SDS-PAGE gel is shown in figure 3.1. 
 
Figure 3 .1Opticin detection by SDS-PAGE. 
 
The native opticin at (1mg/ml) was mixed with sample buffer, and PBS used 
as negative control, was electrophoresed on a 12% SDS-PAGE gel. The 
experiment was repeated three times and a representative SDS-PAGE gel is 
shown. 
- 120 -  
3.1.3 Elecreophoretic analysis of Glycated opticin 
To study the (AGE-opticin) formation the different sugar types being used; MG, 
glucose, fructose, and ribose. SDS-PAGE is a method commonly used to separate 
unfragmented, glycated protein (Ahmed, et al., 1986). The glycation of opticin 
in presence of sugars as seen in diabetic patients with PDR is the first step to 
study the pro- and anti-angiogenic factors in the vicinity of preretinal 
neovascularization. MG (0.1M) selected for all our experiments while glucose, 
fructose, and ribose used only to confirm the glycation on SDS-PAGE. 
3.1.3.1 Glycation of opticin in vitro using SDS-PAGE analysis 
Opticin at (1mg/ml) incubated with MG (0.1M) for 24 hours, and opticin in ratio 
did show lighter cross-linked AGEs (Figure 3.2). The subunits of cross-linked 
AGEs caused the formation of dimers with a approximate molecular weight of 
90 kDa, as determined using the molecular weight markers (lane M).The glycated 
opticin (Figure 3.2, lanes A) showed no glycation at time zero, in contrast, the 
opticin glycated when increase the time up to 24 hours (Figure 3.2, lanes; B, C, 
D). The native opticin where incubated alone used as control. The Mr of glycated 
opticin was approximately twice of the original. (Figure 3.2, lane M). 
 
 
Figure 3.2The image is demonstrated glycation of opticin with MG (0.1M). 
Opticin (1 mg/ml) was incubated alone or in the presence of 0.1 M MG in 0.1 M 
sodium phosphate buffer, pH 7.4 at 37°C for different time courses. M: Marker; O: 
opticin alone; A: zero time; B: 1 hour; C: 6 hours; D: 24 hours. The cross linking 
was determined by silver stain. The experiment was repeated three times and a 
representative result is shown. 
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3.1.3.2 Glycation of opticin for up to 24 hours with MG 
SDS-PAGE was used to study the effect of periods of incubation on AGE 
formation in vitro. Early glycation products were determined for varying time 
intervals as shown in figure 3.3, by using opticin at 1mg/ml and MG (0.1M) in 
0.1 M sodium phosphate buffer (pH 7.4). Results showed a gradual increase in 
the molecular weight of dimers of opticin, which is a characteristic of AGE 
formation, reaching its highest level at 24 hours of incubation. Control sample 
(opticin alone), also at time zero  showed no glycation compared to those 
incubated in the presence of MG (from 1, 6 and 24 hours). Formation of AGEs 
was linearly dependent on the reaction time. 
 
 
 
Figure 3.3 AGE formation in the opticin-MG system for 24 hours. 
Opticin (1 mg/ml) was incubated with 0.1M MG in 0.1 M sodium phosphate 
buffer (pH 7.4) at 37 °C for 1, 6, and 24 hours. This experiment was repeated 
three times (n=3). The bar graph shows the mean ± S.D (*), and (**) signify a 
statistically significant difference (p<0.05 and p<0,001). 
- 122 -  
3.1.3.3 Glycated of opticin with MG in vitro using SDS-PAGE analysis The 
result shows the MG (0.1M) glycated opticin (1mg/ml) when incubated at 
different time courses, and opticin in ratio did show lighter cross-linked AGEs 
(Figure 3.4), the subunits of cross-linked AGEs cause the formation of dimers 
with a molecular weight of about 90 kDa. The glycated opticin (Figure 3.4), lanes 
A showed no glycation at time zero, in contrast the glycation increase when 
increasing the time up to 24 hours. 
 
 
 
 
 
 
Figure 3 .4 Glycation of opticin (1 mg/ml) with MG (0.1M) up to 72 hours. 
The image is demonstrated glycation of opticin with 0.1M MG. Opticin (1 
mg/ml) was incubated alone or in the presence of 0.1 M MG in 0.1 M sodium 
phosphate buffer, pH 7.4 at 37°C for different time.O: opticin alone; A: zero 
time; B: 30 minutes; C: 24 hours; D: 72 hours. The cross linking was determined 
by silver stain. This experiment was repeated three times and a representative 
SDS-PAGE gel is shown. 
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3.1.3.4 Glycation of opticin for up to 72 hours with MG 
 
SDS-PAGE was used to study the effect of periods of incubation on AGE 
formation in vitro. Early glycation products were determined for varying time 
intervals as shown in figure 3.5, by using opticin at 1mg/ml and MG (0.1M) in 
0.1 M sodium phosphate buffer (pH 7.4). Results showed a gradual increase in 
the molecular weight of dimers of glycated opticin, which is as a characteristic 
of AGE formation, reaching its highest at 72 hours incubation. Control sample 
without MG showed no glycation compared to those incubated in the presence 
of MG (0 time, 30 minutes, 24 hours and 72 hours.). Formation of AGEs was 
linearly dependent on the incubation time. 
 
 
 
Figure 3 .5 Incubation of opticin for up to 72 hours with MG. 
The effect of incubation for different time courses on AGE formation in the 
opticin-MG system. Opticin (1 mg/ml) was incubated with 0.1 MMG in 0.1 M 
sodium phosphate buffer of pH 7.4 at 37 °C for 30 minutes, 24, and 72 hours. 
This experiment was repeated three times (n=3). The bar graph shows the mean 
± S.D (*) signify a statistically significant difference (p<0.05). 
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3.1.4 Glycation of opticin in vitro by glucose, fructose, and ribose 
1mg/ml of opticin incubated with 0.5M glucose, 0.5M fructose, and 0.5M ribose, 
for zero time, 24 hours, and 72 hours. The subunits of cross-linked AGEs cause 
the formation of dimers with a molecular weight of 90 kDa respectively. As 
determined using the molecular weight markers (lane M). The glycated opticin 
(Figure 3.6, lanes O) showed no glycation at time zero (Figure 3.6, lanes;G1, F1, 
R1), in contrast, the opticin in the highest glycation when increase the time up to 
72 hours with glucose, fructose, and ribose. Figure 3.6, lanes; G2, F2, R2. The 
native opticin was incubated alone and used as control. The Mr of glycated 
opticin was approximately twice of the original one (Figure 3.6, lane M). 
 
 
 
Figure 3.6 Glycation of opticin with glucose, fructose, and ribose for 72 hours. 
 
The image demonstrates glycation of opticin by glucose, fructose, and ribose. 
Opticin (1 mg/ml) was incubated alone or in the presence of glucose, fructose, or 
ribose in 0.1 M sodium phosphate buffer, pH 7.4 at 37°C for different time 
courses. M: Marker; O: opticin alone; G1: glucose at zero time; F1: fructose at 
zero time; R1: ribose at zero time; G2: glucose at 24 hours; F2: fructose at 24 
hours; R2: Ribose at 24 hours; G3: glucose at 72 hours; F3: fructose at 72 hours; 
R3: ribose at 72 hours. The cross linking was determined by silver stain. The 
experiment was repeated three times and a representative result is shown. 
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3.1.4.1 Glycation of opticin by glucose 
SDS-PAGE was used to study the effect of periods of incubation on AGE formation 
in vitro. Early glycation products were determined for varying time intervals as 
shown in figure 3.7, by using opticin at 1mg/ml and 0.5M glucose in 0.1 M sodium 
phosphate buffer (pH 7.4). Results showed a gradual increase in the molecular 
weight of dimers of glycated opticin, which is as a characteristic of AGE formation, 
reaching its highest at 72 hours incubation. Control sample without glucose showed 
no glycation compared to those incubated in the presence of glucose (0 time, 24 and 
72 hours.) Formation of AGEs was linearly dependent on the incubation time. 
 
 
Figure 3.7 AGE formation in the opticin-glucose system. 
The effect of incubation different time courses on AGE formation in the opticinMG 
system. Opticin (1 mg/ml) was incubated with 0.5 Mglucose in 0.1 M sodium 
phosphate buffer of pH 7.4 at 37 °C for 30 minutes, 24, and 72 hours. This 
experiment was repeated three times (n=3). The bar graph shows the mean ± S.D 
(*) and (**) signify a statistically significant difference (p<0.05, and p<0.001) 
compared with opticin. 
 3.1.4.2 Glycation of opticin by fructose 
SDS-PAGE was used to study the effect of periods of incubation on AGE formation 
in vitro. Early glycation products were determined for varying time intervals as 
shown in figure 3.8, by using opticin at 1mg/ml and 0.5M fructose in 0.1 M sodium 
phosphate buffer (pH 7.4). Results showed a gradual increase in the molecular 
weight of dimers of glycated opticin, which is as a characteristic of AGE formation, 
reaching its highest at 72 hours incubation. Control sample without fructose showed 
no glycation compared to those incubated in the presence of fructose (0 time, 24 
and 72 hours.). Formation of AGEs was linearly dependent on the incubation time. 
 
Figure 3 .8 AGE formation in the opticin-fructose system. 
 
The effect of incubation different time courses on AGE formation in the opticinMG 
system. Opticin (1 mg/ml) was incubated with 0.5 M fructose in 0.1 M sodium 
phosphate buffer of pH 7.4 at 37 °C for 30 minutes, 24, and 72 hours. This 
experiment was repeated three times (n=3). The bar graph shows the mean ± S.D 
(*) and (**) signify a statistically significant difference (p<0.05, p<0.001). 
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3.1.4.3 Glycation of opticin by ribose 
SDS-PAGE was used to study the effect of periods of incubation on AGE formation 
in vitro. Early glycation products were determined for varying time intervals as 
shown in figure 3.9, by using opticin at 1mg/ml and 0.5M ribose in 0.1 M sodium 
phosphate buffer (pH 7.4). Results showed a gradual increase in the molecular 
weight of dimers of glycated opticin which is as a characteristic of AGE formation, 
reaching its highest at 72 hours incubation but the levels was decreased at 72 hours. 
Control sample without ribose showed no glycation compared to those incubated in 
the presence of ribose (0 time, 24 and 72 hours.) Formation of AGEs was linearly 
dependent on the incubation time. 
 
Figure 3 .9 AGE formation in the opticin- ribose system. 
 
The effect of incubation different time courses on AGE formation in the 
opticinribose system. Opticin (1 mg/ml) was incubated with 0.5 Mribose in 0.1 M 
sodium phosphate buffer of pH 7.4 at 37 °C for 30 minutes, 24, and 72 hours. This 
experiment was repeated three times (n=3).). The bar graph shows the mean ± S.D 
(*) and (**) signify a statistically significant difference (p<0.05, p<0.001). 
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3.1.5 Detection of AGE using MALDI/TOF Spectra 
As accuracy of molecular mass determination by SDS-PAGE is severely limited, 
the MALDI-TOF-MS were used for the mass determination of intact, modified 
proteins. (Savas, et al., 2011). MALDI spectra was obtained by incubating native 
opticin (1mg/ml) with MG ( 0.1M) at 37 °C for different time (0-24 hours).The 
molecular ion of native opticin produced as mass peak of m/z 45780 (Figure 
3.10.A). This was calculated. In all of the modified opticin, at least on additional 
peak was observed. The mass were less increasing at time zero of incubation m/z 
(46401) (Figure 3.10.B), while the mass increase in 30 minutes (Figure 3.10.C) 
in to m/z (47094). After 6 hours (Figure 3.10.D), there was a further mass 
increase, components of m/z (47200) and after 24 hours the mass was m/z (47401) 
(Figure 3.10.E). This mass distribution was due to multiple modifications by MG. 
The resulting mass difference was probably caused multiple modifications with 
the Amadori product an early stage Maillard product, as well as post-Amadori 
modifications. Based on this mass shift and a theoretical sequence for this 
species, it should be possible to propose an approximate number of glycation sites 
modified assuming the mass differences for modified Cys, Arg and Lys are 
known. 
The number of sugar molecules condensed on the reactive sites of protein can be 
calculated by using the mass difference (ΔM) between glycated and native 
proteins (Lapolla et al. 2000). MG can form different AGE modifications on 
lysine, arginine, and cysteine residues of the protein resulting in mass difference 
(ΔM) of 531-1531 Da between (native and glycated). The number of MG moles 
per mole of opticin was calculated (Figure 3.11). 
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Figure 3 .10 MALDI-TOF analysis of opticin incubated in MG. 
 
Opticin(1mg/ml) was incubated alone(A) or with MG ( 0.1M) for zero time (B), 
30 minutes (C), 6 hours (D), and 24 hours (E) at 37°C , and then subjected to 
MALDI-TOF-MS as described in materials and methodted. The expirment were 
repeated three times, the. A representative mass spectrum from independent 
experiments is shown for each condition. 
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Figure 3.11 Time course study of average number of moles of MG attached to 
each mole of opticin. 
Opticin (1mg/ml) was incubated with 0.1MG and in buffer. MALDI-TOF-MS 
was used for the analysis of intact protein. The difference in m/z values for each 
sample is used to calculate the number of moles attached to each mole of opticin. 
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Results 
Section 2: in vitro and in vivo 
angiogenesis assays 
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3.2 In vitro angiogenesis assays 
Many in vitro and in vivo angiogenesis assays used to study new therapeutic 
agents that either stimulate or inhibit angiogenesis, In vitro angiogenesis assays 
are used to study a particular step in the angiogenic process: 
Cell proliferation study: A cell proliferation assay was used to identify the effect 
of compounds on BAEC growth in the presence of FGF-2 
Cell Migration/wound-healing study: A cell migration assay was used to 
identify the inhibitory potential of compounds on EC migration when induced 
with FGF-2. 
Cell differentiation study: (Matrigel tube-formation): This assay was used to 
identify the effects of GOPT on tube formation. These assays give an insight into 
the angiogenic cascade, and can recognize molecular mechanisms of action of 
molecules of interest. 
FGF-2 is preferentially involved in the process of angiogenesis (Ornitz et al, 
2001; Barrientos et al, 2008). FGF-2 induces ECs proliferation, migration, and 
angiogenesis in vitro (Basilico and Moscatelli, 1992). 
3.2.1 Cell Proliferation assay 
There are many different ways of performing cell proliferation assays. In this 
thesis a method of direct counting of total cells was carried out, as described in 
the Material and Methods (chapter 2). FGF-2 induced cell proliferation, 
migration in mediated through intracellular signal pathways involving ERK1/2 
(Slevin, et al., 2008). The effect of native opticin on FGF-2-induced angiogenesis 
and antiangiogenic potential of opticin were studied in a proliferation assay (Le 
Goff, et al., 2012). 
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The effect of glycated opticin on FGF-2-induced angiogenesis was studied in a 
proliferation assay, using BAECs on in vitro. The inhibation of anti-angiogenic 
potential of GOPT in a representative experiment is depicted in Figure 3.12. The 
addition of opticin (native and glycated at 25µg/ml) with FGF-2 (25ng/ml) to 
medium containing 2 % FBS. After three days of incubation; 
After three days of incubation, GOPT + FGF-2 significantly less inhibit the cell number 
by 1.7–fold (p= 0.011) arespectively compared with the control cells (Figure 3.1). The 
highest stimulation was induced by FGF-2 alone by 2.0-fold (p=0.0005) compared to 
control cells and a significant inhibition with opticin + FGF-2 by 1.4- fold (p = 0.002). 
Figure 3.12). 
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Figure 3.12 Anti-anti-angiogenic effects of GOPT combined with FGF-2 on 
BAEC proliferation. 
BAECs (1.5x105 cell/ml) were allowed to grow and adhere in 24-well plates. The 
bar graph shows the stimulatory effects of opticin (native and glycated at 25µg 
/ml), FGF-2 (25ng /ml) and their combination on BAEC proliferation after 72 
hours incubation. Cells were counted using a Coulter counter. Experiments were 
performed in triplicate wells and repeated three times (n=3). The bar graph shows 
the mean ± S.D. (*), and (***) signify a statistically significant difference (p ˂ 
0.05, and p<0.001) compared to the control. A representative example is shown. 
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3.2.2 Cell Migration assay a (Wound healing) 
ECs are capable of migration along a gradient of angiogenic molecules such as 
FGF-2. Two methods to assess EC migration were used in this thesis: a wound 
healing assay where migrate into a denuded region created by scraping a 
confluent monolayer of ECs or a modified Boyden chamber chemotaxis assay, 
where ECs orientate and migrate towards FGF-2 through a polycarbonate filter. 
The effect of GOPT on FGF-2-induced angiogenesis was studied using BAEC at 
1.5x105 cell/ml. The confluent and uniform monolayer of BAEC was wounded 
with a sterile blade. (A) Control (B) with FGF-2 (25ng /ml), (C) Opticin (25µg 
/ml), (D) GOPT (25µg /ml), (E) the combination of (opticin/FGF-2) and (F) the 
combination of (GOPT/FGF-2) for 24 hours. The numbers of migrated cells in 
the denuded area were counted (original magnification X 40, scale bar = 100 µm). 
Experiments were performed in triplicate wells and repeated three times. The 
inhibition of anti-angiogenic potential of GOPT in a representative experiment is 
depicted in (Figure 3.13 and 3.14), the resut shows; 
After 24 hours of incubation, GOPT + FGF-2 significantly less inhibit the number of cell 
migration by 2.7–fold (p= 0.002) arespectively compared with the control cells (Figure 
3.13). The highest stimulation was induced by FGF-2 alone by 2.8-fold (p=0.0002) 
compared to control cells and a significant inhibition with opticin + FGF-2 by 1.8- fold 
(p = 0.001) (Figure 3.13). 
In addition, distance of cell migration; 
After 24 hours of incubation, GOPT + FGF-2 significantly less inhibit the distance of 
cell migration by 2.0 –fold (p= 0.0003) arespectively compared with the control cells 
(Figure 3.1). The highest stimulation was induced by FGF-2 alone by 2.2-fold (p=0.003) 
compared to control cells and a significant inhibition with opticin + FGF-2 by 2.2- fold 
(p = 0.0003) (Figure 3.13). 
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Figure 3.13 Effect of opticin1mg/ml (native and Glycated), on cell migration 
induced by FGF-2 on BAEC using a wound healing assay. 
 
The confluent and uniform monolayer of BAEC was wounded with a sterile razor 
blade. Opticin (native and glycated), and FGF-2 were added. After incubation for 
24 hours, the number of migrated cells in the denuded area was counted in five 
random areas and distance of migration per well (original magnification X40, 
Scale bar = 100 µm). The bar graph shows the stimulatory effects on FGF-2 (25ng 
/ml) and of GOPT (25µg /ml). Experiments were performed in triplicate wells 
and repeated three times (n=3). The bar graph shows the mean ± S.D. (*), (**), 
(***) signify a statistically significant difference (p ˂ 0.05, p ˂ 0.01, and 
p<0.001) compared to the control. A representative example is shown. 
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Figure 3.14 The effect of GOPT on FGF-2-induced BAEC migration. 
BAECs were seeded on coverslips at a concentration of 1.5x105  cell/well in 
DMEM containing 15% (v/v)FBS, wounded with a razor blade and incubated for 
24 hour, to observe the number of ECs migrating into the denuded region. Images 
were taken using a phase contrast microscope (original magnification X40, scale 
bar = 100 µm) and a digital camera. Experiments were performed in triplicate 
wells and repeated at least three times. A representative example is shown. 
Wound edage 
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3.2.2.1 Cell migration using the chemotaxis assay (Boyden chamber) 
After 18 hours of incubation, opticin (native and glycated at 25µg/ml), FGF-2 
(25ng/ml) and their combination exerted chemotactic effects on BAEC, and 
significantly increased the movement of cells through the filter, compared to the 
control. BAEC (1.5 x 105 cell/ml) in 100 μl of a medium were added to the upper 
part of a modified Boyden chamber and chemoattractant GOPT, FGF-2, and OPT 
+ FGF-2 were added to the lower part of the Boyden chamber. Cell movement to 
the lower chamber was monitored under an inverted phase contrast microscope, 
and quantified by counting the movements through the porous membrane to the 
lower chamber. Results from Boyden chamber experiments indicated that: 
In addition, distance of cell migration; 
GOPT + FGF-2 significantly less inhibit the distance of cell migration by 1.5 - 
fold (p= 0.01) arespectively compared with the control cells .The highest 
stimulation was induced by FGF-2 alone by 1.9-fold (p=0.01) compared to 
control cells and a significant inhibition with opticin + FGF-2 by 1.5- fold (p = 
0.01 A representative example is shown in (Figure 3.15). 
 
The effects of GOPT and FGF-2 on BAEC chemotaxis (Boyden chamber) were 
determined and show increase in number of migrated cells in comparison opticin 
+ FGF-2 cells, because GOPT had less inhibit effect on FGF-2 than opticin. 
A representative example is shown in (Figure 3.15). 
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Figure 3-15 Effect of GOPT, FGF-2 and their combination on BAEC 
migration BAEC (1.5 x 105 cell/ml) in 100 μl of a medium was added to the upper 
portion of the Boyden chamber. Opticin (native and glycated at 25µg/ml), FGF-2 
(25ng/ml) and their combination were added to the lower chamber and incubated 
for 18 hours. The total numbers of migrated cells were counted. Experiments were 
performed in duplicate wells and repeated three times (n=3). The bar graph shows 
the mean ± S.D. (*) and (**) signify a statistically significant difference (p ˂0.05 
and p<0.01) compared with the control. A representative example is shown. 
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3.2.3 EC formation of tube-like structures in different matrices 
Further examination of anti-anti angiogenic effect of GOPT was carried out by 
measuring the extent of BAEC tube formation in type-I collagen or a 
reconstituted basement membrane, growth factor reduced MatrigelTM. EC tube 
formation assays in different extracellular matrices are an effective way of 
assessing in vitro angiogenesis. The assays are highly reproducible and can adapt 
to test various molecules alone or in combination with others. 
 
3.2.3.1 EC tube formation in a type-I collagen gel-‘sandwich’ method 
BAECs were seeded on coverslips at a concentration of 3.4x104 cell/well in 
DMEM containing 1% FBS. Theinhibation of anti angiogenic possible of GOPT 
in a representative experiment with tube formation assay ‘sandwich’ methods is 
depicted in (Figure 3.16 and 3.17) respectively. The result shows: 
GOPT + FGF-2 significantly less inhibit the distance of cell migration by 4.0 –fold (p= 
0.07) arespectively compared with the control cells. The highest stimulation was induced 
by FGF-2 alone by 4.2-fold (p=0.001) compared to control cells and a significant 
inhibition with opticin + FGF-2 by 2.6 fold (p = 0.01 A representative example is shown 
in (Figure 3.16). There is no further significant differences were obtained when 
compared to the individual stimulation of either opticin by 0.96 fold (p = 0.01), 
GOPT by 0.96 fold (p = 0.013) 
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Figure 3-16 Anti-anti-angiogenic effects of GOPT and FGF-2 on BAEC 
tube formation. 
The bar graph shows the stimulatory effects of opticin (25 µg/ml: native and 
glycated), FGF-2 (25ng /ml) and their combination on BAEC tube formation after 
24 hours. The number of closed areas was counted. Experiments were performed 
in triplicate wells and repeated at least three times (n=3). The bar graph shows 
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the mean ± S.D. (*) and (**) signify a statistically significant difference (p ˂ 0.05 
and p ˂ 0.01) compared with the control. A representative example is shown. 
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Figure 3.17 Photomicrograph showing the anti-anti-angiogenic effects 
of GOPT on FGF-2 on BAEC tube formation in collagen type I. 
(A) Control, (B) FGF-2, (C) Opticin, (D) GOPT,(E) Opticin + FGF-2 , (F) GOPT 
+ FGF-2 The arrow towards the circle indicates a closed area of collagen , which 
was used to quantify the results (original magnification X100). 
F E 
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3.2.3.2 EC tube formation of BAECs in a MatrigelTM matrix 
BAECs were seeded on coverslips at a concentration of .2.4x104 cell/well in 
DMEM containing 2% FBS. The inhibition of anti-angiogenesis potential of 
opticin in a representative experiment using a tube formation assay in MarigelMT 
matrix is depicted in (Figure 3.18 and 3.19) for BAECs respectively. In tube 
formation assay the addition of recombinant opticin (native and glycated) at 25 
µg /ml to MatrigelML and medium containing 2% FBS, and 25ng/ml, the results 
showen; 
GOPT + FGF-2 significantly less inhibit the distance of cell migration by by 4.0 fold (p 
= 0.004) arespectively compared with the control cells. The highest stimulation was 
induced by FGF-2 alone by 4.0 fold (p = 0.002).compared to control cells and a 
significant inhibition with opticin + FGF-2 by 3-fold (p = 0.001). A representative 
example is shown in (Figure 3.18). 
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There is no further significant differences were obtained when compared to the 
individual stimulation of either opticin by 0.9 fold (p = 0.006), GOPT by 1.0 fold 
(p = 0.04) respectively 
There is signficatly lower number of tube formed when FGF-2 was incubated in 
the precences of opticin than GOPT. 
 
 
Figure 3-18 Anti-anti-angiogenic effects of GOPT and FGF-2 on BAEC tube 
formation. 
The bar graph shows the stimulatory effects of opticin (25 µg/ml: native and 
glycated), FGF-2 (25ng /ml) and their combination on BAEC tube formation after 
24 hours. The number of closed areas was counted. Experiments were performed 
in triplicate wells and repeated at least three times (n=3). The bar graph shows 
the mean ± S.D. (*), (**) signify a statistically significant difference (p ˂ 0.05 
and p ˂ 0.01) compared with the control. A representative example is shown. 
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Figure 3-19 Photomicrograph showing the pro-angiogenic effects of Opticin 
on FGF-2 on BAEC tube formation (in Matrigel). 
(A)Control, (B) FGF-2, (C) Opticin, (D) GOPT, (E) Opticin + FGF-2 , (E) GOPT 
+ FGF-2 The arrow towards the circle indicates a closed area of a Matrigel tube, 
which was used to quantify the results (original magnification X100). 
F E 
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3.2.3.3 EC tube formation of HRECs in a MatrigelTM matrix 
HRECs were seeded on coverslips at a concentration of 6.0x105 cell/well in 
DMEM containing 2% FBS. The inhibition of anti-angiogenic potential of 
opticin in a representative experiment using a tube formation assay in MatrigelTM 
matrix is depicted in (Figure 3.20 and 3.21) for HRECs respectively. In tube 
formation assay the addition of recombinant opticin (native and glycated) at 25 
µg/ml to MatrigelML, medium containing 2% FBS, and FGF-2 (25 ng/ml). The 
result shows; GOPT + FGF-2 significantly less inhibit the distance of cell migration by 
by 2.4 fold (p = 0.008) arespectively compared with the control cells (Figure 3.1). The 
highest stimulation was induced by FGF-2 alone by 2.6 fold (p = 0.01).compared to 
control cells and a significant inhibition with opticin + FGF-2 by 1.7-fold (p = 0.01). 
A representative example is shown in (Figure 3.20). 
There is no further significant differences were obtained when compared to the 
individual stimulation of either opticin by 1.0 fold (p = 0.02), GOPT by 1.2 fold 
(p = 0.06) respectively. 
 
 
Figure 3.20 Anti-anti-angiogenic effects of GOPT and FGF-2 on HRECs tube 
formation. 
The bar graph shows the stimulatory effects of opticin (25 µg/ml: native and 
glycated), FGF-2 (25ng /ml) and their combination on HREC tube formation 
after 24 hours. The number of closed areas was counted. Experiments were 
performed in triplicate wells and repeated at least three times (n=3). The bar 
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graph shows the mean ± S.D. (*) signify a statistically significant difference (p ˂ 
0.05) compared with the control. A representative example is shown. 
 
 
 
Figure 3.21 Photomicrograph showing the inhibition of 
antiangiogenic effects of Opticin on FGF-2 on HREC tube 
formation (in Matrigel). 
A Control, (B) FGF-2, (C) Opticin, (D) GOPT, (E) Opticin + FGF-2, (E) 
GOPT + FGF-2, the slide stain with Giemsa stain. The arrow towards the 
circle indicates a closed area of a Matrigel tube, which was used to 
quantify the results (original magnification X100). 
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3.2.3.4 EC tube formation of HRECs in collagen type-I 
HRECs were seeded on coverslips at a concentration of 1.0x106 cell/ml in 
DMEM containing 2% FBS, opticin (native and glycated, and FGF-2 (25 ng/ml) 
The inhibition of anti-angiogenesis potential of opticin in a representative 
experiment using a tube formation assay in MatrigelTM matrix is depicted in 
(Figure 3.22, and 3.23) for HRECs respectively. The result shows; 
GOPT + FGF-2 significantly less inhibit the distance of cell migration by by 1.6 fold (p 
= 0.04) arespectively compared with the control cells. The highest stimulation was 
induced by FGF-2 alone by 2.0 fold (p = 0.04) compared to control cells and a 
significant inhibition with opticin + FGF-2 by 1.0 fold (p = 0.03). A representative 
example is shown in (Figure 3.22). 
 
There is no further significant differences were obtained when compared to the 
individual stimulation of either opticin by 0.8 fold (p = 0.007), GOPT by 1.0 fold 
(p = 0.03) respectively. 
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Figure 3.22. EC tube formation of HRECs in collagen type-I 
The bar graph shows the stimulatory effects of opticin (25 µg/ml: native and 
glycated), FGF-2 (25ng /ml) and their combination on HREC tube formation 
after 24 hours. The number of closed areas was counted. Experiments were 
performed in triplicate wells and repeated at least three times (n=3). The bar 
graph shows the mean ± S.D. (*), and (**) signify a statistically significant 
difference (p ˂ 0.05 and p ˂ 0.01) compared with the control. A representative 
example is shown. 
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Figure 3.23 Photomicrograph showing the anti-anti-angiogenic effects of Opticin 
on FGF-2 on HREC tube formation in collagen type-I. 
(A)Control, (B) FGF-2, (C) Opticin, (D) GOPT,(E) Opticin + FGF-2 , (E) GOPT 
+ FGF-2. The arrow toward the circle indicates a closed area of collagen, which 
was used to quantify the results (original magnification X100). 
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3.2.4 Anti-anti-angiogenic effects of Opticin (native and glycated) and EGF on 
BAEC tube formation in collagen type-I. 
 
BAECs were seeded on coverslips at a concentration of 2.4x104 cell/well in 
DMEM containing 1% FBS, opticin (native glycated) 25ug/ml, and EGF (25 
ng/ml). The reduce of anti angiogenic possible of GOPT in a representative 
experiment with tube formation assay ‘sandwich’ methods is depicted in (Figure 
3.24 and 3.25) respectively. 
 
The result shows; GOPT + EGF significantly less inhibit the distance of cell migration 
by 1.4-fold (p = 1.4) arespectively compared with the control cells (Figure 3.1). The 
highest stimulation was induced by EGF alone by 1.5- fold (p = 0.003) compared to 
control cells and a significant inhibition with opticin + EGF by 1.0- fold (p = 0.01). A 
representative example is shown in (Figure 3.24). 
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BAECs were cultured in DMEM containing 1% FBS, at concentration of 2.4x104 
cell/ml for 24 hours combined with collagen type-I. Experiments were carried 
out 3 times, each time in triplicate. 
 
 
Figure 3.24 Anti-angiogenic effects of GOPT and EGF on BAECs tube formation. 
The bargraph shows the stimulatory effects of opticin 25 µg/ml (native and 
glycated), EGF (25ng /ml) and their combination on BAECs tube formation after 
24 hours. The number of closed areas was counted. Experiments were performed 
in triplicate wells and repeated at least three times (n=3). The bar graph shows 
the mean ± S.D. (*), (**) signify a statistically significant difference (p ˂ 0.05 
and p ˂ 
0.01) compared with the control. A representative example is shown. 
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Figure 3-25 Photomicrograph showing the anti-anti-angiogenic effects of Opticin 
with EGF on BAEC tube formation (in collagen type I). 
(A), Control; (B) EGF; (C) Opticin + EGF; (D) GOPT + EGF. The arrow towards 
the circle indicates a closed area of collagen, which was used to quantify the 
results (original magnification X100). 
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Results Section 3: Opticin 
modulated signalling 
pathways identified 
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3.2.5 Protein phosphorylation of ERK in BAEC treated with GOPT 
ERK1/2 protein activity characterized as its phosphorylated form is required for 
EC proliferation, migration and in angiogenesis (Slevin et al, 2002).  The 
phosphorylation of ERK was initiated by exogenous addition of FGF-2 and 
opticin (native glycated) for 10 min, and protein lysates were subjected to 
Western blotting analysis. Therefore, signalling stimulation studies were carried 
out to understand, the mechanism (Figure 3.26). After 10 minutes stimulation 
with FGF-2 and it`s combination, a significant increase (1.5-fold) in expression 
of phospho-ERK1/2 was observed, compared to the control cells. 
As expected, incubated opticin enable inhibited P-ERK expression induced by 
FGF-2 (10 min); however, in contrast, glycated opticin did not notably reduce 
FGF2-induced P-ERK1/2 (Figure 3.26 A, B). 
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Figure 3.26 Protein phosphorylation of ERK-1 and ERK-2 in BAEC. 
Examination of cell lysates by Western blotting after treatments with GOPT, 
histograms represent relative intensity band of 25µg/ml opticin (native and 
glycated) compared to control cells are normalised to ERK1/2. A, representative 
Western blot gel showing the variation of phospho-ERK1/2 expression, after 10 
minutes of incubation. B, the bar graph shows the analysis performed in function 
of the densitometry of the Western blot gel bands and the results are expressed as 
relative to total-ERK1/2 expression. To check the equal loading of proteins, total- 
ERK1/2 was used as loading control. Each panel was representative of at least three 
independent experiments. 
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3.2.6 Protein phosphorylation of MEK/2 in BAEC treated with GOPT 
The phosphorylation of MEK1/2 was initiated by exogenous addition of FGF-2 
and opticin (native glycated) for 10 min, and protein lysates were subjected to 
Western blotting analysis. Therefore, signalling stimulation studies were carried 
out to understand, the mechanism (Figure 3.27). After 10 minutes stimulation with 
FGF-2 and it`s combination, a significant increase (1.2-fold) in expression of 
phosphoMEK/2 was observed, compared to the control cells. 
As expected, incubated opticin enable inhibited P-MEK expression induced by 
FGF-2 (10 min); however, in contrast, glycated opticin did not notably reduce 
FGF2-induced P-MEK/2 (Figure 3.27 A, B). 
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Figure 3.27 Protein phosphorylation of MEK/2 in BAEC treated with GOPT. 
Examination of cell lysates by Western blotting after treatments with GOPT, 
histograms represent relative intensity band of 25µg/ml opticin (native and 
glycated) compared to control cells are normalised to MEK/2. .A, representative 
Western blot gel showing the variation of phosphor-MEK/2 expression, after 10 
minutes of incubation. B, the bar graph shows the analysis performed in function 
of the densitometry of the Western blot gel bands and the results are expressed as 
relative to total-MEK/2 expression. To check the equal loading  of proteins, 
totalMEK/2 was used as loading control. Each panel was representative of at least 
three independent experiments. 
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3.2.7 Protein phosphorylation of AKT in BAEC treated with GOPT 
The phosphorylation of AKT was initiated by exogenous addition of FGF-2 
(25ng/ml) and opticin (25µg/ml); native or glycated) for 10 min, and protein lysates 
were subjected to Western blotting analysis. Therefore, signalling stimulation 
studies were carried out to understand, the mechanism (Figure 3.28). After 10 
minutes stimulation with FGF-2 and it`s combination, a significant increase 
(1.0fold) in expression of phospho-AKT was observed, compared to the control 
cells. As expected, incubated opticin enable inhibited P-AKT expression induced 
by FGF-2 (10 min); however, in contrast, glycated opticin did not notably reduce 
FGF2-induced P-AKT (Figure 3.28 A, B). 
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Figure 3.28 Protein phosphorylation of AKT in BAEC treated with GOPT. 
 
Examination of cell lysates by Western blotting after treatments with GOPT, 
histograms represent relative intensity band of 25µg/ml opticin (native and 
glycated) compared to control cells are normalised to AKT when treated with FGF- 
2 (25 ng/ml). A, representative Western blot gel showing the variation of phosphor- 
AKT expression, after 10 minutes of incubation. B, the bar graph shows the 
analysis performed in function of the densitometry of the Western blot gel bands 
and the results are expressed as relative to total-AKT expression. To check the 
equal loading of proteins, total-AKT was used as loading control. Each panel was 
representative of at least three independent experiments. 
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3.2.8 Protein phosphorylation of p38 in BAEC treated with GOPT 
The phosphorylation of p38 was initiated by exogenous addition of FGF-2 
(25ng/ml) and opticin (25µg/ml); native or glycated) for 10 min, and protein lysates 
were subjected to Western blotting analysis. Therefore, signalling stimulation 
studies were carried out to understand, the mechanism (Figure 3.29). After 10 
minutes stimulation with FGF-2 and it`s combination, a significant increase 
(0.5fold) in expression of phospho-p38 was observed, compared to the control 
cells. As expected, incubated opticin enable inhibited P-p38 expression induced by 
FGF2 (10 min); however, in contrast, glycated opticin did not notably reduce FGF- 
2induced P-p38 (Figure 3.29 A, B). 
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Figure 3.29 Protein phosphorylation of p38 in BAEC treated with GOPT. 
Examination of cell lysates by Western blotting after treatments with GOPT, 
histograms  represent  relative  intensity  band  of  25µg/ml  opticin  (native  and 
glycated) compared to control cells are normalised to p38 when treated with FGF- 
2 (25 ng/ml). A, representative Western blot gel showing the variation of phosphor- 
p38 expression, after 10 minutes of incubation. B, the bar graph shows the analysis 
performed in function of the densitometry of the Western blot gel bands and the 
results are expressed as relative to total-p38 expression. To check the equal loading 
of proteins, total-p38 was used as loading control. Each panel was representative 
of at least three independent experiments. 
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3.2.9 Protein phosphorylation of JNK2 in BAEC treated with GOPT 
The phosphorylation of JNK2 was initiated by exogenous addition of FGF-2 
(25ng/ml) and opticin (25µg/ml); native or glycated) for 10 min, and protein lysates 
were subjected to Western blotting analysis. Therefore, signalling stimulation 
studies were carried out to understand, the mechanism (Figure 3.30). After 10 
minutes stimulation with FGF-2 and it`s combination, a significant increase 
(2.0fold) in expression of phospho-JNK2 was observed, compared to the control 
cells. As expected, incubated opticin enable inhibited P-JNK2 expression induced 
by FGF-2 (10 min); however, in contrast, glycated opticin did not notably reduce 
FGF2-induced P-JNK2 (Figure 3.30 A, B). 
 
 
 
B. 
 
 
Figure 3.30.Protein phosphorylation of JNK2 in BAEC treated with GOPT 
Examination of cell lysates by Western blotting after treatments with GOPT, 
histograms represent relative intensity band of 25µg/ml opticin (native and 
glycated) compared to control cells are normalised to JNK2 when treated with 
FGF-2 (25 ng/ml). A, representative Western blot gel showing the variation of 
phospho-JNK2 expression, after 10 minutes of incubation. B, the bar graph shows 
the analysis performed in function of the densitometry of the Western blot gel 
bands and the results are expressed as relative to total-JNK2 expression. To check 
the equal loading of proteins, total-JNK2 was used as loading control. 
Each panel was representative of at least three independent experiments. 
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3.2.10 Measurement of CML in diabetic mice 
 
It is very clear from Western blots the CML expression in diabetic mice more than 
the non-diabetic mice. (A), in diabetic mouse eyes the CML increased by 
1.5 folds than non-diabetic mouse. (Figure3.31, A&B). 
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Figure 3.31 Western blots showing the expression of CML 
Three mice where used or each expirment (A) A representative Western blots 
showing the expression of CML in treated non-diabetic and diabetic mice. (B) The 
bar graphs show the expression of CML in the diabetic mice compare to non 
diabetic mice. This figure is representative of at least three independent 
experiments. 
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3.2.11 Glycated opticin reduce binding to collagen type-I 
The binding of GOPT to collagen type-I was investigated using ELISA. The 
experiment demonstrated that native opticin binds collagen with increasing its 
concentration, and bind more effectively than glycated opticin. (Figure 3.32). 
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Figure 3.32 Opticin (native and glycated) binding to collagen type-I. 
The diagram shows binding of GOPT and opticin following interaction with a 
fixed concentration of collagen type-I (50µg/ml) in PBS preincubated with 
increasing concentration of opticin and GOPT. The expirment was performed 
in triplicate. 
Opticin 
GOPT 
165  
3.2.12 Glycated opticin binding to FGFR 
The opticin may not modulate the binding of FGF-2 to its receptor and not change 
the FGFR affinity to its ligand in contrast to GOPT may modulate the binding of 
FGF-2 to its receptor and change the FGFR affinity to its ligand (Figure 3.33). 
 
 
 
 
 
 
Figure 3.33 Glycated opticin binding to FGFR. The diagram shows binding of 
opticin (Glycated and native) following interaction with a fixed concentration of 
FGFR, 2µg/ml preincubated with increasing concentration of opticin and glycated 
opticin.with 2µg/ml FGF-2. Each data point taken from four or five replicate wells. 
The expirment was performed in triplicate. 
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Results 
Section 4: Immunochemistry 
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3.2.13 Immunofluorescence Analysis 
For examination of glycated opticin on focal adhesion, BAECs were stained 
with anti-paxillin, anti-α2β1, and anti-vinculin antibodies, followed by Alexa 
Flour® 488 nm-conjugated anti-mouse antibody. The cells were visualized by 
confocal microscopy. Nuclei were stained with DAPI, Paxillin, vinculin, 
andα2β1 stained green, while the Actin stained red. 
In order to investigate the effect of GOPT +FGF-2 on vinculin integrin 
engagement with ECM, spreading experiments were performed in the presence 
of vinculin. (Figure 3.34). 
In normal cells the vinculin looks like (control), if stimulated cells with FGF-2 
the vinculin appears in special localization in perpherial of the cell. Whit the 
opticin in present of FGF-2 disturping the normal pattern of vinculin expressed. 
In glycated opticin in present of FGF-2, the vinculin appears on the cells 
become normal looking. 
The disturping is a part of anti-angiogenic prosses which can slow them down 
from moving which has been observed in present of opticin +FGF-2. But if 
replaced with glycate opticin + FGF-2 it is not very elective, so continous 
spreading and ready to move. 
The same results were obtained when cells treated with paxillin. (Figure 3.35), 
and α2β1 (Figure 3.36). 
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Figure 3.34 Immunofluorescence detection /Anti vinculin. 
BAEC 2.4x104 cells/ml were seeded on collagen-I coated coverslips for 1 h. 
Opticin 25 µg/ml (native and glycated) in present FGF-2 at 25ng/ml for 10 
minutes prior to fixation as described in material and methods. 
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Figure 3.35 Immunofluorescence detection /Anti paxillin. 
BAEC 2.4x104 cells/ml were seeded on collagen-I coated coverslips for 1 h. 
Opticin 25 µg/ml (native and glycated) in present FGF-2 at 25ng/ml for 10 
minutes prior to fixation as described in material and methods. 
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BAECs incubated with α2β1 
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Figure 3-36 Immunofluorescence detection / α2β1. 
BAEC 2.4x104 cells/ml were seeded on collagen-I coated coverslips for 1 hour. 
Opticin 25 µg/ml (native and glycated) in present FGF-2 at 25ng/ml for 10 
minutes prior to fixation as described in material and methods. 
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3.2.14 Immunolocalization of opticin and AGEs in same section 
Eyes from diabetic and non diabetic mice were sectioned by freezing 
microtome. Sections (4µm) were incubated with affinity-purified anti-mouse 
antibody (1:200), and anti-CML (2:200) followed by secondry anti-body as 
explained in the martial and methods. The slides visualized under laser 
microscope. The opticin was very clear in diabetic and non diabetic mouse, 
while the localization of AGEs identified (Figures 3.37-39). 
 
 
Figure 3.37 The localization of AGEs in diabetic mouse eye, the arrow shows 
the localization of AGEs. (Low mignification X100). 
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Figure 3.38 The co- localization of opticin and AGEs in diabetic mouse eyes 
(the yellow arrow), the arrow shows the localization of opticin (green arrow) 
(Low mignification X100). 
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Figure 3.39 The co-localization of opticin and AGEs in diabetic mouse eyes. 
The blue arrow in red in red circle shows the co-localization of opticin and 
AGEs, white arrow opticin, orange arrows nuclei, and yellow arraw colleagen 
fibers.(High mignification X400). 
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3.2.15 Immunolocalization of opticin and AGEs separated in different 
sections. Eyes from diabetic and non diabetic mice were sectioned by freezing 
microtome. Sections (4um) were incubated with affinity-purified anti-goat 
antibody opticin (1:200), and anti-CML (2:200) as explained in the material and 
methods each antibody incubated in different section. The slides visualized 
under light microscope. The opticin was very clear in diabetic and non diabetic 
mouse, and the localization of AGEs identified (Figures 3.40-42). 
Figure 3.40 The localization of 
AGEs in diabetic mouse eyes. 
The arrow showes the 
localization of AGEs (Low 
mignification X100). 
 
 
. 
 
 
 
 
 
 
Figure 3.41 The localization of 
opticin in nondiabetic mouse 
eyes. The arrow showes the 
localization of opticin (Low 
mignification X100). 
 
 
 
 
 
Figure 3.42 Diabetic mouse eye 
used as control no anti-bodies 
added (Low mignification X100). 
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4. Discussion 
Opticin belongs to a family of small leucine-rich repeat proteins and 
proteoglycans (SLRPs). SLRPs have been shown to be able to bind various cell 
surface receptors, growth factors, cytokines and other ECM components 
resulting in the ability to influence various cellular functions. (Margaret et al., 
2012). Opticin is an extracellular matrix glycoprotein associated with the 
collagen network of the vitreous and is an important regulator of angiogenesis. 
Opticin is present in significant quantities in the vitreous of the eye and localizes 
to the cornea, iris, ciliary body, optic nerve, choroid, retina, and fetal liver. 
Opticin may noncovalently bind collagen fibrils and regulate fibril morphology, 
spacing, and organization. During ocular development, the vitreous cavity 
contains a network of blood vessels that regress before birth in human and shortly 
after birth in mice; they are subsequently replaced by secondary (mature) 
vitreous, a transparent and avascular gel. This vitreous remains avascular unless 
pathological blood vessels derived from the retina, (a process called preretinal 
neovascularization) invade it. Vitreous contains a network of collagen fibrils, 
essential to its gel structure (Bishop, 2000). These collagen fibrils provide a 
substrate for preretinal neovascularization by offering a scaffold for new blood 
vessel growth and in that way-allowing invasion into the cortical vitreous 
(Bishop, 2000; McLeod, 2007). This is an important cause of blindness occurring 
in conditions such as proliferative diabetic retinopathy (PDR) and, retinopathy 
of prematurity (ROP). Visual loss is caused by vitreous haemorrhage and/or 
tractional detachment induced by contraction of fibrous tissue associated with 
preretinal neovascularization (McLeod, 2007). This project investigates how 
glycated opticin effect angiogenesis, it is as reduce anti-angeiogenic when 
compared with using the opticin alone. It has being found that opticin decreased 
the EC network formation in collagen and MatrigelTM formed following addition 
of FGF-2 (25 ng/ml) (Le Goff et al., 2012). Fibroblast growth factor (FGF-2) and 
vascular endothelial cell growth factor (VEGF) are the two major angiogenic 
factors in the retina. 
This is first time were the opticin glycaged in vito, however other proteins which 
linked to the eyes which have related to the diabetes and disaffect their functions 
being glycated like α-crystallin exposed to various sugars and their derivatives, 
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whose levels are elevated in diabetes and lead to cataract formation (Kumar et 
al., 2007 ). Our results show the opticin appears at 45kDa, which agree to 
previous work, which showed major bands of opticin at 45kDa (Le Goff and 
Bishop, 2007). The SDS-PAGE method was used to follow the glycation 
reaction. 72 hours incubations of opticin with glucose, fructose, ribose, and 
methylglyoxal led to the formation of cross-linked AGEs. Furthermore, the 
glycation of protein with methylglyoxal modifies lysine and arginine residues 
(Naila, 2014) very quickly, which accordingly leads to excessive protein cross- 
linking, which is detected via cross-linking on SDS-PAGE. These AGEs are 
characterised by their fluorescence, brown colour and formation of intra- and 
intermolecular cross-linking (Maillard, 1912; Xu et al., 2003). Glycation also 
takes place on cysteine residues (Nadeem and Debabrata, 2013). The major AGE 
adducts formed on proteins from glyoxal and methylglyoxal are CML and CEL, 
respectively (Baynes and Thorpe, 2000; Thornalley, 1996). Some AGEs, such as 
CML and pentosidine have become highly useful biomarkers of glycoxidative 
damage (Khalifah et al., 1999). The same sugars where used for glycation of 
lenticular proteins has been suggested to be responsible for the formation of a 
significant fraction of lens protein modifications present in the aged human 
lenses and in diabetic and brunescent cataractous lenses (Mikhail 2007), and the 
resultant modified protein may possess carbonyl groups (Chaplen 1998). MG is 
formed mostly inside cells but a small fraction leaks out and so glycation of both 
cellular and extracellular proteins by MG increases (Duran-Jimenez BD et al., 
2009; Karachalias et al., 2010). Methylglyoxal was used in this study owing to 
the fact that it can be formed by both the fragmentation and dehydration of 
glucose and Amadori products. Methylglyoxal is a reactive dicarbonyl, which is 
believed to contribute to the development of diabetic complications either as a 
direct toxin or as a precursor for AGEs. It was reported that methylglyoxal 
induces free radical generation, with its concentration in diabetes increased 
(Artenie et al., 2004; Beisswenger et al., 1999; Vander Jagt and Hunsaker, 2003). 
Glucose and fructose are the two most important simple sugars for human 
consumption. They have the same molecular formula, C6H12O6, but have 
different structures. Since glucose is the most abundant sugar in blood, to date, 
glycation by glucose is the most studies. However, glucose has the slowest 
glycation rate because the reactivity of each sugar is dependent on the percentage 
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of sugar in the open chain (carbonyl) structure (Bunn and Higgins, 1981). The 
formation of AGEs occurs at a faster rate under conditions of hyperglycemia, 
dyslipidemia and oxidative stress. For example, it has been demonstrated in vitro 
that the rate of the formation of intracellular AGEs may be 14-fold faster in 30 
mM glucose compared to 5 mM glucose (Giardino et al., 1994). In addition to 
direct glyation reactions, glucose autoxidation also contributes to the formation 
of stable AGEs (Wolff, 1987).A recent study showed that Glcmodified bovine 
serum albumin also inhibited growth of bovine retinal capillary pericytes but did 
not inhibit growth of bovine aortic endothelial cells (Kim et al.,2012). Fructose 
is a highly reactive reducing sugar. It also undergoes the Maillard reaction with 
proteins and amino acids, producing reactive intermediates, cross-linking of 
proteins, and forming brown and fluorescent polymeric materials (Stefan and 
Monika, 2011). The role of ribose in glycation and cross-linking of collagen has 
been investigated in vitro studies of the triggering of skin ageing (Tanaka et al., 
1988). Luciano and colleagues (2008) prepared proteins glycated with ribose in 
a study of AGEs and their effects on pancreatic islet beta cells. Direct effects of 
AGEs on cellular viability and related insulin secretion of beta cells resulting 
from their exposure to glycated serum by incubation with ribose have been 
evaluated. Results showed reduced cellular proliferation with a corresponding 
increase in cell necrosis and cell apoptosis rate in comparison with untreated cells 
after 5 days of exposure to glycation conditions (Luciano et al., 2008). Compared 
with glucose, ribose is more active in glycation of proteins and the formation of 
AGEs (Khalifah et al., 1996). 
In this study, opticin was glycated in vitro using different sugars. Biochemical 
studies including MALDI-TOF-MS analysis and SDS-PAGE under denaturing 
conditions. Due to excessive glycation by MG and presence of multiple 
heterogeneous glycation products, the individual peaks for each modification 
could not be observed in the intact protein. Such individual modifications were 
reported for MALDI-TOF-MS analysis of intact lysozyme glycated with glucose 
and fructose in vitro (Lapolla et al., 1996). Glycation depends upon the number 
of lysine, arginine, and cysteine residues present in a protein and their 
accessibility to solvent containing the glycating agent. The methylglyoxal readily 
reacts with opticin under our experimental conditions and result in structural 
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modifications. Incubation of opticin with MG resulted in the broadening of peaks 
and shift towards the high molecular mass. Similar peak shape has been described 
for lysozyme glycated with MG in an earlier report (Kislinger et al., 2005). 
There are 26 arginine, 8 lysine and 6 cysteine residues in each chain of opticin 
which result in 40 glycation target sites. So theoretically, 80 glycation sites are 
present in a dimeric opticin molecule. Our results show that up to 40 moles of 
MG may be attached to opticin by incubating with 0.1M MG, 0.5M glucose, 
0.5M fructose, and 0.5 M ribose. Considering the presence of 20 reactive amino 
acid in each chain of opticin dimer, this may result in complete saturation of 
glycation sites after 24h. In vitro glycated HSA modifications are reported 
ranging from a minimum of 10 moles per mole of protein to a maximum of 40 
moles per moles of protein (Ahmed and Thornalley, 2002). Crosslinking may 
differ markedly with different proteins due to the fact the protein folding and 
context can be important factors controlling glycation (Bai et al., 1989). There is 
conflicting reports on the reactivates of glucose, fructose, and its process of 
producing AGEs. 
During eye development, the primary vitreous contains the hyaloid vessels, but 
when primary vitreous undergo programmed regression shortly after birth in 
mice (and before birth in humans) where they are replaced by the transparent, 
virtually acellular, secondary (mature) vitreous demonstrates anti-angiogenic 
properties. In adult, it is possible that opticin helps to protect against abnormal 
angiogenesis, which could result in re-growth of vessel into the normally 
avascular vitreous which producing PDR. M Le Goff hypothesized that opticin 
might influence developmental changes in blood vessels in the vitreous cavity 
and retina, and pathologic processes in which blood vessels grow into the 
vitreous (Le Goff et al., 2011) A feature of diabetes is protein glycation. 
Structural studies indicate that opticin may become glycated if exposed to high 
sugar level. In this project, we have already demonstrated this to be true, and here 
we went to investigate the effect of glycation on the anti-angiogenic properties 
of opticin. The results presented showed that opticin inhibited FGF-2- induce 
proliferation; however, when cells were preincubated with glycated opticin the 
inhibition of FGF-2– induced proliferation was signify  reduced. Similarly, 
glycation of opticin signify reduce its ability to inhibit endothelial cell migration 
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and tube formation. Some studies have partially explained the effect of glycation 
of proteins on its function, for example, glycation of FGF-2 had an 
antiproliferative effect on endothelial cell (Duraisamy et al., 2003). The 
mechanisms of impaired angiogenesis induced by AGEs were partly explained 
by Liu et al (2012 ) who demonstrated in vitro using endothelial cells and mouse 
aortas that methylglyoxal (the highly reactive AGEs precursor) reduces 
endothelial angiogenesis through RAGE-mediated, peroxynitrite-dependent and 
autophagy-induced vascular endothelial growth factor receptor 2 (VEGFR2).The 
growth factors no doubt act in synergy to mediate the steps of angiogenesis, 
including cell proliferation, migration and tube formation (Grant et al., 2004) , 
and the major elements of vascular growth not perturbed by glycated opticin. At 
the onset of PDR it seems that while the concentration of the pro-angiogenic 
molecules (e.g. FGF-3, VEGF, IGF-1,and TNF) increases, the ability of these 
containing anti-angiogenic molecules (e.g. angiostatin, PEDF, TSP, andopticin) 
to prevent angiogenesis is not sufficient, practically for example opticin if 
glycated doesn`t function any more. So its function may be impaired and could 
be crucial determinant enabling debilitating haemorrhagic vascularisation (Simó 
et al., 2002). The results presented here show that BAECs and HRECs did 
respond to FGF-2 in cell migration in an expected manner. The two cell types 
produced very similar results, indicating that both macrovessel and microvessel 
ECs were responding to FGF-2 when compared to control cells. 
AGEs and their intermediates have been implicated in pathophysiological 
dysfunction associated with the vascular complications of diabetes mellitus, such 
as retinopathy (Brownlee, 1995). Mitogen-activated protein kinase (MAPK) 
pathways are evolutionarily conserved kinase modules that link extracellular 
signals to the machinery that controls fundamental cellular processes such as 
growth, proliferation, differentiation, migration and apoptosis (Figure 4.1). 
When FGF-2 stimulates the phosphorylation of ERK it leads to activation of 
early response genes that have prime importance in various biological 
phenomena (Slevin et al, 2000) including cell invasion, migration and 
proliferation (Kaladdhar et al., 2003) MEK1/2 and  ERK1/2 also promotes 
proliferation in endothelial cells (Pages et al., 2000; Pages et al., 1993). FGF-2- 
induced increase in JNK which is pro-angiogenic (Uchida et al., 2008) and also 
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p38 pro-apoptotic (Ferrari et al., 2006). FGF-2 has a dual role in the control of 
endothelial cell apoptosis. On one hand, FGF-2 up-regulates VEGF expression, 
which is required for TGF-1 induction of apoptosis; on the other hand, it protects 
endothelial cells from apoptosis through a VEGF-independent mechanism. The 
p38 isoforms have opposing effects on the same substrate (Rousseau, 2007). In 
addition, the amount of p38 MAPK activity should determine the networks of 
substrates being phosphorylated, which in turn would impinge on the cellular 
response, there is evidence that strong p38 MAPK activation is likely to engage 
apoptosis, whereas lower levels of p38 MAPK activity tend to be associated with 
cell survival (Dolado, 2008). 
The experiments showed in this thesis opticin decreased FGF-2-induced 
phosphorylation of, ERK1/2, MEK1/2 (MAPK kinase), JNK and p38 (MAPK) 
MAPKs phosphorylation is known to play crucial roles in cell migration and 
tubular morphogenesis (Mathew et al., 2007). It is important to understand signal 
mechanisms when opticin glycated. In order to understand the mechanism why 
glycated opticin affected its inhibit-anti-angiogenic capability the glycated 
opticin were incubated with FGF-2. Western blots demonstrate that pre- 
incubation of BAEC with opticin reduced the ability of FGF-2 increase the 
MAPK signal pathways (e.g. JNK, ERK, and p38) which link to angiogenesis. 
However, in the presence of glycated opticin there was significantly weaker 
inhibition of FGF-2 induce signal, so there is increase in phosphorylation 
expression compared to the cells treated with opticin. These results suggest the 
glycation of opticin reduce its ability to inhibit intracellular signalling via FGF- 
2 and/or its receptors. 
The vitreous is normally able to resist EC invasion and the succeeding 
consequences of neovascularization, which may occur under pathological 
conditions (Neely, 1998; Campocchiaro, 2000). The failure and prevention of 
vessel invasion may be due partly to the influence of angiogenic inhibitors (Lutty 
el al., 1985), as several studies have assigned anti-angiogenic properties to the 
vitreous. 
As opticin is shown to combine with collagen fibrils (Rcardon et al., 2000) it is 
proposed that opticin would not diffuse out of the matrix, therefore not affecting 
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activated ECs in the state of tube formation, but only affecting ECs once they 
began the invasion process. 
Initiation of focal complexes via integrin or growth factor signalling results in 
dynamic changes in cytoskeletal architecture, a hallmark of cell motility (Kim et 
al., 2011). 
The presence of opticin in the vitreous along with findings observed here suggest 
that not only is opticin of structural importance (Bishop 2000; Hindson el al, 
2005) but also may contribute to inhibition in the vitreous along with other 
vascular molecules including TGF-P (Eisenstein and Grant-Bertacchini, 1991) 
PEDF (Dawson el al., 1999) TSP-I (Sheibani el al., 2000) and chondromodulin- 
l (Funaki el al., 2001). 
Decorin binds  various ECM  components, also  inhibited EC  migration and 
formation in type-I collagen gels, when ECs were grown on decorin coated 
surfaces (Davies el al., 2001).Many studies reported that decorin has 
antiangiogenic activity under certain circumstances Konerirajapuram el al 
(2005) showed decorin can inhibit VEGF, FGF-2, and serum-induced HUVEC 
migration and tube formation on Matrigel in a similar morphological 
representation as opticin. Decorin interact with α2β1 integrin via its 
glycosaminoglycan chain, and it is proposed that decorin expression in 
angiogenic ECs promotes angiogenesis in a collagen type-I-rich environment by 
signalling through insulin-like growth factor 1 receptor and influencing α2β1 
integrin activity (Fiedler et al., 2008). Endogenous inhibitors of angiogenesis that 
have been previously identified in the vitreous include PEDF and TSP-I and 
cleaved fragments of larger molecules including angiostatin and endosiatin 
(O'Reilly et al., 1994; Dawson et al., 1999; Sheibani et al., 2000; Tombran-Tink 
et al., 2003; Maatta et al., 2007). 
Many recent studies have elucidated that each developmental/cellular event is 
often regulated by a combination of multiple signalling pathways, and a 
significant number of extracellular proteins act as extracellular signalling 
coordinators. These proteins are known as matricellular proteins (Dellett et al., 
2012). FGFs implement their biological actions by activating cell surface 
fibroblast growth factor receptors (FGFRs). 
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The class  III SLRP opticin is an extracellular matrix  glycoprotein inhibits 
processes involved in angiogenesis through several mechanisms. It inhibits the 
pro-angiogenic actions of the growth factors (Le Goff et al., 2004). However, 
opticin also inhibits angiogenesis through other mechanisms, as it is effective at 
inhibiting the stimulatory actions of growth factors that it does not bind including 
FGF-1 and VEGF12ι. Other mechanisms through which opticin inhibits 
angiogenesis are through direct growth factor receptor interactions with VEGFR- 
1 and FGFR-2, thereby reducing biological activity mediated by these receptors 
and by interacting with integrins involved in angiogenesis including αVβ3 and 
α5βl thereby affecting integrin-ligand binding and/or outside-to-inside signalling 
and indirectly suppressing signalling through growth factor receptors. Opticin 
instead has a different mode of action, i.e. it binds to the ECM rather than the 
integrins themselves (Le Goff et al., 2012). 
Le Goff provides evidence that opticin binds collagen and thereby inhibits α1β1 
and α2β1 integrin binding to the collagen. Opticin thereby decreases the strength 
of EC adhesion to collagen, and the weakened adhesion is insufficient to promote 
angiogenesis ( Le Goff et al., 2012).Opticin inhibits the interaction between 
FGF2 and FGF-Rl (A) and VEGF165 to VEGF-R2 (B) in a dose-dependent 
manner. Therefore in both cases the binding of opticin to the growth factor 
inhibits the interaction of the growth factor with its receptor. The reports have 
exposed that the increased formation of AGEs in the vitreous may be implicated 
in the development of diabetic retinopathy via inducing the production of bFGF 
(by retinal Müller cells (Le Goff et al., 2012). 
Binding to RAGE activates a variety of signalling pathways leading to increased 
oxidative stress and synthesis of local growth factors, cytokines and adhesion 
molecules (Le Goff et al., 2012). Therefore, here we wanted to investigate if 
glycation of opticin affected its ability to bind directly with FGF-2 and interfere 
with FGF-2 integrin, thus potently affecting its ability to inhibit angiogenesis. 
The results of the ELISA assays in our experiments suggest that two possibilities 
either opticin binds to FGF-2 prevents its binding to receptors, or opticin binds 
to FGFR preventing FGF-2 binding. Further investigation should carry on 
finding which these true or with the combination of both. 
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Glycated opticin may modulate the binding of FGF-2 to its receptor and change 
the FGFR affinity to its ligand. We notice when glycated the opticin reduce its 
ability to bind to collagen. The importance of collagen type-I lies on the in initiate 
the early stages of angiogenesis. (Vernon and Sage 1995), via outside-in 
signalling through α1β1 and/or α2β1 integrins (Senger et al., 2002; Valdramidou 
et al., 2008). Therefore seems that one of the mechanisms through which 
glycated opticin, opticin losses its ability as anti-angiogenic by modulation of 
binding to collagen, that haven observed when we used the binding assy. 
Furthermore it has been shown that collagen type-I can initiate the early stages 
of angiogenesis via outside-in signalling through α1β1 and/or α2β1 integrins, 
which lead to change cell shape, contractility, and polymerization and 
arrangement of cytoskel et al actin into stress fibres (Davis and Senger 2005; 
Hoang et al.,2004; Senger et al., 2002). 
Several studies have highlighted the importance of strong interactions between 
these integrins and their extracellular ligands in pathological angiogenesis (Davis 
and Senger 2005; Senger et al., 2002). 
Bishop 2012 shows that opticin, by binding to collagen type-I, and II, hinders 
strong EC interactions with both α1β1and α2β1 integrins, resulting in a failure of 
formation of focal adhesions and actin stress fibres. 
Many of the known ECM inhibitors of angiogenesis exert their effects by 
perturbing integrin binding and signalling pathways, including endorepellin, 
arresten, tumstatin, endostatin, and canstatin (Mongiat et al., 2003; Sudhakar, 
2003). 
Proteoglycans are existent in mammalian tissues, both on cell surfaces and in the 
extracellular matrix, where they play fundamental roles in development, 
homeostasis, and disease (Sarrazin et al., 2011; Iozzo, 2011). 
The ocular distribution of the SRLP core proteins has been studied in some 
animal species. For example, decorin was detected throughout the neurosensory 
retina of the mouse and rat (Ali et al., 2011; Inatani et al., 1999) Its importance 
in retinal development has been demonstrated in a recent study of the avian 
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embryo, where inhibition of decorin function led to loss of polarization in retinal 
progenitor cells, along with many other abnormalities (Zagris et al., 2011). 
Biglycan distribution has been examined in the mouse eye, where it was located 
throughout the retina in both embryological and adult stages (Ali et al., 1992). 
Opticin is thought to be secreted by the ciliary body into the vitreous cavity where 
it co-localizes with the fine network of collagen fibrils that maintains the gel state 
of the vitreous and the inner-limiting lamina, a basement membrane on the inner 
surface of the retina (Le Goff et al., 2012; Bishop 2000; Ramesh, 2004) 
Glycation can induce abnormal cross-links between vitreous collagen fibrils 
leading to dissociation from hyaluronic acid and resultant destabilisation of gel 
structure. AGEs accumulate in the vitreous of aged people and diabetic patients. 
Even though nonglycational physiological and biochemical processes also 
contribute to vitreous degeneration, it seems likely that AGEs may play a 
significant role in diabetic and aging vitreous dysfunction. In terms of Maillard 
products and diabetic retinopathy, clinical studies have demonstrated that the 
levels of AGEs in the serum, skin or cornea (Sell et al., 1992; Sato et al., 2001) 
correlate with the onset or grade of diabetic retinopathy. AGEs are significantly 
increased in diabetic retinopathy patients. AGEs are localized in retinal vessels 
and neuroglia of diabetic patients where they exert a range of deleterious effects 
on cell function (Gardiner et al., 2003; Hammes et al 1999; Stitt et al., 1997). In 
vivo and in vitro studies suggest that elevated AGE level occurring in diabetes 
may be an important factor in retinopathy initiation and progression . 
Our result shows the distributions of the opticin mostly in front of the eye and 
small amount in retina and vitreous. Furthermore, the diabetic mouse has more 
AGEs than the non-diabetic mouse, and the co-localization of AGEs with opticin 
was very clear in diabetic mouse compared with non-diabetic mouse, that 
suggested that opticin was glycated, can also being suggested by Western blot 
results. 
This accumulation of AGEs in retina may play a causative role in the corneal 
epithelial disorders of diabetic patients. 
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Figure 4 .1 Signal pathways; Extracellular receptors are integral transmembrane 
proteins and make up most receptors. Signal transduction occurs as a result of a ligand 
binding to the outside.Ligand to cell membrane receptor FGFs signal to the nucleus by 
binding to FGFR and activate multiple signal transduction pathways, including those 
involving Ras, MAPKs ,ERKs, Src, p38, MAPKs, JNK, and PKC .Three signaling 
pathways activated by Integrin receptors are cytoskeletal organization, cell proliferation and 
cell survival pathways. Integrins do not themselves possess a kinase domain or enzymatic 
activity but rely on specific ECM ligands The signaling events mediated by RAGE are 
complex. RAGE signaling depending on the intensity and duration of RAGE ligation, 
specific signaling modules such as ERK1/2, p38 MAPK, and NF-κB. 
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Conclusion. 
Opticin can be glycated in vitro by exposed it to different reducing sugars. Our 
results show that up to 40 moles of MG may be attached to opticin by incubating 
with 0.1M MG, 0.5M glucose, 0.5M fructose, and 0.5 M ribose. Considering the 
presence of 20 reactive amino acid in each chain of opticin dimer, this may result 
in complete saturation of glycation sites after 24h. It is clear that our findings 
strongly suggest an important role for GOPT in modulation of angiogenesis. Here 
we demonstrat that when opticin was glycated with methylglyoxal produce 
formation of a glycated molecule that significantly lost its ability to reduce 
endothelial proliferation, cell migration and tube formation this might be one 
mechanism through which the angiogenic switch is altered in pro-angiogenic 
proliferative retinopathy. Whilst native opticin inhibited FGF-2 induced cell 
growth, glycated opticin had a much weaker effect. Native opticin also inhibited 
EGF-induced cell growth whilst glycated opticin had a weaker effect. Glycated 
opticin may modulate the binding of FGF-2 to its receptor and change the FGFR 
affinity to its ligand. Western blots demonstrate that pre-incubation of BAEC 
with opticin reduced the ability of FGF-2 increasing the MAPK signal pathways 
(e.g. JNK, ERK, and p38) which linked to angiogenesis. However in the presence 
of glycated opticin there was increase in phosphorylation expression of ERK, 
JNK, p38, and MEK, compared to the cells treated with opticin. These results 
suggest the glycation of opticin reduce its ability to inhibit intracellular signalling 
via FGF-2 and/or its receptors. We notice when glycated the opticin had reduced 
it ability to bind to collagen. After exposure of BAECs on collagen type-I to 
opticin 
(native and glycated), vinculin, α2β1, and paxillin-containing focal adhesions 
and actin stress fibres in glycated opticin not more appeared than native opticin. 
This could be evidence when opticin glycated cause less binds to collagen and 
thereby reduce inhibits α2β1 integrin binding to the collagen that effect the 
opticin to promote angiogenesis which may play a causative role in the corneal 
epithelial disorders of diabetic patients. 
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Future work 
 Studies should be directed at confirming these finding in a model of 
glycation and it is important of opticin in modulation of vascular 
regression vascular development. 
 To examine signalling pathways in more depth. 
 To investigate signalling pathways affected by glycation of opticin. 
To consider pre-clinical trials of glycation to prevent of opticin to 
inhibit PDR in the eye. 
 Study GOPT on in vivo by using CAMB assay. 
 To study if there is any relation of GOPT with cancer in vitro. 
 How to treat GOPT with inhibitors. 
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